KOL | Harry Roger BüllerDepartment of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands | From KU Leuven Department of Cardiovascular ... |
Currículum de kol para Harry Roger Büller
| Year | |
|---|---|
| 2022 | Department of Medicine, Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands |
| 2021 | From KU Leuven Department of Cardiovascular Sciences, Vascular Medicine and Hemostasis, Leuven, Belgium (P.V.); Anthos Therapeutics, Cambridge, MA (B.A.Y., J.S., D.B.); International Trial Expertise Advisory and Services (A.S.) and the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (H.R.B.) - both in Amsterdam; Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.); and the Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada (J.I.W.). Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands (H.R.B.). |
| 2020 | From the Faculty of Medical Sciences, State University of Groningen, Groningen, the Netherlands (M.O.); Department of Vascular Medicine, Amsterdam University Medical Centre, Amsterdam, the Netherlands (H.R.B., N.V.Es.); Department of Radiology, Haaglanden Medical Centre, The Hague, the Netherlands (D.K.); Department of Radiology, Nederlands Kanker Instituut, Amsterdam, the Netherlands (S.F.O.); Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, U.S.A. (T.M.); Department of Intensive Care Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands (D.G.); 7. National Institute of Public Health, Ministry of Health, Bilthoven, the Netherlands (J.V.D.); Department of Vascular Medicine, Maastricht University, Maastricht, the Netherlands (H.T.C.); Edinburgh Imaging, Queens Medical Research Institute, University of Edinburgh, Edinburgh, U.K.(E.J.R.V.B.) Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands |
| 2019 | Department of Vascular Medicine, Academic Medical Center, Universiteit van Amsterdam, Amsterdam, The Netherlands. Dept of Vascular Medicine, Amsterdam Cardiovascular Science, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands |
| 2018 | Department of Vascular Medicine, Academic Medical Centre Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| 2017 | Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, AZ, Amsterdam, The Netherlands. From Academic Medical Center and Slotervaartziekenhuis, Amsterdam, the Netherlands; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Université de Bretagne Occidentale, Brest, France; Hospital of Padua, Padua, Italy; Clinica Universidad de Navarra, Pamplona, Spain; Virgen del Rocio Hospital, Seville, Spain; Karolinska Institutet, Stockholm, Sweden; Warsaw Medical University, Warsaw, Poland; Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France; University of Utah, Salt Lake City, Utah; University Hospital Leuven, Leuven, Belgium; and University G. D'Annunzio, Chieti-Pescara, Italy. |
| 2016 | Center for Experimental and Molecular Medicine, Amsterdam Medical Center, Amsterdam, The Netherlands |
| 2015 | Academic Medical Center University of Amsterdam Department of Vascular Medicine Amsterdam the Netherlands |
| 2014 | From the College of Public Health, University of Oklahoma Health Sciences Center (G.E.R., M.M., A.W.); Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (P.A.); División Hemostasia, Academia Nacional de Medicina, Buenos Aires, Argentina (A.N.B.); Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (H.B.); SA Pathology–Department of Hematology, Flinders Medical Center, Adelaide, South Australia, Australia (A.G.); Thrombosis and Thrombophilia Centre, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (B.J.H.); Boston University School of Medicine, MA (E.M.H.); Thrombosis Research Institute, London, United Kingdom (A.K.); Center for Thrombosis and Hemostasis, Johannes Gutenberg University, Mainz, Germany (S.V.K.); Department of Laboratory Medicine, University of Yamanashi, Tamaho, Yamanashi, Japan (Y.O.); and McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (J.I.W.). Department of General Practice, Academic Medical Centre, University of Amsterdam, Amsterdam and |
| 2013 | Department of Vascular Medicine, F4-140, Academic Medical Centre, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands Academic Medical Center, Amsterdam (H.R.B.) |
| 2012 | Academic Medical Center, Department of Vascular Medicine, Amsterdam (H.R.B.) Vascular Medicine, AMC, Amsterdam, the Netherlands |
| 2011 | Internal Medicine, Academic Medical Center, Amsterdam, Netherlands, From the Academic Medical Center and Slotervaart Hospital, Amsterdam |
Harry Roger Büller: Estadísticas de influencia
Sacar un reporte
| Concept | World rank |
|---|---|
| d‐dimer test | #1 |
| ft4 level patients | #1 |
| replacement vka | #1 |
| method factor | #1 |
| protein mortality | #1 |
| embolism randomized | #1 |
| noncarriers annual incidence | #1 |
| uesvt | #1 |
| questionnaires thrombosis | #1 |
| vte difference | #1 |
| 25mg apixaban | #1 |
| initial treatment patients | #1 |
| elevated fviii | #1 |
| matisse clinical trials | #1 |
| scores riete score | #1 |
| graft patency patency | #1 |
| 3633 patients edoxabantreated | #1 |
| netherlands vka | #1 |
| acenocoumarol initial treatment | #1 |
| preference doacs | #1 |
| intravenous injections lmwh | #1 |
| amplify trial apixaban | #1 |
| compression ultrasound dvt | #1 |
| preferred oral anticoagulant | #1 |
| heparins vitamin antagonists | #1 |
| scenarioanalysis | #1 |
| pulmonary embolism basis | #1 |
| lmwh edoxaban | #1 |
| patients tb402 | #1 |
| perelated death category | #1 |
| thrombophlebitis tomography | #1 |
| ankle brachial prevalence | #1 |
| principal safety | #1 |
| patients retropubic prostatectomy | #1 |
| severity clinical presentation | #1 |
| thromboembolism relatives | #1 |
| patients advanced prostate | #1 |
| warfarin cancer patients | #1 |
| dvt 56 | #1 |
| absolute thrombotic risk | #1 |
| combination ddimer testing | #1 |
| treat thrombosis | #1 |
| death vte studies | #1 |
| laalleles | #1 |
| diagnosis deepvein thrombosis | #1 |
| individualized duration | #1 |
| specificity pulmonary embolism | #1 |
| pulmonary embolism studies | #1 |
| laalleles platelets | #1 |
| departments orthopedic surgery | #1 |
| org aptt | #1 |
| protein resistance control | #1 |
| heparins data | #1 |
| presenting location women | #1 |
| anticoagulant fondaparinux | #1 |
| extended anticoagulation doacs | #1 |
| presenting location vte | #1 |
| rivaroxaban replacement | #1 |
| 023 relatives | #1 |
| normal lung scan | #1 |
| tomography angiography vte | #1 |
| pulmonary embolism fondaparinux | #1 |
| intrinsic coagulation vivo | #1 |
| 0·2 edoxabantreated | #1 |
| dose response apixaban | #1 |
| incidence venous | #1 |
| dvt 3 | #1 |
| fetal loss miscarriage | #1 |
| treatment venous | #1 |
| rabinov | #1 |
| prophylaxis crt | #1 |
| pvo qscan | #1 |
| endotoxemia tests | #1 |
| presentation 1 week | #1 |
| vte airline pilots | #1 |
| matisse trials | #1 |
| doac recipients | #1 |
| studies ttr | #1 |
| pulmonary angiography strategies | #1 |
| antidote vitamin | #1 |
| matisse dvt | #1 |
| vte fatal | #1 |
| unexplained dvt | #1 |
| relatives tafi levels | #1 |
| abelacimab | #1 |
| limited screening 95 | #1 |
| factor viii homocysteine | #1 |
| thiazoles venous | #1 |
| oral rivaroxaban treatment | #1 |
| symptomatic venous | #1 |
| apc resistance factor | #1 |
| mutation relatives | #1 |
| evaluable patients apixaban | #1 |
| vitamin anticoagulants | #1 |
| venography tests | #1 |
| realtime bmode ultrasonography | #1 |
| travel venous thromboembolism | #1 |
| 2 diagnostic management | #1 |
| category fxainhibitors | #1 |
| proportion pulmonary embolism | #1 |
| subcutaneous idraparinux | #1 |
| postthrombotic symptoms patients | #1 |
| incidence ctni | #1 |
| cancer patients cdr | #1 |
| 00515 | #1 |
| thrice daily gentamicin | #1 |
| venous thrombosis hyperglycemia | #1 |
| lmwh departments | #1 |
| respondents 60 | #1 |
| chest perfusion scintigraphy | #1 |
| placebo rnapc2 | #1 |
| analysis hokusai | #1 |
| undvt | #1 |
| uesvt mortality | #1 |
| thromboembolism treated | #1 |
| death venous thromboembolism | #1 |
| synthetic selective factor | #1 |
| relatives elevated levels | #1 |
| qscan | #1 |
| 500 org | #1 |
| ipe expert radiologists | #1 |
| exclusion pulmonary | #1 |
| survival fondaparinux | #1 |
| carriers relative risks | #1 |
| progression svt | #1 |
| factual hemorrhage heparin | #1 |
| 8h flight | #1 |
| increasing levels ft4 | #1 |
| normal ddimer concentration | #1 |
| patients tests prevalence | #1 |
| fetal loss stillbirth | #1 |
| atherosclerosis hemophilia patients | #1 |
| venous thrombosis pregnancy | #1 |
| fviii vte | #1 |
| treated vka | #1 |
| travel‐related venous thrombosis | #1 |
| heparins cancer spread | #1 |
| studies 3 months | #1 |
| vte occurred | #1 |
| risk percentage points | #1 |
| uesvt uedvt | #1 |
| proximal extent ipe | #1 |
| patients idraparinux | #1 |
| doses 75 microg | #1 |
| thrombo‐embolic events | #1 |
| cancer patients cvcs | #1 |
| 6 months avidin | #1 |
| therapeutic doses lmwh | #1 |
| vitamin antagonist patients | #1 |
| ultrasound compression ultrasound | #1 |
| dalteparin major bleeding | #1 |
| bleeding risk lmwh | #1 |
| fibrinolysis levels | #1 |
| double heterozygous carriers | #1 |
| prospective management study | #1 |
| enoxaparin initial treatment | #1 |
| elevated cardiac troponins | #1 |
| distal clots | #1 |
| vka treatment treatment | #1 |
| crt cvc | #1 |
| patients reduceddose noacs | #1 |
| hokusaivte trial | #1 |
| 12 kg1 enoxaparin | #1 |
| rnapc2 inhibition | #1 |
| clinically suspected dvt | #1 |
| tb402 50 | #1 |
| models development studies | #1 |
| longhaul flight | #1 |
| embolism radionuclide | #1 |
| perelated death classification | #1 |
| clinically suspected cancer | #1 |
| 9 incidence | #1 |
| venous thrombus growth | #1 |
| achieved inr patients | #1 |
| patients antithrombotic prescriptions | #1 |
| coagulation factors markers | #1 |
| pyridines recurrence | #1 |
| cdr ddimer test | #1 |
| patients initial heparin | #1 |
| fviii women | #1 |
| dalteparin 6 months | #1 |
| svt lmwh | #1 |
| venous thromboembolism idraparinux | #1 |
| nadroparin therapeutic dose | #1 |
| anticoagulants double | #1 |
| rnapc2 united states | #1 |
| single‐detector row | #1 |
| ldfr symptomatic legs | #1 |
| apc resistance tests | #1 |
| dvt anticoagulants | #1 |
| ultrasonography diagnostic | #1 |
| cvc crt | #1 |
| 378 patients edoxaban | #1 |
| vte location | #1 |
| heparin initial treatment | #1 |
| subcutaneous nadroparin placebo | #1 |
| age multiple comorbidities | #1 |
| deficiency proteins | #1 |
| relatives antithrombin | #1 |
| deep vein thrombosis | #1 |
| heparinoid | #1 |
| age recurrent vte | #1 |
| enoxaparin warfarin antiplatelet | #1 |
| vka netherlands | #1 |
| ultrasonography dvt | #1 |
| idraparinux 6 months | #1 |
| lmwh users incidence | #1 |
| initial treatment dvt | #1 |
| apixaban extended treatment | #1 |
| relevant bleeding | #1 |
| equinox study | #1 |
| monoclonal antibodies apc | #1 |
| elevated biomarkers hospital | #1 |
| infections gentamicin | #1 |
| venous thrombosis vwf | #1 |
| dimer clinical | #1 |
| tb402 prevention | #1 |
| cancer edoxaban | #1 |
| perfusion scan | #1 |
| silent dvt | #1 |
| vka share | #1 |
| combination cdrscore | #1 |
| cancer 145 patients | #1 |
| selective ddimer thresholds | #1 |
| quantitative ddimer testing | #1 |
| somittrial | #1 |
| idrabiotaparinux idraparinux | #1 |
| tinaquant assay comparison | #1 |
| outcome recurrent | #1 |
| ambulatory computers | #1 |
| acenocoumarol efficacy | #1 |
| sspe proximal | #1 |
| wellsrule | #1 |
| dvt 69 | #1 |
| 0·620·74 | #1 |
| isolated deficiencies proteins | #1 |
| baseline characteristics duration | #1 |
| presenting vte location | #1 |
| apixaban conventional therapy | #1 |
| ufh grade 1a | #1 |
| cdr physicians | #1 |
| survival lmwh | #1 |
| neoplasms heparin | #1 |
| compression ultrasonography | #1 |
| patients unexplained dvt | #1 |
| extensive screening cancer | #1 |
| rfviia fondaparinux | #1 |
| submassive elevated ctni | #1 |
| botticelli dvt dose‐ranging | #1 |
| local radiologist | #1 |
| standard therapy months | #1 |
| anticoagulation period | #1 |
| daily dalteparin treatment | #1 |
| reduceddose noacs stroke | #1 |
| patients enoxaparin vkas | #1 |
| 547253 | #1 |
| quantitative ddimer test | #1 |
| tsh antitpo | #1 |
| thrombophilia patients doacs | #1 |
| symptomatic legs dvt | #1 |
| fxiaso enoxaparin | #1 |
| probability ventilation | #1 |
| beneficial lmwh | #1 |
| echocardiography normotensive patients | #1 |
| weight heparinoid | #1 |
| outpatients symptomatic dvt | #1 |
| nadroparin patients | #1 |
| failure rate efficiency | #1 |
| leg veins patients | #1 |
| nonhigh cdr | #1 |
| dimer result | #1 |
| elevated levels fviii | #1 |
| casedescription | #1 |
| pvoq | #1 |
| controlledstudy | #1 |
| symptomatic recurrent vte | #1 |
| thrombosis vitamin | #1 |
| rate recurrent | #1 |
| successful attenuation | #1 |
| malignancy achieved inr | #1 |
| idraparinux vte | #1 |
| fviii homocysteine | #1 |
| elevated fviii age | #1 |
| revascularisation procedures patients | #1 |
| crptest | #1 |
| simplified rule proportion | #1 |
| edoxabantreated | #1 |
| ultrasonography leg veins | #1 |
| absolute annual incidences | #1 |
| vte risk day | #1 |
| patients wells rule | #1 |
| double reports | #1 |
| nondiagnostic lung scan | #1 |
| coagulation fibrinolytic proteins | #1 |
| mdct expert radiologist | #1 |
| 12 months edoxaban | #1 |
| prophylaxis idraparinux | #1 |
| gogh dvt trial | #1 |
| initial heparin edoxaban | #1 |
| 95 elevated ctni | #1 |
| doacs initial heparin | #1 |
| compression ultrasonography detection | #1 |
| enoxaparin vkas treatment | #1 |
| ctscanreading | #1 |
| heparin acenocoumarol | #1 |
| strategies diagnostic management | #1 |
| level loss patency | #1 |
| subcutaneous length life | #1 |
| probabilityscan | #1 |
| subsequent diagnosis malignancy | #1 |
| rule exclusion | #1 |
| association travel | #1 |
| vkas efficacy | #1 |
| months standard therapy | #1 |
| departments pharmacological prophylaxis | #1 |
| lmwh plasma levels | #1 |
| lmwh venous thrombosis | #1 |
| patients compression ultrasonography | #1 |
| rhir lmwh | #1 |
| acute recurrent patients | #1 |
| efficiency subgroups | #1 |
| idraparinux standard therapy | #1 |
| duration heparin treatment | #1 |
| quantitative dimer | #1 |
| embolism sensitivity | #1 |
| bleeding rates quality | #1 |
| role exclusion | #1 |
| gastrointestinal cancer edoxaban | #1 |
| abnormal vaginal bleeding | #1 |
| major bleeding cancer | #1 |
| 560 pharmacies | #1 |
| time recombinant | #1 |
| reduceddose noacs warfarin | #1 |
| oral edoxaban dose | #1 |
| clinical probability exclusion | #1 |
| ivte clinical practice | #1 |
| axa activity 5 | #1 |
| clinically suspected uedvt | #1 |
| ufh grade | #1 |
| 123362 | #1 |
| efficacy outcome | #1 |
| fviii hyperhomocysteinemia | #1 |
| oral apixaban treatment | #1 |
| recurrent vte statin | #1 |
| wells rules | #1 |
| adjusted dose ufh | #1 |
| protecht shr | #1 |
| beta thromboglobulin org | #1 |
| inr studies | #1 |
| women elevated levels | #1 |
| excluded pulmonary | #1 |
| hokusai‐vte cancer study | #1 |
| upper extremity uedvt | #1 |
| referral basis | #1 |
| normotensive patients studies | #1 |
| uesvt recurrent vte | #1 |
| patients acute recurrent | #1 |
| vka recipients | #1 |
| standardintensity vkas doacs | #1 |
| lowmolecularweight heparin 95 | #1 |
| strategies abdominal pelvic | #1 |
| normal dimer | #1 |
| aged nadroparin | #1 |
| khorana | #1 |
| puerperium diagnostic suspicion | #1 |
| 95ci tb402 | #1 |
| netherlands lmwh | #1 |
| elderly outpatients combination | #1 |
| patients khorana | #1 |
| normal levels fviii | #1 |
| iii plg | #1 |
| pulmonary embolism tests | #1 |
| ddimer test combination | #1 |
| severe presentation patients | #1 |
| anticoagulants probability | #1 |
| study centre duration | #1 |
| smoking patency | #1 |
| pvo ctscan | #1 |
| combined training gps | #1 |
| threemonth incidence | #1 |
| feasibility venography | #1 |
| clinically relevant disease | #1 |
| vte procoagulant activity | #1 |
| prolactin venous thrombosis | #1 |
| cus strategies | #1 |
| edoxaban risk factors | #1 |
| advanced malignancy | #1 |
| nadroparin aspirin | #1 |
| ldf diagnosis | #1 |
| united states rnapc2 | #1 |
| heparin initial | #1 |
| 7268 patients | #1 |
| molecular weight fondaparinux | #1 |
| cancer patients patients | #1 |
| normal ddimer result | #1 |
| category perelated death | #1 |
| heparins inhibition | #1 |
| 36 papers | #1 |
| topic thrombophlebitis | #1 |
| simplified geneva score | #1 |
| efficacy vte | #1 |
| einstein dvt patients | #1 |
| efficacy conventional treatment | #1 |
| ventricular dysfunction edoxaban | #1 |
| pulmonary embolism carriers | #1 |
| vte trial | #1 |
| prothrombin individuals | #1 |
| 50 years combination | #1 |
| uedvt recurrent vte | #1 |
| leg ultrasonography patients | #1 |
| probability cdr | #1 |
| activecontrol placebo | #1 |
| recurrence major bleeding | #1 |
| standalone ddimer testing | #1 |
| 65±9years | #1 |
| patients deep | #1 |
| avidin placebo | #1 |
| prescriptionbased | #1 |
| rabinovpaulin | #1 |
| safety idraparinux | #1 |
| association protein levels | #1 |
| protein levels mortality | #1 |
| excluding pulmonary | #1 |
| obstetric complications relatives | #1 |
| normohomocysteinemic relatives hyperhomocysteinaemia | #1 |
| anticoagulant treatment patients | #1 |
| falsenormal | #1 |
| prothrombin 20210a mutation | #1 |
| recommendations dvt | #1 |
| prevention topic guidelines | #1 |
| ivte | #1 |
| patients examiner | #1 |
| proportion 75 years | #1 |
| suspected perfusion scan | #1 |
| ventilation scan chest | #1 |
| simple diagnostic strategy | #1 |
| rivaroxaban acute dvt | #1 |
| ddimer test patients | #1 |
| efficacy heparin therapy | #1 |
| symptomatic pts | #1 |
| prevalence coagulation | #1 |
| guidelines abi | #1 |
| compression ultrasonography patients | #1 |
| antithrombotic prescriptions adherence | #1 |
| combination cdrs | #1 |
| unexplained dvt patients | #1 |
| ifngamma pselectin | #1 |
| pulmonary embolism metaanalysis | #1 |
| 250 patients cancer | #1 |
| 3 rfviia | #1 |
| previous surveys netherlands | #1 |
| phase doacs | #1 |
| levonorgestrel desogestrelcontaining | #1 |
| 5395 patients | #1 |
| alternative diagnoses patients | #1 |
| cdr normal | #1 |
| extended treatment edoxaban | #1 |
| inherited thrombophilia patients | #1 |
| early time recurrence | #1 |
| predefined outcomes vte | #1 |
| polyethylenglycolhirudin | #1 |
| 95 intracranial | #1 |
| diagnostic strategies strategies | #1 |
| fviii venous thromboembolism | #1 |
| reported incidence vte | #1 |
| wound haematoma | #1 |
| uesvt median | #1 |
| members symptomatic carriers | #1 |
| treatment idraparinux | #1 |
| probability normal | #1 |
| carriers thrombophilic defects | #1 |
| wells cdr | #1 |
| avidin vte | #1 |
| dalteparin vte treatment | #1 |
| asymptomatic extension | #1 |
| hokusaivte study | #1 |
| low levels ft4 | #1 |
| cdrscore | #1 |
| p0001 saline | #1 |
| intensity vkas doacs | #1 |
| relatives normal fviii | #1 |
| inr range ttr | #1 |
| ddimer test | #1 |
| milliliter enoxaparin | #1 |
| cancer patients ufh | #1 |
| fxainhibitors vka recipients | #1 |
| obese hemophilic patients | #1 |
| rfviia idraparinux | #1 |
| pulmonary angiography study | #1 |
| d‐dimer level | #1 |
| xageneration | #1 |
| loss subsequent pregnancy | #1 |
| lmwh rtap | #1 |
| rnapc2 groups | #1 |
| lmwhmediated | #1 |
| gentamicin patients netilmicin | #1 |
| chest perfusion scan | #1 |
| cancer patients uedvt | #1 |
| women edoxaban | #1 |
| uesvt patients | #1 |
| diagnostic strategies patients | #1 |
| vitamin antagonists time | #1 |
| timerequirement | #1 |
| studies doac treatment | #1 |
| safety 60 dose | #1 |
| lmwh replacement | #1 |
| chromogenic endotoxin | #1 |
| tests venography | #1 |
| subsequent symptomatic cancer | #1 |
| study ecq | #1 |
| ccus 4 | #1 |
| suspected deep | #1 |
| followup overt cancer | #1 |
| control anticardiolipin antibodies | #1 |
| cdr ddimer levels | #1 |
| bmi fondaparinux | #1 |
| elevated fviii patients | #1 |
| messages justification | #1 |
| einsteinextension | #1 |
| ldf cus | #1 |
| idraparinux placebo | #1 |
| local radiologist experts | #1 |
| annual incidence patients | #1 |
| idraparinux 25 | #1 |
| —brachial | #1 |
| standardintensity vkas | #1 |
| poc test patients | #1 |
| doacs factor | #1 |
| ddimer levels cdr | #1 |
| rivaroxaban standard therapy | #1 |
| coagulation clinical | #1 |
| 7268 patients suspected | #1 |
| screening carriers | #1 |
| sensitivity 100 percent | #1 |
| fondaparinux rfviia injection | #1 |
| avws prevalence | #1 |
| initial heparin patients | #1 |
| travellers thrombosis | #1 |
| plateletactivating antibodies risk | #1 |
| edoxaban east asian | #1 |
| strategies ultrasonography | #1 |
| fondaparinux unfractionated | #1 |
| withheld | #1 |
| patients mismatched scan | #1 |
| heparins cancer patients | #1 |
| s1p1activation | #1 |
| patients clinical probability | #1 |
| relatives mutation | #1 |
| relative risks carriers | #1 |
| vte addition | #1 |
| elevated ctni patients | #1 |
| venous thromboembolism episode | #1 |
| apixaban randomized patients | #1 |
| guideline adherence justification | #1 |
| hellp syndrome mutations | #1 |
| selective beta‐blocker treatment | #1 |
| procoagulant factors levels | #1 |
| total vte patients | #1 |
| 50 rivaroxaban | #1 |
| ctscan qscan | #1 |
| embolism wells | #1 |
| long haul flights | #1 |
| placebo 25mg apixaban | #1 |
| anticoagulants chemotherapy | #1 |
| pulmonary embolism | #1 |
| presentation major | #1 |
| test venography | #1 |
| heparin vitamin | #1 |
| carriers recurrence | #1 |
| rivaroxaban dvt treatment | #1 |
| superficial thrombophlebitis incidence | #1 |
| enoxaparin tb402 | #1 |
| adjunct thrombolysis | #1 |
| influenza case patients | #1 |
| administration lmwh | #1 |
| idraparinux months | #1 |
| 750 μg l1 | #1 |
| cstatistic major bleeding | #1 |
| calfvein thrombi | #1 |
| death category | #1 |
| year prophylaxis | #1 |
| randomized studies efficacy | #1 |
| comparison vidas assay | #1 |
| riskstroponin | #1 |
| clinical uedvt | #1 |
| hokusai‐vte trial | #1 |
| diagnostic management patients | #1 |
| cancer clinical presentation | #1 |
| patients malignancy | #1 |
| idraparinux patients | #1 |
| presence venous thrombosis | #1 |
| recurrent thromboembolism enoxaparin | #1 |
| sgs pretest probability | #1 |
| submassive incidence | #1 |
| doacs cirrhosis patients | #1 |
| single dose tb402 | #1 |
| pulmonary angiography ultrasonography | #1 |
| uedvt terms | #1 |
| symptomatic recurrent | #1 |
| presentation category | #1 |
| acute treatment lmwh | #1 |
| cdr dimer | #1 |
| vte arterial | #1 |
| edoxaban cancer patients | #1 |
| oral administration bsf | #1 |
| variable d‐dimer thresholds | #1 |
| venous thrombosis mutations | #1 |
| quantitative ddimer tests | #1 |
| vivo coagulation factor | #1 |
| doubleheterozygotes | #1 |
| fviii concentration | #1 |
| intravenous unfractionated | #1 |
| risk homozygous women | #1 |
| p0424 | #1 |
| pulmonary embolism role | #1 |
| vte day | #1 |
| carriers pulmonary embolism | #1 |
| older patients cdr | #1 |
| rnapc2 patients | #1 |
| tb402 12 kg1 | #1 |
| major bleeds vka | #1 |
| amplify trial | #1 |
| 5‐snp scores | #1 |
| current comprehensions | #1 |
| heparin org 10172 | #1 |
| tests pulmonary embolism | #1 |
| 5 avidin infusion | #1 |
| netherlands 5 years | #1 |
| predefined outcomes | #1 |
| patients inherited thrombophilia | #1 |
| residual thrombotic mass | #1 |
| 15 lmwh | #1 |
| cancer cdr | #1 |
| idraparinux versus | #1 |
| mutation arg506 | #1 |
| international thrombosis experts | #1 |
| intestinal microbiota coagulation | #1 |
| 2630 pilots | #1 |
| relevant major | #1 |
| desogestrelcontaining coagulation factors | #1 |
| oral anticoagulants phase | #1 |
| timeperiod | #1 |
| patients advanced malignancy | #1 |
| acenocoumarol heparin | #1 |
| recurrent vte immobilization | #1 |
| reduceddose noacs | #1 |
| ventilation lung scanning | #1 |
| probability categories | #1 |
| extended anticoagulation apixaban | #1 |
| failure diagnostic management | #1 |
| wells simplified | #1 |
| evaluable patients 95 | #1 |
| embolism suspected | #1 |
| 393 patients warfarin | #1 |
| incidental symptomatic vte | #1 |
| platelets iqr | #1 |
| thromboembolism 3 | #1 |
| rnapc2 groups placebo | #1 |
| dvt costs | #1 |
| positive vte | #1 |
| hemorrhage heparin | #1 |
| patients normal tests | #1 |
| acquired atiii deficiency | #1 |
| patients laalleles | #1 |
| respondents lmwh | #1 |
| heparin vitamin antagonist | #1 |
| patients uedvt uesvt | #1 |
| qscan 3 weeks | #1 |
| aptt org | #1 |
| pulmonary embolism cdr | #1 |
| abnormal ipg | #1 |
| idraparinux vitamin antagonist | #1 |
| enoxaparin primary efficacy | #1 |
| orthopedic thromboprophylaxis | #1 |
| cdrs patients | #1 |
| avidin idrabiotaparinux | #1 |
| venography feasibility | #1 |
| 0·2 3633 patients | #1 |
| cdrscore combination | #1 |
| orthopedic surgery netherlands | #1 |
| suspected cdr | #1 |
| bleeding clinically | #1 |
| types major bleeding | #1 |
| cip diagnostic management | #1 |
| individuals air travel | #1 |
| tests prevalence abi | #1 |
| 97 compression ultrasonography | #1 |
| category death | #1 |
| wells clinical | #1 |
| consensus strategy strategy | #1 |
| original wells | #1 |
| vitamin antagonists treatment | #1 |
| popliteal veins sensitivity | #1 |
| pregnancyrelated complications relatives | #1 |
| vte study | #1 |
| controlled trials thrombophilia | #1 |
| 5 years lmwh | #1 |
| ml1 ctpa | #1 |
| outcome clinically | #1 |
| wells rule primary | #1 |
| reocclusion antithrombotic drug | #1 |
| proximal location ipe | #1 |
| ddimer result | #1 |
| safety clinical utility | #1 |
| pulmonary embolism life | #1 |
| segmental subsegmental | #1 |
| venous thromboembolism edoxaban | #1 |
| 20210a mutation | #1 |
| decisions duration | #1 |
| 95 3633 patients | #1 |
| venous thrombosis recurrence | #1 |
| aptt org 10172 | #1 |
| combination nonhigh cdr | #1 |
| 3 idraparinux | #1 |
| aged venous | #1 |
| thrombophilia late loss | #1 |
| fviii normal levels | #1 |
| lowmolecularweight heparin category | #1 |
| lmwh immobilization | #1 |
| rtap lmwh | #1 |
| idraparinux | #1 |
| failure cip | #1 |
| false normal | #1 |
| bleeding einstein | #1 |
| patients artificial graft | #1 |
| cstatistic model discrimination | #1 |
| 2479 relatives | #1 |
| risk pulmonary embolism | #1 |
| lmwhs 95 | #1 |
| prediction models recurrence | #1 |
| xainhibitors | #1 |
| baseline pvo | #1 |
| dose daily edoxaban | #1 |
| clinical decision rule | #1 |
| rfviia 3 | #1 |
| pulmonary embolism idraparinux | #1 |
| org heparin | #1 |
| frequency venous thromboembolism | #1 |
| safety outcome | #1 |
| suspected symptomatic | #1 |
| intracranial clinical presentation | #1 |
| rivaroxaban lmwh vka | #1 |
| recurrent thrombosis pts | #1 |
| acenocoumarol therapy acenocoumarol | #1 |
| obese controls difference | #1 |
| treatment experimental thrombosis | #1 |
| clinical presentation category | #1 |
| non‐invasive diagnostic work‐up | #1 |
| bleeding risk treatment | #1 |
| patients protein deficiencies | #1 |
| edoxaban dalteparin | #1 |
| conventional therapy enoxaparin | #1 |
| pioped study study | #1 |
| 53 amputations | #1 |
| fetal loss carriers | #1 |
| uedvt clinical | #1 |
| einsteindvt | #1 |
| patients ivte | #1 |
| ddimer test result | #1 |
| hokusai vte cancer | #1 |
| coagulationinhibiting | #1 |
| dimer test | #1 |
| progression vte | #1 |
| flebography | #1 |
| ultrasound strategies patients | #1 |
| hyperhomocysteinemia relatives | #1 |
| patients treatment duration | #1 |
| management study | #1 |
| vkas lmwh | #1 |
| noacs prevention | #1 |
| enoxaparin heparin treatment | #1 |
| lowmolecularweight heparin treatment | #1 |
| 69 conclusions | #1 |
| recurrent vte doacs | #1 |
| doacs anatomical extent | #1 |
| ecq ankle brachial | #1 |
| wellscdr | #1 |
| warfarin cstatistic | #1 |
| enoxaparin vkas | #1 |
| diagnostic strategy primary | #1 |
| recurrence bleeding risk | #1 |
| normal venogram | #1 |
| 5mg apixaban | #1 |
| age∗10μg | #1 |
| cart lower levels | #1 |
| idraparinux recurrent thromboembolism | #1 |
| treatment cumulative incidence | #1 |
| elderly patients dvt | #1 |
| lmwh acute treatment | #1 |
| included patients study | #1 |
| combination cdr | #1 |
| thrombosis vte | #1 |
| 3633 patients edoxaban | #1 |
| systematic search cteph | #1 |
| plasma concentration fviii | #1 |
| anticoagulant treatment vte | #1 |
| simplified wells rule | #1 |
| probability lung scan | #1 |
| vte risk coc | #1 |
| extra hospital visits | #1 |
| compression ultrasonography presentation | #1 |
| hokusaivte trial patients | #1 |
| crp test patients | #1 |
| dvt impedance plethysmography | #1 |
| abdominal pelvic strategies | #1 |
| clinical probability risk | #1 |
| rule cdr | #1 |
| dvt symptomatic | #1 |
| patency smokers | #1 |
| fxainhibitors | #1 |
| deepvein thrombosis incidence | #1 |
| 208791 | #1 |
| smoking graft patency | #1 |
| clinical probability patients | #1 |
| lmprovement | #1 |
| levels procoagulant factors | #1 |
| ili score | #1 |
| calf dvt ultrasound | #1 |
| scores occult cancer | #1 |
| easier monitoring | #1 |
| animal female heparin | #1 |
| strategy abdominal pelvic | #1 |
| recurrent dvt dvt | #1 |
| edoxaban warfarin groups | #1 |
| wellscdrscore | #1 |
| factor viii relatives | #1 |
| impedance thrombophlebitis | #1 |
| heparin survival | #1 |
| standard therapy rivaroxaban | #1 |
| standard treatment idraparinux | #1 |
| women factor leiden | #1 |
| rule dimer | #1 |
| early discharge strategies | #1 |
| wells rule exclusion | #1 |
| dose rnapc2 | #1 |
| tb402 enoxaparin | #1 |
| practiceassistants | #1 |
| scan pulmonary embolism | #1 |
| current practise | #1 |
| mortality postthrombotic symptoms | #1 |
| cancer patients cancer | #1 |
| constans score | #1 |
| sustained antithrombotic effects | #1 |
| relatives normal levels | #1 |
| lmwh delivery | #1 |
| pharmacological methods prophylaxis | #1 |
| endogenous activated protein | #2 |
| comparator individuals 95 | #2 |
| women therapeutic doses | #2 |
| pentasaccharide fondaparinux | #2 |
| ultrasonography patients | #2 |
| months 25 | #2 |
| normohomocysteinemic relatives | #2 |
| relation coagulation factors | #2 |
| safety pravastatin therapy | #2 |
| pharmacological strategies | #2 |
| vein compressibility | #2 |
| endotoxininduced activation coagulation | #2 |
| embolism primary | #2 |
| hospitalbased strategies | #2 |
| dimer thresholds | #2 |
| computerized impedance | #2 |
| fvl carriers carriers | #2 |
| employees longhaul flight | #2 |
| fibrinolytic proteins | #2 |
| subsegmental emboli | #2 |
| gauge plethysmography | #2 |
| fviii increased risk | #2 |
| enoxaparin difference | #2 |
| patients hemorr2hages | #2 |
| limits cancer | #2 |
| anticoagulated patients permanent | #2 |
| ddimer assay | #2 |
| secondary strategies | #2 |
| medscape | #2 |
| protein rnapc2 | #2 |
| amuse strategy | #2 |
| plasma d‐dimer concentration | #2 |
| simplified wells | #2 |
| apixaban lmwh vka | #2 |
| recombinant nematode | #2 |
| venous thromboembolism enoxaparin | #2 |
| hmb primary outcome | #2 |
| adapted ddimer thresholds | #2 |
| efficiency strategy | #2 |
| hyperglycemia diagnosis | #2 |
| thyroid hormone coagulation | #2 |
| compression doppler | #2 |
| plasmin activity inhibition | #2 |
| suspected pulmonary | #2 |
| clinical prediction model | #2 |
| coagulation factors prolactin | #2 |
| vidas assay | #2 |
| bleeding rate patients | #2 |
| f5 r506q | #2 |
| received edoxaban | #2 |
| common alternative diagnoses | #2 |
| treatment deep | #2 |
| gcpg | #2 |
| sr34006 | #2 |
| intrinsic cascade | #2 |
| sustained antithrombotic | #2 |
| heparin nadroparin | #2 |
| diagnostic lung | #2 |
| tinaquant vidas | #2 |
| patients khorana score | #2 |
| healthcare settings findings | #2 |
| incidental venous | #2 |
| negative ageadjusted ddimer | #2 |
| biomarkers casecontrol studies | #2 |
| prolactin relation | #2 |
| efficiency diagnostic strategies | #2 |
| patients low probability | #2 |
| venographically | #2 |
| bleeding complications treatment | #2 |
| beta‐receptor blockade | #2 |
| rivaroxaban thiazoles | #2 |
| global public awareness | #2 |
| antagonists vka | #2 |
| risk khorana | #2 |
| age‐adjusted d‐dimer testing | #2 |
| wells cdr cdr | #2 |
| ventilation scanning | #2 |
| quality warfarin treatment | #2 |
| recurrence thromboembolism | #2 |
| fibrinolysis influenza | #2 |
| test cancer | #2 |
| treated anticoagulants | #2 |
| oral direct inhibitors | #2 |
| ufh survival | #2 |
| presentation dvt | #2 |
| screening fvl | #2 |
| interleukin‐10 response | #2 |
| concomitant thrombophilic | #2 |
| patients peripheral graft | #2 |
| thromboinflammation cardiovascular disease | #2 |
| acquired antithrombin | #2 |
| referred patients secondary | #2 |
| nonpermanent heart failure | #2 |
| 8292 patients | #2 |
| blood coagulation inhibition | #2 |
| heparin treatment influenza | #2 |
| incidence recurrent | #2 |
| clinical pretest probability | #2 |
| hokusai vtecancer study | #2 |
| mild risk factor | #2 |
| years 36 | #2 |
| outcome symptomatic | #2 |
| alife study | #2 |
| vitamin antagonist rivaroxaban | #2 |
| apixaban enoxaparin warfarin | #2 |
| duration anticoagulant treatment | #2 |
| raskob | #2 |
| clinically suspected | #2 |
| mutations propeptide | #2 |
| hemorr2hages atria scores | #2 |
| exclude pulmonary | #2 |
| bleeding edoxaban | #2 |
| deficiencies proteins | #2 |
| measurement ankle brachial | #2 |
| low‐molecular‐weight heparin | #2 |
| coagulation fibrinolytic | #2 |
| statins recurrent vte | #2 |
| lowmolecularweight heparin women | #2 |
| rfviia injection rfviia | #2 |
| influenza prothrombotic state | #2 |
| graft occlusion patients | #2 |
| 95 0·2 | #2 |
| undiagnosed malignancy | #2 |
| suspected upper | #2 |
| major bleeding intermediate | #2 |
| amadeus study | #2 |
| symptomatic outpatients | #2 |
| lower clinical utility | #2 |
| thrombosis normal | #2 |
| pravastatin therapy children | #2 |
| mutation 35 | #2 |
| annual incidences | #2 |
| current clinical challenges | #2 |
| ate cancer patients | #2 |
| n832 | #2 |
| decision rule | #2 |
| primary hospitalbased strategies | #2 |
| arterial thrombotic disease | #2 |
| impedance plethysmography diagnosis | #2 |
| incidental vte | #2 |
| rnapc2 | #2 |
| rnapc2 doses | #2 |
| 95 cancer patients | #2 |
| life treatment duration | #2 |
| 3306 patients | #2 |
| vte svt | #2 |
| thromboembolism thrombophilia | #2 |
| uedvt efficiency | #2 |
| patients prior vte | #2 |
| 95 dvt | #2 |
| embolism safely | #2 |
| khorana protecht | #2 |
| vte elevated fviii | #2 |
| treatment ttr | #2 |
| model cancer patients | #2 |
| levels coagulation factors | #2 |
| performance constans rule | #2 |
| treated edoxaban | #2 |
| heparin effective | #2 |
| crd42017056309 | #2 |
| cdr variables cdr | #2 |
| coumarin sensitivity | #2 |
| composite scores area | #2 |
| exposure flights | #2 |
| rule proportion | #2 |
| major clinically | #2 |
| vitamin antagonists quality | #2 |
| lmwh users | #2 |
| hellp syndrome prevalence | #2 |
| 6 months scores | #2 |
| death vte | #2 |
| regression pravastatin | #2 |
| 8 wk risk | #2 |
| euro138 | #2 |
| secondary efficiency | #2 |
| hasbled score hemorr2hages | #2 |
| subcutaneous length | #2 |
| inflammation neutrophils thrombosis | #2 |
| intermediate phenotype vte | #2 |
| prothrombin pulmonary embolism | #2 |
| pulmonary embolism asthma | #2 |
| events severe | #2 |
| angioplasty clopidogrel | #2 |
| thrombophilic disorders | #2 |
| risk anticoagulation therapy | #2 |
| surgical casts | #2 |
| major bleeding edoxaban | #2 |
| nct00633893 | #2 |
| single administration tb402 | #2 |
| uedvt performance | #2 |
| warfarintreated | #2 |
| administration rviia | #2 |
| heparin compounds | #2 |
| vte orthopedic surgery | #2 |
| cdr wells cdr | #2 |
| brain metastases doacs | #2 |
| efficiency original score | #2 |
| serum tnf activity | #2 |
| recombinant hirudin cgp | #2 |
| plasma concentrations endotoxin | #2 |
| analysis venous | #2 |
| enoxaparin warfarin | #2 |
| mutations cleavage sites | #2 |
| central localization | #2 |
| recurrent vte risk | #2 |
| lmwh efficacy | #2 |
| fibrinolysis pentoxifylline | #2 |
| resource utilisation treatment | #2 |
| standardised time intervals | #2 |
| crnm bleeds | #2 |
| idraparinux vitamin | #2 |
| pregnancy coc | #2 |
| venous thrombophlebitis | #2 |
| major bleeding cindexes | #2 |
| cancer recurrent vte | #2 |
| scan normal | #2 |
| mdct reference standard | #2 |
| c1173t dimorphism | #2 |
| pregnancy venous thrombosis | #2 |
| rule combined | #2 |
| primary healthcare secondary | #2 |
| duration anticoagulant | #2 |
| factor iia | #2 |
| clinical probability estimate | #2 |
| uedvt cancer patients | #2 |
| rivaroxaban 30 bid | #2 |
| travel venous | #2 |
| thrombophilic defects risk | #2 |
| risk deep | #2 |
| uptake noacs | #2 |
| ddimer determination | #2 |
| blood coagulation rnapc2 | #2 |
| extended constans score | #2 |
| vte 12 | #2 |
| hokusai vte | #2 |
| ufh 6 months | #2 |
| suspected pulmonary embolism | #2 |
| patients abi measurement | #2 |
| wells cdr patients | #2 |
| ageadjusted ddimer testing | #2 |
| nematode anticoagulant | #2 |
| venous | #2 |
| pulmonary embolism efficacy | #2 |
| absolute incidence | #2 |
| primary efficacy outcome | #2 |
| heparin administered | #2 |
| score dimer | #2 |
| sspe patients patients | #2 |
| vte 1000 personyears | #2 |
| 17 apixaban | #2 |
| normal ddimer test | #2 |
| exclusion pulmonary embolism | #2 |
| simplired test | #2 |
| failure rate strategy | #2 |
| 95 comparator individuals | #2 |
| pulmonary embolism purpose | #2 |
| principal safety outcome | #2 |
| patients oral factor | #2 |
| impedance plethysmography patients | #2 |
| n1423 | #2 |
| recurrent deep | #2 |
| computed venous | #2 |
| embolism deep | #2 |
| 20210a mutations | #2 |
| relevant patient subgroups | #2 |
| levothyroxine exposure | #2 |
| major bleeding recurrent | #2 |
| cha2ds2vasc nri | #2 |
| bleeding occurred | #2 |
| influenza coagulation | #2 |
| cancer addition | #2 |
| svt vte | #3 |
| 6575 years | #3 |
| inhibition blood coagulation | #3 |
| studies hemorrhage | #3 |
| ddimer assays | #3 |
| safety acenocoumarol | #3 |
| safely | #3 |
| 3633 patients | #3 |
| efficacy heparin | #3 |
| bleeding major | #3 |
| factors prothrombin | #3 |
| ft4 risk | #3 |
| introduction mdct | #3 |
| studies cus strategies | #3 |
| female humans inhibitors | #3 |
| vein thrombosis | #3 |
| incidence total vte | #3 |
| diagnosis pulmonary embolism | #3 |
| cancer randomised trials | #3 |
| patients 6575 years | #3 |
| deep vein | #3 |
| crt cancer patients | #3 |
| patients ultrasonography | #3 |
| proximalvein thrombosis | #3 |
| treatment vitamin antagonists | #3 |
| revised geneva efficiency | #3 |
| extensive screening | #3 |
| diagnosis deep | #3 |
| nct00643201 | #3 |
| subcutaneous fondaparinux | #3 |
| impedance predictive | #3 |
| definition perelated death | #3 |
| safely excluded | #3 |
| patients gastrointestinal cancer | #3 |
| dvt systematic differences | #3 |
| ventilation scan | #3 |
| predictable pharmacokinetics | #3 |
| female hemorrhage humans | #3 |
| monoclonal replacement | #3 |
| normal ctnt presentation | #3 |
| pulmonary embolism‐related death | #3 |
| prolactin controls | #3 |
| selectine | #3 |
| vte low | #3 |
| cancer patients ipe | #3 |
| gestalt 95 | #3 |
| idiopathic venous | #3 |
| platelet agents | #3 |
| vte performance | #3 |
| 3month vte incidence | #3 |
| iii deficiency | #3 |
| treatment low | #3 |
| enoxaparin follow | #3 |
| patients 6 months | #3 |
| cancer patients ate | #3 |
| oral hormonal cross | #3 |
| incidence enoxaparin | #3 |
| dvt einstein | #3 |
| axa activity | #3 |
| coagulation influence | #3 |
| rnapc2 fviia | #3 |
| activecontrol | #3 |
| 20210ga | #3 |
| recurrence thrombophlebitis | #3 |
| sensitivity compression | #3 |
| treatment vte recurrence | #3 |
| products follow | #3 |
| recurrent thromboembolic | #3 |
| heparin edoxaban | #3 |
| primary rule | #3 |
| safely exclude | #3 |
| knee factor | #3 |
| strategies efficiency | #3 |
| vte denmark | #3 |
| apc protective | #3 |
| patients venography | #3 |
| composite stroke | #3 |
| vte venous thrombosis | #3 |
| heparin heparin | #3 |
| venous arterial | #3 |
| clinical models patients | #3 |
| treatment lowmolecularweight heparin | #3 |
| low probability models | #3 |
| dalteparin difference | #3 |
| thrombophlebitis treatment | #3 |
| thiophenes venous | #3 |
| venous thromboembolism thrombophilia | #3 |
| lmwh pph | #3 |
| dvt primary | #3 |
| dose reduction edoxaban | #3 |
| older children vte | #3 |
| mutation venous | #3 |
| dip placebo | #3 |
| primary wells rule | #3 |
| detection dvt | #3 |
| placebo n4 | #3 |
| lowmolecularweight humans length | #3 |
| stable acute | #3 |
| vte 3 | #3 |
| protein thrombophilia | #3 |
| administration rnapc2 | #3 |
| recombinant hirudin rhir | #3 |
| incidental pulmonary embolism | #3 |
| users incidence | #3 |
| chemotherapy prophylaxis | #3 |
| idrabiotaparinux | #3 |
| venous thromboembolism apixaban | #3 |
| coagulation air travel | #3 |
| ddimer threshold | #3 |
| bleeding 3 | #3 |
| gestalt probability | #3 |
| patients proximalvein thrombosis | #3 |
| 100 years year | #3 |
| venous thrombosis positive | #3 |
| dimer blood | #3 |
| venous thrombosis cancer | #3 |
| prevalence hemostatic abnormalities | #3 |
| wells rule dvt | #3 |
| pulmonary embolism gestalt | #3 |
| ctnt risk stratification | #3 |
| lmwh | #3 |
| therapy venous | #3 |
| simplified wells specificity | #3 |
| cdr combination | #3 |
| negative predictive proportion | #3 |
| patients wells | #3 |
| hokusai‐vte | #3 |
| wells rule gestalt | #3 |
| hasbled | #3 |
| death clinical studies | #3 |
| cohort study employees | #3 |
| mechanisms heparin | #3 |
| favour lmwh | #3 |
| outpatient treatment dvt | #3 |
| pph lmwh | #3 |
| hf severity risk | #3 |
| patients incidental vte | #3 |
| idrabiotaparinux warfarin | #3 |
| capillary blood sample | #3 |
| dvt major | #3 |
| multiple comorbidities polypharmacy | #3 |
| embolism‐related | #3 |
| venous thromboembolism | #3 |
| prevalence avws | #3 |
| subcutaneous lmwh | #3 |
| cardiac troponine | #3 |
| lowmolecularweight heparin placebo | #3 |
| outpatients dvt | #3 |
| tfindependent | #3 |
| dvt hip | #3 |
| outcome venous | #3 |
| nadroparin placebo | #3 |
| patients ft4 level | #3 |
| discontinuation ufh | #3 |
| single diagnostic | #3 |
| travel venous thrombosis | #3 |
| vte major burden | #3 |
| tinaquant assay | #3 |
| pulmonary embolism primary | #3 |
| 3month incidence | #3 |
| age annual incidence | #3 |
| intravenous loading dose | #3 |
| ultrasonography strategies | #3 |
| fxiaso | #3 |
| presenting location | #3 |
| 02011 | #3 |
| influence heparins | #3 |
| failurerate | #3 |
| standard therapy treatment | #3 |
| atria hemorr2hages | #3 |
| thrombophilic defect | #3 |
| topic heparin heparin | #3 |
| 95 wells rule | #3 |
| baseline values placebo | #3 |
| endogenous apc | #3 |
| healthy donor fmt | #3 |
| einstein patients | #3 |
| ipe cancer patients | #3 |
| thombosis | #3 |
| tb‐402 | #3 |
| combination wells score | #3 |
| heparins cancer | #3 |
| diagnosis pulmonary | #3 |
| time venous thrombosis | #3 |
| “gestalt | #3 |
| probability dimer | #3 |
| einstein studies | #3 |
| thromboembolism low | #3 |
| 12month study period | #3 |
| warfarin subgroup | #3 |
| alternative diagnoses | #3 |
| approaches primary | #3 |
| plethysmography impedance | #3 |
| cancer active cancer | #3 |
| patients venous | #3 |
| normal result | #3 |
| pulmonary embolism models | #3 |
| adult patients vte | #3 |
| pad smokers | #3 |
| einstein dvt | #3 |
| antithrombin iii concentrate | #3 |
| factor viiic | #3 |
| thromboembolism background | #3 |
| treatment vka | #3 |
| desogestrelcontaining | #3 |
| venous thrombosis travel | #3 |
| compensated dic | #3 |
| cleavage sites apc | #4 |
| netherlands pulmonary | #4 |
| vte treatment patients | #4 |
| 3587 | #4 |
| oral rivaroxaban | #4 |
| venous thrombosis levels | #4 |
| chinese korean ethnicity | #4 |
| venography patients | #4 |
| rule pulmonary | #4 |
| preexisting heparin | #4 |
| sankyo | #4 |
| thromboembolism study | #4 |
| hyperhomocysteinemic relatives | #4 |
| total vte | #4 |
| thrombosis symptomatic | #4 |
| patients dimer | #4 |
| vka treatment | #4 |
| dimer assays | #4 |
| extended treatment | #4 |
| vitamin antagonist treatment | #4 |
| 35±4 | #4 |
| vte global burden | #4 |
| 335 patients | #4 |
| mbe patients | #4 |
| daily netilmicin | #4 |
| warfarin 3 months | #4 |
| primary failure rate | #4 |
| venous thromboembolism patients | #4 |
| patients primary healthcare | #4 |
| fibrin generation test | #4 |
| ultrasonography venous | #4 |
| dose noacs | #4 |
| noacs netherlands | #4 |
| impedance plethysmography | #4 |
| refuted | #4 |
| thromboembolism factor | #4 |
| received warfarin | #4 |
| patients edoxaban | #4 |
| travel thrombosis | #4 |
| symptomatic deep | #4 |
| clinically relevant bleeding | #4 |
| predilution postdilution | #4 |
| women normal levels | #4 |
| clot resolution | #4 |
| thromboembolism systematic | #4 |
| lowmolecularweight heparin | #4 |
| global burden vte | #4 |
| vte netherlands | #4 |
| lmwhs standard heparin | #4 |
| patients nonpermanent | #4 |
| serial impedance | #4 |
| bleeding anticoagulants | #4 |
| diagnosis uedvt | #4 |
| patients crcl 60 | #4 |
| safety pravastatin | #4 |
| patients clinically | #4 |
| thrombosis ischemic stroke | #4 |
| death survey | #4 |
| embolism roc | #4 |
| global disease burden | #4 |
| disease vte | #4 |
| embolism background | #4 |
| enoxaparin female humans | #4 |
| prophylaxis lmwh | #4 |
| vte total | #4 |
| vte global | #4 |
| edoxaban patients | #4 |
| procoagulant factors | #4 |
| enoxaparin day | #4 |
| thrombophilia 95 | #4 |
| hemorr2hages | #4 |
| series venograms | #4 |
| women apc resistance | #4 |
| risk vkas | #4 |
| thromboembolism arterial | #4 |
| treatment unfractionated heparin | #4 |
| vitamin antagonists | #4 |
| 10172 | #4 |
| postthrombotic symptoms | #4 |
| patients fondaparinux | #4 |
| vitamin antagonists patients | #4 |
| 150 microg desogestrel | #4 |
| noacs cancer patients | #4 |
| negative point | #4 |
| amadeus trial | #4 |
| patient category | #4 |
| embolism dimer | #4 |
| episode venous | #4 |
| diagnostic management strategies | #4 |
| ageadjusted cutoff patients | #4 |
| patients venous thromboembolism | #4 |
| estrogen therapy patients | #4 |
| thrombosis deep | #4 |
| activation fibrinolytic | #4 |
| clot lysis patients | #4 |
| protecht | #4 |
| patients submassive | #4 |
| life duration | #4 |
| risk occult cancer | #4 |
| point dimer | #4 |
| rivaroxaban 20 | #4 |
| measurement abi | #4 |
| dutch orthopedic | #4 |
| population rivaroxaban | #4 |
| hemostatic profile | #4 |
| leiden carriers | #4 |
| arterial thrombotic | #4 |
| lmwh female heparin | #4 |
| thrombophilic families | #4 |
| diagnostic prediction models | #4 |
| doac studies | #4 |
| idiopathic venous thrombosis | #4 |
| chromogenic compounds | #4 |
| 150 microg levonorgestrel | #4 |
| pregnancies carriers | #4 |
| levels ft4 | #4 |
| patients alternative diagnosis | #4 |
| cancer vwf | #4 |
| proximal patients | #4 |
| control anticoagulation | #4 |
| thromboembolism vitamin | #4 |
| 6 months prophylaxis | #4 |
| disease burden vte | #4 |
| “reversal | #4 |
| primary pulmonary embolism | #4 |
| rfviia injection | #4 |
| abdomen relationship | #4 |
| thromboembolism occurred | #4 |
| criteria dose reduction | #4 |
| coagulation endotoxin | #4 |
| ddimer assay patients | #4 |
| chemotherapy vte prophylaxis | #4 |
| chads2 p0001 | #4 |
| lowmolecular weight heparins | #4 |
| questionnaires venous | #4 |
| gramnegative bacteria humans | #4 |
| vte highincome countries | #4 |
| embolism tomography | #4 |
| thrombosis air | #4 |
| tinaquant | #4 |
| nct00571649 | #4 |
| thromboembolism treatment | #4 |
| probability prospective | #4 |
| chemotherapy shr | #4 |
| 0651 | #4 |
| patient education treatment | #4 |
| coagulation factors risk | #4 |
| lmwh cancer patients | #4 |
| recurrent vte months | #4 |
| rviia thrombin generation | #4 |
| serial impedance plethysmography | #4 |
| apixaban efficacy | #4 |
| thrombosis uedvt | #4 |
| advanced cancer 95 | #4 |
| contraindications treatment | #4 |
| diagnostic management | #4 |
| vte 6 | #5 |
| secondary dvt | #5 |
| transfusion blood loss | #5 |
| consensus strategy | #5 |
| thromboembolism idraparinux | #5 |
| panwards | #5 |
| dvt prevalence | #5 |
| diagnostic strategies | #5 |
| preschool contraceptives | #5 |
| bleeding cancer | #5 |
| pulmonary embolism patients | #5 |
| lmwh incidence | #5 |
| fviii families | #5 |
| hirudin treatment | #5 |
| outcome major | #5 |
| ft4 level | #5 |
| patients wells score | #5 |
| treatment acute dvt | #5 |
| thrombosis leg | #5 |
| pregnancy pph | #5 |
| rivaroxaban enoxaparin vka | #5 |
| patients subtherapeutic | #5 |
| thrombosis upper | #5 |
| patients parenteral anticoagulants | #5 |
| normal ctpa | #5 |
| lmwh recommended | #5 |
| fviia rnapc2 | #5 |
| venous thromboembolism studies | #5 |
| ventricular dysfunction echocardiography | #5 |
| vka patients | #5 |
| suspected uedvt | #5 |
| cancer strategy | #5 |
| patients recurrent dvt | #5 |
| upper extremity thrombosis | #5 |
| recurrent dvt patients | #5 |
| exclusion venous thromboembolism | #5 |
| factor leiden 95 | #5 |
| clinical probability assessment | #5 |
| daiichi sankyo | #5 |
| incidence prognostic significance | #5 |
| day rivaroxaban | #5 |
| clinical presentation clinical | #5 |
| fh patients cvd | #5 |
| southern latin america | #5 |
| netilmicin patients | #5 |
| secondary venous thrombosis | #5 |
| patients pulmonary embolism | #5 |
| sensitivity negative predictive | #5 |
| asymptomatic carriers mutation | #5 |
| 8491 | #5 |
| coc pregnancy | #5 |
| repeated ultrasonography | #5 |
| treatment fondaparinux | #5 |
| efficiency patients | #5 |
| gestalt | #5 |
| cdr patients | #5 |
| clinical probability | #5 |
| vte patients cancer | #5 |
| thromboembolism studies | #5 |
| inhibition plasminogen activation | #5 |
| low molecularweight humans | #5 |
| low‐molecular‐weight | #5 |
| thrombophlebitis ultrasonography | #5 |
| diagnosis questionnaire | #5 |
| iii plasminogen | #5 |
| elevated plasma level | #5 |
| embolism reproducibility | #5 |
| adjusted dimer | #5 |
| molecularweight heparin | #5 |
| thromboembolism thrombosis | #5 |
| isolated calfvein thrombosis | #5 |
| hokusai | #5 |
| compression ultrasound | #5 |
| thrombosis primary | #5 |
| endogenous activated | #5 |
| predilution | #5 |
| deepvein thrombosis | #5 |
| specificity thrombophlebitis | #5 |
| coronary angioplasty angioplasty | #5 |
| endotoxin testing | #5 |
| previous venous thromboembolism | #5 |
| outpatients hospital | #5 |
| risk prediction scores | #5 |
| medea study | #5 |
| severe pph women | #5 |
| pad smoking | #5 |
| dimer combination | #5 |
| patients superficial thrombophlebitis | #5 |
| thromboembolism | #5 |
| cgp 39393 | #5 |
| women warfarin | #5 |
| heparin compared | #5 |
| vte factor | #5 |
| burden vte | #5 |
| phlebography plethysmography | #5 |
| endotoxin chimpanzees | #5 |
| 8292 | #5 |
| 2 rules | #5 |
| antithrombotic drug treatment | #5 |
| blood coagulation mechanism | #6 |
| thrombosis guidelines | #6 |
| simplired dimer | #6 |
| outcome occurred | #6 |
| subcutaneous nadroparin | #6 |
| lmwh cancer | #6 |
| d‐dimer testing | #6 |
| risk khorana score | #6 |
| clinically relevant subgroups | #6 |
| effects ufh | #6 |
| myocardial infarction ctni | #6 |
| grade 1a ufh | #6 |
| lmwh users users | #6 |
| perioperative blood loss | #6 |
| efficiency proportion | #6 |
| fviia inhibition | #6 |
| embolism pulmonary | #6 |
| patients tests | #6 |
| patients anticoagulation clinic | #6 |
| c1173 | #6 |
| factor leiden carriers | #6 |
| women hyperhomocysteinemia | #6 |
| proportion cancer patients | #6 |
| symptoms intermittent claudication | #6 |
| apixaban treatment dose | #6 |
| conventional therapy treatment | #6 |
| compression stockings patients | #6 |
| cancer primary patients | #6 |
| dimer cut | #6 |
| severe antithrombin | #6 |
| 39393 | #6 |
| levonorgestrel desogestrel | #6 |
| enoxaparin incidence | #6 |
| patients pulmonary angiography | #6 |
| treatment intermittent claudication | #6 |
| initial heparin treatment | #6 |
| funding bayer | #6 |
| vka | #6 |
| dvt trial | #6 |
| pulmonary embolism presence | #6 |
| vte controls | #6 |
| warfarin venous thromboembolism | #6 |
| thrombophilic defects | #6 |
| fixeddose regimen | #6 |
| low absolute risk | #6 |
| probability pulmonary | #6 |
| endotoxin assays | #6 |
| wells rule | #6 |
| standardized morbidity ratio | #6 |
| vte anticoagulant treatment | #6 |
| recurrent pulmonary | #6 |
| patients lowmolecularweight heparin | #6 |
| patients suspected | #6 |
| 393 patients | #6 |
| antagonists treatment | #6 |
| thromboembolism bleeding | #6 |
| oral edoxaban | #6 |
| subcutaneous low | #6 |
| effects levonorgestrel | #6 |
| ft4 patients | #6 |
| diagnostic workup | #6 |
| severe dic | #6 |
| oral anticoagulants dabigatran | #6 |
| combined utility | #6 |
| assay fibrin | #6 |
| anticoagulants hemorrhage | #6 |
| amplify | #6 |
| treatment pulmonary embolism | #6 |
| patients diagnostic | #6 |
| selective beta | #6 |
| patients proximal | #6 |
| pembqol questionnaire | #6 |
| endotoxininduced activation | #6 |
| leiden | #6 |
| 10±4 | #6 |
| anticoagulants female | #6 |
| duration rivaroxaban | #6 |
| synthetic pentasaccharides | #6 |
| arterial cardiovascular | #6 |
| svt extension | #6 |
| neoplasms pulmonary embolism | #6 |
| repeatedly normal | #6 |
| treatment svt | #6 |
| patients iohexol | #6 |
| stressinduced hyperglycaemia | #6 |
| subjects vte | #6 |
| incidence recurrence | #6 |
| 12month cumulative incidence | #6 |
| daily gentamicin | #6 |
| treatment ufh | #6 |
| patients uedvt | #6 |
| dalteparin dose | #6 |
| risk increasing levels | #6 |
| dabigatran etexilate dabigatran | #6 |
| venograms | #6 |
| rate major bleeding | #6 |
| embolism ventricular | #6 |
| patients factor mutation | #6 |
| symptomatic legs | #6 |
| ultrasonography normal | #6 |
| elisapositive | #6 |
| prevalence vte | #6 |
| 049 95 | #6 |
| isolated deficiencies | #6 |
| anticoagulant treatment | #6 |
| edoxaban efficacy | #6 |
| vte cancer | #6 |
| carriers defects | #7 |
| specific antidotes | #7 |
| venous thrombosis treatment | #7 |
| nondiagnostic lung scans | #7 |
| dvt ipg | #7 |
| thromboembolism vte | #7 |
| etexilate oral | #7 |
| negative predictive npv | #7 |
| blood coagulation humans | #7 |
| day initial treatment | #7 |
| aspirin combined | #7 |
| patients standard heparin | #7 |
| arterial cardiovascular disease | #7 |
| recurrent dvt | #7 |
| rates edoxaban | #7 |
| doppler skin | #7 |
| treatment doac | #7 |
| perelated death | #7 |
| placebo rivaroxaban | #7 |
| ottawa score | #7 |
| combination ipg | #7 |
| noncompressibility | #7 |
| proportion older patients | #7 |
| neoplasms pulmonary | #7 |
| heparin org | #7 |
| thromboembolism adult | #7 |
| deepvein thrombosis patients | #7 |
| vitamin antagonists vka | #7 |
| pulmonary embolism sensitivity | #7 |
| mutations factor viii | #7 |
| negative ddimer test | #7 |
| anticoagulant parameters | #7 |
| spiral sensitivity | #7 |
| unselected women | #7 |
| vte cancer diagnosis | #7 |
| leg ultrasonography | #7 |
| general practitioners guideline | #7 |
| major bleeding rate | #7 |
| major bleeding vkas | #7 |
| stockings control | #7 |
| statin treatment risk | #7 |
| levels factor viii | #7 |
| 220 dabigatran | #7 |
| thrombophlebitis adolescent | #7 |
| incidence recurrent vte | #7 |
| diagnosis venous thrombosis | #7 |
| ufh treatment | #7 |
| rivaroxaban 10 | #7 |
| thrombophilia pregnancy loss | #7 |
| coagulation humans | #7 |
| relation prolactin levels | #7 |
| 680 | #7 |
| inhibitor apixaban | #7 |
| 597939 | #7 |
| relation levels | #7 |
| vka therapy | #7 |
| prothrombin risk | #7 |
| phenprocoumon polymorphism | #7 |
| silent pulmonary embolism | #7 |
| major bleeding | #7 |
| mpc1609 | #7 |
| diagnostic suspicion | #7 |
| thromboembolism total | #7 |
| plasma levels ifngamma | #7 |
| factor female humans | #7 |
| carriers venous thromboembolism | #7 |
| presence cteph | #7 |
| primary efficacy | #7 |
| antithrombin protein | #7 |
| embolism prospective | #7 |
| tnf injection | #7 |
| protein protein deficiencies | #7 |
| tb402 | #7 |
| primary dvt | #7 |
| lung scan | #7 |
| administration bsf | #7 |
| anticoagulation unprovoked vte | #8 |
| increased fibrinolytic | #8 |
| arg506 factor | #8 |
| unprovoked vte patients | #8 |
| aged phlebography | #8 |
| duration treatment | #8 |
| recurrent vte bleeding | #8 |
| products humans | #8 |
| 150 enoxaparin | #8 |
| tests pulmonary | #8 |
| administration low | #8 |
| levonorgestrelcontaining | #8 |
| warfarin hazard ratio | #8 |
| occult cancer patients | #8 |
| leiden prothrombin | #8 |
| v617f jak2 | #8 |
| treatment venous thrombosis | #8 |
| vka lmwh | #8 |
| prevention vte | #8 |
| analysis apixaban | #8 |
| risk employees | #8 |
| 1599 patients | #8 |
| severe preeclampsia patients | #8 |
| overt cancer | #8 |
| anticoagulants antineoplastic | #8 |
| enoxaparin vka | #8 |
| cancer pulmonary embolism | #8 |
| p0001 hasbled score | #8 |
| 97 95 | #8 |
| years cumulative incidence | #8 |
| point ultrasonography | #8 |
| patients symptomatic vte | #8 |
| oac adherence | #8 |
| contrast venography | #8 |
| consecutive outpatients | #8 |
| wells scores | #8 |
| current approach | #8 |
| funding daiichi | #8 |
| international organisations | #8 |
| fxi aso | #8 |
| nafronyl | #8 |
| venous thrombosis hyperhomocysteinaemia | #8 |
| vascular endothelial barrier | #8 |
| deficiency antithrombin | #8 |
| proximal deep | #8 |
| low clinical probability | #8 |
| xii deficient | #8 |
| inr determination | #8 |
| proximal deepvein thrombosis | #8 |
| normal computed | #8 |
| ufh initial treatment | #8 |
| ageadjusted ddimer cutoff | #8 |
| pvoct | #8 |
| recurrent vte mb | #8 |
| objectively confirmed | #8 |
| homocysteine markers | #8 |
| chemotherapy low risk | #8 |
| lmwh grade 1a | #8 |
| apixaban enoxaparin | #8 |
| probability lung | #8 |
| carriers fvl | #8 |
| heparin vitamin antagonists | #8 |
| oral glucocorticoids risk | #8 |
| initial heparin | #8 |
| comorbidity polypharmacy | #8 |
| prospective management | #8 |
| testing rule | #8 |
| thrombosis prophylaxis | #8 |
| patients excluded | #8 |
| inherited thrombophilic | #8 |
| compression surveys | #8 |
| euro55 | #8 |
| dimer concentration | #8 |
| structured algorithm | #8 |
| symptomatic deepvein thrombosis | #8 |
| optimal intensity | #8 |
| risks dvt | #8 |
| vitamin antagonists vkas | #8 |
| thrombosis adolescent | #8 |
| acute symptomatic vte | #8 |
| oral apixaban | #8 |
| discontinuation anticoagulant treatment | #8 |
| inr values patients | #8 |
| nondiagnostic scan | #8 |
| dimer tests | #8 |
| agnelli | #8 |
| bnp ctnt | #8 |
| physicians stockings | #8 |
| 0·2 | #8 |
| patients extended anticoagulation | #8 |
| persistent risk factors | #8 |
| vte score | #8 |
| cancer factor | #9 |
| characteristics severity | #9 |
| major bleeding treatment | #9 |
| patients active cancer | #9 |
| crcl 60 | #9 |
| placebo plasma levels | #9 |
| comorbidities polypharmacy | #9 |
| incidental pulmonary | #9 |
| serotonin platelet | #9 |
| lmwh mortality | #9 |
| acute medical illnesses | #9 |
| bled bleeding | #9 |
| discontinuing anticoagulation | #9 |
| treatment edoxaban | #9 |
| embolism venous | #9 |
| therapeutic dose patients | #9 |
| enoxaparin factor | #9 |
| atiii concentrates | #9 |
| thrombosis compared | #9 |
| thrombosis venous thromboembolism | #9 |
| male oligosaccharides | #9 |
| heparin therapy patients | #9 |
| oral antithrombins | #9 |
| thrombosis thromboinflammation | #9 |
| apixaban oral factor | #9 |
| cancer episode | #9 |
| vte relatives | #9 |
| compression stockings prevention | #9 |
| patients fxa inhibitors | #9 |
| prothrombin 20210a | #9 |
| treatment prophylaxis | #9 |
| combination stroke | #9 |
| generation pill | #9 |
| tafi levels | #9 |
| strategies dimer | #9 |
| postdilution | #9 |
| abnormal vaginal | #9 |
| factors thrombophlebitis | #9 |
| lipoproteina women | #9 |
| edoxaban major bleeding | #9 |
| weight heparin | #9 |
| vte rcts | #9 |
| hemorr2hages atria | #9 |
| carriers factor leiden | #9 |
| oral contraceptive pregnancy | #9 |
| fondaparinux cancer patients | #9 |
| cofact | #9 |
| concomitant cancer | #9 |
| cancer cell extravasation | #9 |
| fxa inhibitor | #9 |
| diagnosis mdct | #9 |
| anticoagulant pathways | #9 |
| diagnostic prediction model | #9 |
| büller | #9 |
| homocysteine women | #9 |
| method enoxaparin | #9 |
| incidence postthrombotic syndrome | #9 |
| normal ddimer | #9 |
| ultrasonogram | #9 |
| nonpermanent | #9 |
| months efficacy | #9 |
| iii concentrate | #9 |
| independent committee | #9 |
| longterm treatment vte | #9 |
| daiichisankyo | #9 |
| thromboembolism cancer | #9 |
| cancer patients lmwh | #10 |
| venous thrombosis | #10 |
| factor levels patients | #10 |
| leg veins | #10 |
| thr incidence | #10 |
| magellan study | #10 |
| oral administration dabigatran | #10 |
| treatment vitamin | #10 |
| extremity deep | #10 |
| rabbits administration | #10 |
| 100 years discontinuation | #10 |
| major bleeding crnmb | #10 |
| lmwh studies | #10 |
| embolism clinical | #10 |
| dvt lower extremity | #10 |
| hypocoagulable state | #10 |
| year years | #10 |
| retrospective study efficacy | #10 |
| factor prevention | #10 |
| inr cases | #10 |
| inherited thrombophilic factors | #10 |
| incidence major bleeding | #10 |
| bled scores | #10 |
| patients endotoxemia | #10 |
| animal heparin | #10 |
| subcutaneous metaanalysis | #10 |
| thrombophlebitis adult | #10 |
| induced coagulation | #10 |
| treatment uedvt | #10 |
| rfviia blood loss | #10 |
| venous thromboembolic event | #10 |
| oral thrombin inhibitor | #10 |
| ageadjusted cutoff | #10 |
| schedule heparin | #10 |
| simplified geneva | #10 |
| incidence 1000 personyears | #10 |
| asymptomatic pulmonary embolism | #10 |
| cus diagnosis | #10 |
| normohomocysteinemic | #10 |
| rates recurrent vte | #10 |
| aged antithrombin | #10 |
| cancer patients vte | #10 |
| injection avidin | #10 |
| deficiencies antithrombin | #10 |
| probability pulmonary embolism | #10 |
| cvd fh patients | #10 |
| nadroparine | #10 |
| treatment aprotinin | #10 |
| crp test | #10 |
| intimamedia thickness imt | #10 |
| thrombosis background | #10 |
| snp scores | #10 |
| anticoagulants | #10 |
| embolism patients | #10 |
| vte efficacy | #10 |
| wells | #10 |
| ddimer concentration | #10 |
| magellan trial | #10 |
| severity clinical | #10 |
| single loss | #10 |
| fondaparinux risk | #10 |
| heparin nomogram | #10 |
| 598 patients | #10 |
| 4470 | #10 |
| patients venous thrombosis | #10 |
| fii mutation | #10 |
| protein dic | #10 |
| vnv | #10 |
| gramnegative septicemia | #10 |
| 1215 patients | #10 |
| pregnancy carriers | #10 |
| patients cancer vte | #11 |
| pregnancyrelated complications | #11 |
| fondaparinux hemorrhage | #11 |
| cancer patients evidence | #11 |
| lmwh pregnancy | #11 |
| dvt | #11 |
| clinical pretest | #11 |
| reference testing | #11 |
| screening cancer | #11 |
| crnmb 95 | #11 |
| pyridines thiazoles | #11 |
| carriers factor | #11 |
| ufh studies | #11 |
| 880 patients | #11 |
| intensity anticoagulation | #11 |
| 750 μg | #11 |
| oral dabigatran | #11 |
| thromboembolism major | #11 |
| incidence major | #11 |
| recombinant human tnf | #11 |
| dabigatran enoxaparin | #11 |
| ldfr | #11 |
| pulmonary embolism incidence | #11 |
| sulfates dermatan | #11 |
| weight humans | #11 |
| gps training | #11 |
| org 10172 | #11 |
| endotoxin pentoxifylline | #11 |
| patients cvcs | #11 |
| levels prolactin | #11 |
| cancer patients dvt | #11 |
| patients anticoagulant treatment | #11 |
| gentamicin treatment patients | #11 |
| patients probability | #11 |
| pcc dabigatran | #11 |
| embolism recurrence | #11 |
| hospital lmwh | #11 |
| haemophilia vwd | #11 |
| air travel | #11 |
| heparinoid org | #11 |
| inhibitors hemorrhage | #11 |
| vte vwf | #11 |
| pulmonary angiography venography | #11 |
| factor venous | #11 |
| medical conferences | #11 |
| lmwh pregnancies | #11 |
| embolism prevalence | #11 |
| knee clinical trials | #11 |
| variation inr | #11 |
| adult anticoagulants | #11 |
| d‐dimer levels | #11 |
| previous venous | #11 |
| edoxaban | #11 |
| mutations prevalence | #11 |
| combination dimer | #11 |
| 30 microg ethinylestradiol | #11 |
| endotoxin assay | #11 |
| proximal veins | #12 |
| pioped study | #12 |
| factor leiden prothrombin | #12 |
| peghirudin | #12 |
| 9295 | #12 |
| humanized arthroplasty | #12 |
| subsegmental pulmonary emboli | #12 |
| venous thromboembolism incidence | #12 |
| vka noacs | #12 |
| control metaanalysis | #12 |
| outcomes venous thromboembolism | #12 |
| patients incidental | #12 |
| recurrent vte | #12 |
| doseadjustment | #12 |
| vte recurrence risk | #12 |
| fondaparinux unfractionated heparin | #12 |
| geneva score | #12 |
| concomitant disorders | #12 |
| months primary | #12 |
| thrombosis dvt | #12 |
| recurrent vte anticoagulation | #12 |
| stopping anticoagulation | #12 |
| livebirth rate | #12 |
| outpatient management patients | #12 |
| anticoagulant factor | #12 |
| noacs vka | #12 |
| annual incidence vte | #12 |
| treatment crt | #12 |
| proximal vein | #12 |
| female heparin humans | #12 |
| thrombin generation fibrinolysis | #12 |
| hirulog1 | #12 |
| event recurrence | #12 |
| observation risk | #12 |
| warfarin treated | #12 |
| ageadjusted ddimer | #12 |
| patients lupus anticoagulant | #12 |
| anticoagulation unprovoked | #12 |
| safety efficiency | #12 |
| warfarin therapy inr | #12 |
| nephro | #12 |
| warfarin recurrent vte | #12 |
| topic venous | #12 |
| hemodynamically stable | #12 |
| 72 children | #12 |
| bnp cardiac troponin | #12 |
| bayer schering pharma | #12 |
| thrombophilic | #12 |
| dvt treatment | #12 |
| patients lmwhs | #12 |
| perelated | #12 |
| 9702 | #12 |
| crd42013003526 | #12 |
| deficient women | #12 |
| prevention venous thrombosis | #12 |
| risk venous | #12 |
| women factor | #12 |
| paulin | #12 |
| major hip | #13 |
| antithrombin iii activity | #13 |
| levels factor | #13 |
| safety doacs | #13 |
| time prothrombin | #13 |
| obesity haemophilia patients | #13 |
| 95 carriers | #13 |
| spiral computed tomography | #13 |
| concomitant antiplatelet therapy | #13 |
| dimer testing | #13 |
| inferiority efficacy | #13 |
| vte female humans | #13 |
| nct00986154 | #13 |
| pselectin patients | #13 |
| daily subcutaneous | #13 |
| inhibition tnf | #13 |
| dabigatran vte | #13 |
| clinical decision rules | #13 |
| category studies | #13 |
| vte | #13 |
| arterial thromboembolism ate | #13 |
| thrombosis acute | #13 |
| vte groups | #13 |
| thrombosis young | #13 |
| superficial thrombophlebitis | #13 |
| randomized cross | #13 |
| heparin low | #13 |
| dimer threshold | #13 |
| groups inr | #13 |
| plethysmograms | #13 |
| ufh dalteparin | #13 |
| continuous intravenous heparin | #13 |
| bleeding events edoxaban | #13 |
| safety oral | #13 |
| bayer healthcare | #13 |
| strain gauge plethysmography | #13 |
| dvt lower | #13 |
| patients anticoagulant | #13 |
| hematologic pregnancy trimester | #13 |
| arixtra | #13 |
| uedvt | #13 |
| conventional anticoagulants | #13 |
| association venous thrombosis | #13 |
| vte 64 | #13 |
| vte major | #13 |
| plethysmography | #13 |
| dabigatran 220 | #13 |
| rivaroxaban thiophenes | #13 |
| factor viii apc | #13 |
| deepvein thrombosis dvt | #13 |
| treatment venous thromboembolism | #13 |
| marder score | #13 |
| recombinant hirudin rhirudin | #13 |
| 86 percent | #13 |
| selective testing | #13 |
| indication anticoagulation | #13 |
| prevention venous thromboembolism | #13 |
| vte recurrence 95 | #13 |
| occult cancer | #13 |
| factor leiden mutation | #13 |
| patients thrombophilia | #13 |
| recurrent venous | #14 |
| factor viii levels | #14 |
| vte statin | #14 |
| 12 kg1 | #14 |
| treated lmwh | #14 |
| edoxaban warfarin | #14 |
| patients outpatients | #14 |
| bolus intravenous injection | #14 |
| standard heparin | #14 |
| ultrasound strategies | #14 |
| anticoagulant rivaroxaban | #14 |
| doseranging study | #14 |
| treatment duration patients | #14 |
| patients acute vte | #14 |
| aged plethysmography | #14 |
| gastrointestinal bleeding patients | #14 |
| aged anticoagulants | #14 |
| atiii deficiency | #14 |
| thrombosis | #14 |
| dvt lower extremities | #14 |
| unprovoked vte vte | #14 |
| patients vka therapy | #14 |
| pregnancy venous | #14 |
| thrombophilia patients | #14 |
| safety edoxaban | #14 |
| higher ddimer levels | #14 |
| vte months | #14 |
| low molecular | #14 |
| revised geneva | #14 |
| 17 placebo | #14 |
| lmwh vka | #14 |
| limited screening | #14 |
| riete score | #14 |
| female fibrin | #14 |
| plasminogen apoa | #14 |
| aspirin women | #14 |
| incidence severe pph | #14 |
| obstetric complications women | #14 |
| fvl carriers | #14 |
| edoxaban oral factor | #14 |
| acute deep | #14 |
| crnm | #14 |
| effects hyperthyroidism | #14 |
| cancer patients anticoagulation | #14 |
| placebo rfviia | #14 |
| loss women | #14 |
| awareness pad | #14 |
| thromboembolism age | #14 |
| conventionaltherapy | #14 |
| experimental endotoxaemia | #14 |
| patients dvt | #14 |
| symptomatic pulmonary | #14 |
| cadherins endothelium | #14 |
| recurrent venous thromboembolism | #14 |
| costs dvt | #14 |
| cteph incidence | #15 |
| abdominal pelvic | #15 |
| thrombinography | #15 |
| studies pulmonary | #15 |
| thyroid hormone excess | #15 |
| patients ctpa | #15 |
| factor leiden | #15 |
| control subjects prevalence | #15 |
| doacs aspirin | #15 |
| activation contact | #15 |
| hyperthyroidism atrial fibrillation | #15 |
| enoxaparin vte | #15 |
| edoxaban treatment | #15 |
| primary safety outcome | #15 |
| thrombosis diagnosis | #15 |
| generation oral | #15 |
| prophylaxis venous thromboembolism | #15 |
| inr range | #15 |
| treatment 12 months | #15 |
| diagnosis venous | #15 |
| pregnancy outcome pregnancy | #15 |
| inr patient | #15 |
| lmwh ufh | #15 |
| thrombus growth | #15 |
| vitaminkantagonists | #15 |
| antagonist vka | #15 |
| cardiovascular diseases thrombosis | #15 |
| coagulation | #15 |
| fondaparinux efficacy | #15 |
| arg506 | #15 |
| lomoparan | #15 |
| anticoagulants patients | #15 |
| symptomatic events | #15 |
| khorana score | #15 |
| clinically relevant endpoints | #15 |
| patients vitamin antagonists | #15 |
| experimental thrombosis | #15 |
| 500 pg | #15 |
| established vte | #15 |
| recombinant factor viia | #15 |
| arg562 | #15 |
| probability assessment | #15 |
| subcutaneous enoxaparin | #15 |
| coc vte | #15 |
| oral direct factor | #15 |
| subcutaneous regimen | #15 |
| prior venous thromboembolism | #15 |
| vte khorana score | #16 |
| factor inhibitor | #16 |
| analysis rivaroxaban | #16 |
| vterelated death | #16 |
| 100 95 | #16 |
| thromboembolism time | #16 |
| major bleeding anticoagulation | #16 |
| bleeding aged | #16 |
| major bleeding events | #16 |
| subsequent pregnancy loss | #16 |
| factors major | #16 |
| netilmicin gentamicin | #16 |
| thrombosis adult | #16 |
| postthrombotic syndrome children | #16 |
| 6 months placebo | #16 |
| combination clinical | #16 |
| test clinical | #16 |
| warfarin acenocoumarol | #16 |
| impaired fibrinolysis | #16 |
| deep venous thrombosis | #16 |
| dvt lmwh | #16 |
| venous thrombosis warfarin | #16 |
| ddimer levels patients | #16 |
| occult cancer detection | #16 |
| cancer cancer patients | #16 |
| recurrent symptomatic | #16 |
| thrombosis association | #16 |
| positivity threshold | #16 |
| thrombosis low | #16 |
| thrombosis haemostasis | #16 |
| viia activity | #16 |
| arterial vascular events | #16 |
| women unexplained | #16 |
| abdomino | #16 |
| cancer screening patients | #16 |
| patients acenocoumarol | #16 |
| risk clinically | #16 |
| avws patients | #16 |
| female humans vte | #17 |
| endotoxemia bacteremia | #17 |
| scan classification | #17 |
| pharmo record linkage | #17 |
| patients overt hypothyroidism | #17 |
| 12 months patients | #17 |
| anticoagulants drug | #17 |
| vte edoxaban | #17 |
| 516 patients | #17 |
| thromboembolism patients | #17 |
| incidence pts | #17 |
| permanent patients | #17 |
| fibrinolysis treatment | #17 |
| lmwhs patients | #17 |
| ctscans | #17 |
| excessive blood loss | #17 |
| women mutation | #17 |
| gentamicin netilmicin | #17 |
| lower specificity | #17 |
| factors venous | #17 |
| compared enoxaparin | #17 |
| factor monoclonal | #17 |
| mutation women | #17 |
| anticoagulants clinical | #17 |
| anticoagulant therapy patients | #17 |
| 2688 | #17 |
| dvt prevention | #17 |
| topic hemorrhage humans | #17 |
| rivaroxaban oral factor | #17 |
| fragment f1 | #17 |
| hematoma heparin | #17 |
| recurrent vte events | #17 |
| diagnosis svt | #17 |
| prohemostatic | #17 |
| management crt | #17 |
| vkorc1 gene | #17 |
| thrombosis clinical | #17 |
| dimer assay | #17 |
| patients impedance | #17 |
| warfarin hazard | #18 |
| combined form | #18 |
| edoxaban vte | #18 |
| 4 clinical | #18 |
| thrombosis pulmonary | #18 |
| poc test | #18 |
| simplired | #18 |
| venous thromboembolism rivaroxaban | #18 |
| lmwh doacs | #18 |
| apc thrombin generation | #18 |
| 023 | #18 |
| women pregnancy loss | #18 |
| antithrombotic treatment patients | #18 |
| sanofi aventis | #18 |
| weight adjusted | #18 |
| diagnostic strategy | #18 |
| relevant nonmajor | #18 |
| proximal vein thrombosis | #18 |
| stable anticoagulation | #18 |
| flight hours | #18 |
| patients strategy | #18 |
| thromboembolism venous | #18 |
| cancer vte | #18 |
| commercial airline pilots | #18 |
| treatment vkas | #18 |
| favor lmwh | #18 |
| hivinfected patients cart | #18 |
| outcome events | #18 |
| aptt heparin | #18 |
| intravenous heparin therapy | #18 |
| annual incidence | #18 |
| vka edoxaban | #18 |
| thrombosis total | #18 |
| vka vte | #18 |
| prothrombin g20210a | #18 |
| venous thromboembolism relatives | #19 |
| patients derivation | #19 |
| ipdma | #19 |
| recurrent venous thrombosis | #19 |
| antibodynegative | #19 |
| dvt rivaroxaban | #19 |
| lmwh patients | #19 |
| active search | #19 |
| oral dabigatran enoxaparin | #19 |
| systemic activation coagulation | #19 |
| versions version | #19 |
| venography sensitivity | #19 |
| patients prevalence | #19 |
| endogenous fibrinolysis | #19 |
| acute recurrent | #19 |
| recurrence vte | #19 |
| ddimer tests | #19 |
| doubleblinding | #19 |
| patients major bleeding | #19 |
| symptomatic dvt | #19 |
| thromboembolism administration | #19 |
| abnormal ultrasound | #19 |
| studies factor | #19 |
| patients elevated biomarkers | #19 |
| local angiogenesis | #19 |
| 56 95 | #19 |
| fondaparinux enoxaparin | #19 |
| extended oral | #19 |
| low platelets | #19 |
| vwf vte | #19 |
| prognostic echocardiography | #19 |
| increased risk relatives | #19 |
| retropubic prostatectomy | #19 |
| vitamin antagonist | #19 |
| subcutaneous dalteparin | #19 |
| fibrinolytic response | #19 |
| increased fibrinolytic activity | #19 |
| edoxaban dose | #19 |
| adjusted dose | #19 |
| coagulation studies | #19 |
| 35 women | #19 |
| treatment heparin | #19 |
| objective testing | #19 |
| ufh lmwh | #19 |
| patients sspe | #19 |
| distance treatment | #20 |
| recurrence bleeding | #20 |
| dabigatran 150 | #20 |
| thrombosis ultrasonography | #20 |
| cancer severity | #20 |
| subsegmental | #20 |
| versions questionnaire | #20 |
| injections subcutaneous | #20 |
| established atherosclerosis | #20 |
| anticoagulation clinic | #20 |
| ctnt bnp | #20 |
| antagonists vkas | #20 |
| symptomatic venous thrombosis | #20 |
| thrombophilia vte | #20 |
| antitpo | #20 |
| single criterion | #20 |
| abi risk factors | #20 |
| control situation | #20 |
| residual venous | #20 |
| pregnancyrelated vte | #20 |
| standardtherapy hazard ratio | #20 |
| proteins thrombin | #20 |
| incidences death | #20 |
| blindly | #20 |
| synthetic cross | #20 |
| statin vte | #20 |
| malignancy time | #20 |
| compared ufh | #20 |
| portola | #20 |
| abi measurement | #20 |
| therapy rivaroxaban | #20 |
| life venous thrombosis | #20 |
| calf veins | #20 |
| nadroparin | #20 |
| warfarin edoxaban | #20 |
| absolute risk | #20 |
| intravenous injections | #20 |
| impedance plethysmography ipg | #20 |
| new agent | #20 |
| shr 95 | #20 |
| guidance ssc | #20 |
| carriers prothrombin | #20 |
| prothrombin mutation | #20 |
| risk thrombophilia | #20 |
| patients ddimer testing | #20 |
| treatment vte | #20 |
| diagnostic workup patients | #20 |
| excluded patients | #20 |
| occult malignancy | #21 |
| thrombosis anticoagulants | #21 |
| outcome incidence | #21 |
| current standard treatment | #21 |
| thromb | #21 |
| deep venous | #21 |
| discriminatory performance | #21 |
| risk cohort study | #21 |
| vte patients | #21 |
| doacs lmwhs | #21 |
| treatment apixaban | #21 |
| hemodynamically stable patients | #21 |
| patients 3 months | #21 |
| concomitant anti | #21 |
| d‐dimer | #21 |
| venogram | #21 |
| disease ischemic | #21 |
| hemostatic abnormalities | #21 |
| carriers noncarriers | #21 |
| internists cardiologists | #21 |
| major bleeding patients | #21 |
| treatment acenocoumarol | #21 |
| fibrinolysis inflammation | #21 |
| ddimer concentrations | #21 |
| prothrombin 20210 | #21 |
| distance quality | #21 |
| patientyears | #22 |
| riskbenefit ratio | #22 |
| time inr | #22 |
| anticoagulants heparin | #22 |
| venous thromboembolic | #22 |
| treatment dvt | #22 |
| bleeding treatment | #22 |
| acute vte | #22 |
| daily enoxaparin | #22 |
| lpa plasminogen | #22 |
| patients severe hf | #22 |
| doppler venous thrombosis | #22 |
| dichotomously | #22 |
| cttr | #22 |
| dimer age | #22 |
| vascular endotoxins | #22 |
| anticoagulants humans | #22 |
| host defense response | #22 |
| cmax ctrough | #22 |
| hormonal cross | #22 |
| patients immobilization | #22 |
| dose subcutaneous | #22 |
| thrombophilia screening | #22 |
| safety treatment | #22 |
| alternative anticoagulation | #22 |
| ttr inr | #22 |
| recurrent thromboembolism | #22 |
| public awareness | #22 |
| patients recurrent symptoms | #22 |
| vte studies | #23 |
| kakkar | #23 |
| 011 | #23 |
| fondaparinux | #23 |
| odis | #23 |
| development dic | #23 |
| time platelet | #23 |
| normal angiogram | #23 |
| gentamicin patients | #23 |
| venous arterial thrombosis | #23 |
| thromboembolism anticoagulants | #23 |
| n1157 | #23 |
| percentage increase | #23 |
| recurrence venous | #23 |
| rivaroxaban dosing | #23 |
| prevalence venous thromboembolism | #23 |
| life pulmonary embolism | #23 |
| standardduration | #23 |
| cancer patients risk | #23 |
| hasbled score | #23 |
| 5392 | #23 |
| patients coagulation disorders | #23 |
| elevated ctni | #23 |
| enoxaparin 40 | #23 |
| lower extremity amputation | #23 |
| ambulatory cancer patients | #23 |
| clotbound thrombin | #23 |
| 2 investigators | #23 |
| bidirectional relation | #23 |
| direct factor inhibitors | #23 |
| parameters fibrinolysis | #24 |
| patients severe bleeding | #24 |
| prevalence deficiencies | #24 |
| presence dvt | #24 |
| independent external validation | #24 |
| years episode | #24 |
| overt hyperthyroidism | #24 |
| viiic | #24 |
| levels fviii | #24 |
| month incidence | #24 |
| ddimer testing | #24 |
| therapy heparin | #24 |
| desogestrel levonorgestrel | #24 |
| subtherapeutic | #24 |
| followup incidence | #24 |
| specific antidote | #24 |
| a21gly | #24 |
| food drugs | #24 |
| rates venous thromboembolism | #24 |
| thrombosis carriers | #24 |
| bleeding complication | #24 |
| lowmolecularweight humans | #24 |
| 049 | #24 |
| recurrent pulmonary embolism | #24 |
| patients acute treatment | #24 |
| predefined criteria | #24 |
| patients abnormal perfusion | #24 |
| safety fondaparinux | #24 |
| ufh patients | #24 |
| fondaparinux placebo | #24 |
| recurrent thromboembolism patients | #24 |
| lmwh treatment | #25 |
| vte clinical | #25 |
| amadeus | #25 |
| specificity efficiency | #25 |
| fatima | #25 |
| expert radiologists | #25 |
| fibrinogen degradation | #25 |
| influence smoking | #25 |
| middeldorp | #25 |
| willebrand factor adamts13 | #25 |
| xii activity | #25 |
| thromboembolism acute | #25 |
| sepsis intravascular coagulation | #25 |
| cha2ds2vasc chads2 | #25 |
| anatomical extent | #25 |
| perfusion lung scan | #25 |
| suggestions improvement | #25 |
| factors anticoagulants | #25 |
| treatment symptomatic | #25 |
| patients gastrointestinal bleeding | #25 |
| f1 2 levels | #25 |
| studies lmwh | #25 |
| rate recurrent vte | #26 |
| viia complex | #26 |
| homozygous carriers | #26 |
| major bleeding bleeding | #26 |
| unprovoked vte | #26 |
| doacs vitamin antagonists | #26 |
| 9715 | #26 |
| edoxaban vka | #26 |
| miscarriage stillbirth | #26 |
| patients cdr | #26 |
| patients essential thrombocythaemia | #26 |
| venous thromboemboli | #26 |
| specificity negative predictive | #26 |
| dalteparin ufh | #26 |
| parameters risk | #26 |
| treatment lmwh | #26 |
| events year | #26 |
| rethoracotomy | #26 |
| thromboprophylaxis hospitalized patients | #26 |
| ecq | #26 |
| edoxaban versus | #26 |
| failure rate | #26 |
| hormonal manipulation | #26 |
| patients symptomatic dvt | #26 |
| asymptomatic carriers | #26 |
| months studies | #27 |
| treating physician | #27 |
| anticoagulants blood | #27 |
| unprovoked venous | #27 |
| patients major hemorrhage | #27 |
| female heterozygote | #27 |
| anticoagulants factor | #27 |
| thrombosis venous | #27 |
| airline pilots | #27 |
| patients elevated levels | #27 |
| cancer spread | #27 |
| patients 50 | #27 |
| thrombocytopenia antibodies | #27 |
| combined training | #27 |
| thrombophlebitis | #27 |
| extremity venous | #27 |
| 0·63 | #27 |
| perfusion lung | #27 |
| lmwh prophylaxis | #27 |
| training gps | #27 |
| vte thr | #27 |
| low molecularweight heparin | #27 |
| current guidance | #27 |
| nonmajor | #27 |
| lowmolecularweight heparin patients | #27 |
| npv patients | #27 |
| vte doacs | #27 |
| venous thromboembolism carriers | #27 |
| day 35 | #27 |
| enoxaparin female | #27 |
| noncarriers 95 | #27 |
| anticoagulation women | #28 |
| vte 6 months | #28 |
| presentation followup | #28 |
| 2½ | #28 |
| cancer venous thromboembolism | #28 |
| 4650 | #28 |
| vitamin aged | #28 |
| pph severe pph | #28 |
| apc plasma | #28 |
| pembqol | #28 |
| coagulation tissue factor | #28 |
| tests diagnostic | #28 |
| anticoagulants compared | #28 |
| patients unprovoked | #28 |
| objective tests | #28 |
| rfviia placebo | #28 |
| receiving rivaroxaban | #28 |
| acutely medical patients | #28 |
| monitoring therapy | #28 |
| specific reversal agent | #28 |
| factors recurrent | #28 |
| unexplained | #28 |
| therapeutic doses | #28 |
| hirudin therapy | #28 |
| embolism retrospective | #28 |
| pulmonary embolism recurrence | #29 |
| thrombosis treatment | #29 |
| pulmonary embolism death | #29 |
| diagnosis dvt | #29 |
| dvt pulmonary embolism | #29 |
| aspirin placebo | #29 |
| thrombosis 95 | #29 |
| authors incidence | #29 |
| blind trials | #29 |
| years year | #29 |
| aminoglycoside therapy | #29 |
| spread cancer | #29 |
| dutch famine | #29 |
| acenocoumarol patients | #29 |
| 8240 | #29 |
| cindexes | #29 |
| pulmonary angiography | #29 |
| thrombo | #29 |
| 1000 individuals | #29 |
| oral glucocorticoids | #29 |
| major bleeding rivaroxaban | #29 |
| sex‐specific differences | #29 |
| dabigatran pcc | #29 |
| septicemia | #29 |
| bleeding increased | #29 |
| patients standard therapy | #29 |
| recurrence svt | #29 |
| pbac score | #29 |
| prediction scores | #29 |
| aged morpholines | #29 |
| heparin versus | #29 |
| g20210a mutation | #29 |
| current management strategies | #29 |
| direct oral anticoagulants | #29 |
| plateletactivating antibodies | #29 |
| resistance activated protein | #29 |
| patients avws | #29 |
| administration pentoxifylline | #30 |
| residual thrombosis | #30 |
| 1000 personyears incidence | #30 |
| doac vka | #30 |
| subcutaneous heparin | #30 |
| costs diagnosis | #30 |
| thromboembolism warfarin | #30 |
| xii factor | #30 |
| new anticoagulants | #30 |
| ufh vte | #30 |
| support techniques | #30 |
| markers coagulation activation | #30 |
| patients vte | #30 |
| f1 2 | #30 |
| rule patients | #30 |
| 95 risk | #30 |
| vte coc | #30 |
| prevention venous | #30 |
| embolism risk | #30 |
| cancer venous | #30 |
| direct oral factor | #30 |
| women recurrent miscarriage | #31 |
| activation blood coagulation | #31 |
| placebo observation | #31 |
| ufh fondaparinux | #31 |
| inhibitor edoxaban | #31 |
| recurrent vte patients | #31 |
| prevalence probability | #31 |
| rfviia novoseven | #31 |
| recurrent patients | #31 |
| incidence pph | #31 |
| 8755 | #31 |
| imaging sensitivity specificity | #31 |
| events 95 | #31 |
| experimental endotoxemia | #31 |
| 2 antiplasmin | #31 |
| bled | #31 |
| iii activity | #31 |
| thromboembolism adolescent | #31 |
| analysis reviewers | #31 |
| dimer cutoff | #31 |
| patients deepvein thrombosis | #31 |
| apixaban placebo | #31 |
| standardtherapy | #31 |
| ventilation scintigraphy | #31 |
| vte ufh | #31 |
| recurrent episode | #31 |
| extended prophylaxis | #31 |
| rhir | #31 |
| pharmacological prophylaxis | #31 |
| term risk | #31 |
| antithrombotic therapies | #31 |
| dvt pulmonary | #31 |
| thromboprophylaxis risk | #31 |
| 0206 | #31 |
| incidence cteph | #31 |
| low clinical | #32 |
| treatment anticoagulants | #32 |
| factors thrombolytic | #32 |
| negative dimer | #32 |
| warfarin vte | #32 |
| khorana score patients | #32 |
| age adjusted | #32 |
| year 95 | #32 |
| varicosis | #32 |
| leiden mutation | #32 |
| ufh | #32 |
| resistance activated | #32 |
| suspected patients | #32 |
| generation patients | #32 |
| normal genotype | #32 |
| netherlands predictive | #32 |
| negative septicemia | #32 |
| international society thrombosis | #32 |
| parenteral anticoagulation | #32 |
| factor female | #32 |
| parenteral anticoagulants | #32 |
| active implementation | #33 |
| low probability | #33 |
| subcutaneous male | #33 |
| mega study | #33 |
| prophylaxis vte | #33 |
| rhirudin | #33 |
| additional tests | #33 |
| pulmonary angiogram | #33 |
| heparin lmwh | #33 |
| activation factors | #33 |
| apixaban treatment | #33 |
| warfarin risks | #33 |
| factor viii patients | #33 |
| data meta | #33 |
| nephrotoxicity gentamicin | #33 |
| cancer patients diagnosis | #33 |
| thromboembolism young | #33 |
| anticoagulant protein | #33 |
| chapter patients | #33 |
| unitage | #33 |
| thrombosis lower | #34 |
| control trials | #34 |
| lmwh unfractionated heparin | #34 |
| bilateral venography | #34 |
| grade 1a | #34 |
| phytonadione | #34 |
| deficiency protein | #34 |
| 590 | #34 |
| 9241 | #34 |
| hemorrhage heparin humans | #34 |
| warfarin adult | #34 |
| apcsr | #34 |
| vte thrombophilia | #34 |
| pregnancy loss women | #34 |
| compare efficacy | #34 |
| 3 months treatment | #34 |
| 10 95 | #34 |
| plasmin alpha | #34 |
| anticoagulant | #34 |
| subsegmental pulmonary embolism | #34 |
| vte compared | #34 |
| reocclusion patients | #34 |
| prevention model | #35 |
| activation coagulation | #35 |
| lung scanning | #35 |
| patients efficiency | #35 |
| radiologists diagnosis | #35 |
| weekly subcutaneous | #35 |
| rviia | #35 |
| 36 95 | #35 |
| enoxaparin prevention | #35 |
| embolism | #35 |
| anticoagulants benzimidazoles | #35 |
| risk members | #35 |
| statin association | #35 |
| pph blood loss | #35 |
| surgery hip | #35 |
| neoplasms venous | #35 |
| peripheral endovascular | #36 |
| treatment acute vte | #36 |
| dose reduction patients | #36 |
| regular monitoring | #36 |
| catheterrelated infection | #36 |
| factors travel | #36 |
| fibrinolytic activation | #36 |
| thrombophilia venous | #36 |
| inherited risk factors | #36 |
| venous thromboembolism dabigatran | #36 |
| fibrinogen depletion | #36 |
| viii levels | #36 |
| studies echocardiography | #36 |
| hellp patients | #36 |
| novoseven | #36 |
| 4139 | #36 |
| riskbenefit | #36 |
| venous thromboembolic disease | #36 |
| 1698 | #36 |
| levels coagulation | #36 |
| acute symptomatic | #36 |
| iii antithrombin | #36 |
| 287 patients | #36 |
| factors thrombophilia | #37 |
| cumulative incidence vte | #37 |
| rivaroxaban thromboprophylaxis | #37 |
| screening occult | #37 |
| risk venous thrombosis | #37 |
| risk factors pts | #37 |
| lwmh | #37 |
| ctpa patients | #37 |
| magellan | #37 |
| suspected venous | #37 |
| venography | #37 |
| genotype 95 | #37 |
| recombinant hirudin | #37 |
| excluding | #37 |
| bagsvaerd | #37 |
| outcome composite | #37 |
| warfarin 95 | #37 |
| perelated mortality | #37 |
| thrombosis humans | #37 |
| vte increased | #37 |
| anticoagulants prevention | #37 |
| anticoagulant action | #37 |
| ototoxicity nephrotoxicity | #37 |
| prophylactic heparin | #37 |
| pad studies | #37 |
| tat complexes | #37 |
| coagulation protein | #38 |
| recurrence day | #38 |
| congenital deficiencies | #38 |
| vte cancer patients | #38 |
| submassive pulmonary | #38 |
| 2835 | #38 |
| rivaroxaban placebo | #38 |
| vte bleeding | #38 |
| patients ddimer levels | #38 |
| doac lmwh | #38 |
| fetal loss women | #38 |
| catheterrelated thrombosis | #38 |
| nonmajor bleeding | #38 |
| sensitivity biomarkers | #38 |
| age recurrence | #38 |
| 3306 | #38 |
| restenosis reocclusion | #38 |
| anticoagulants female humans | #38 |
| 10 total | #38 |
| superficial vein thrombosis | #39 |
| submassive | #39 |
| time compression | #39 |
| embolus | #39 |
| low molecular weight | #39 |
| fibrin fibrinogen | #39 |
| diagnostic prediction | #39 |
| systemic inflammatory responses | #39 |
| continued treatment | #39 |
| children familial hypercholesterolemia | #39 |
| 277 patients | #39 |
| incidence cancer | #39 |
| specificity patients | #39 |
| septic syndrome | #39 |
| subcutaneous intention | #39 |
| enoxaparin placebo | #39 |
| compression stocking | #39 |
| incidence patients | #39 |
| heparins lmwhs | #39 |
| doacs | #39 |
| thrombinantithrombin complexes | #40 |
| endotoxininduced | #40 |
| grade 1a patients | #40 |
| patients normal | #40 |
| therapeutic dosages | #40 |
| episode venous thromboembolism | #40 |
| standardized definition | #40 |
| anticoagulant therapy | #40 |
| international clinical | #40 |
| ambulatory cancer | #40 |
| dalteparin treatment | #40 |
| bleeding | #40 |
| fviiic | #40 |
| pemb | #40 |
| common femoral vein | #40 |
| anticoagulation therapy patients | #40 |
| clotting activation | #40 |
| arterial vascular | #40 |
| tfmp | #40 |
| activatable fibrinolysis | #40 |
| day 6 months | #40 |
| placebo 6 months | #41 |
| calf vein thrombosis | #41 |
| cancer lmwh | #41 |
| submassive pulmonary embolism | #41 |
| risk recurrent vte | #41 |
| pentasaccharides | #41 |
| lowmolecularweight heparins | #41 |
| heparin therapy | #41 |
| 95 genotype | #41 |
| dabigatran etexilate | #41 |
| endotoxin induced | #41 |
| triage tests | #41 |
| lung scintigraphy | #41 |
| anticoagulated patients | #41 |
| 7268 | #41 |
| thrombosis administration | #42 |
| prophylaxis venous | #42 |
| cell extravasation | #42 |
| stroke thrombosis | #42 |
| anticoagulation risk | #42 |
| neoplasms thrombosis | #42 |
| major contributor | #42 |
| patients vasopressors | #42 |
| patients silent | #42 |
| netilmicin | #42 |
| standardization committee | #42 |
| patients prospective | #42 |
| type graft | #42 |
| 8101 | #42 |
| draft document | #43 |
| venous thrombosis thrombophilia | #43 |
| vkas patients | #43 |
| fetal loss | #43 |
| post‐thrombotic syndrome | #43 |
| heparin risk | #43 |
| initial treatment | #43 |
| ischemic events | #43 |
| 543 patients | #43 |
| rtap | #43 |
| probability patients | #43 |
| warfarin anticoagulants | #43 |
| monthly incidence | #43 |
| cancer adjusted | #43 |
| venous thromboembolism vte | #43 |
| patients vte risk | #43 |
| rate venous | #44 |
| nonvka oral anticoagulants | #44 |
| patients tinzaparin | #44 |
| mild hyperhomocysteinaemia | #44 |
| experimental venous thrombosis | #44 |
| enoxaparin risk | #44 |
| protein sepsis | #44 |
| recurrent vte 95 | #44 |
| uedvt patients | #44 |
| factors thromboembolism | #44 |
| role coagulation | #44 |
| restoration euthyroidism | #44 |
| expert physicians | #44 |
| 10–14 | #44 |
| 20 30 | #44 |
| 95 pulmonary embolism | #44 |
| edoxaban therapy | #44 |
| efficiency models | #44 |
| indications patients | #44 |
| dvt patients | #45 |
| revascularisation procedures | #45 |
| dose lmwh | #45 |
| 95 warfarin | #45 |
| oral direct | #45 |
| years algorithm | #45 |
| fondaparinux patients | #45 |
| wells score | #45 |
| treated warfarin | #45 |
| dose adjusted | #45 |
| patients bnp | #45 |
| coagulation activation | #45 |
| venous thrombotic | #45 |
| coumarin therapy | #45 |
| bleeding rivaroxaban | #46 |
| abtpo | #46 |
| patients unprovoked vte | #46 |
| extended duration | #46 |
| treatment model | #46 |
| major bleeding placebo | #46 |
| day levels | #46 |
| healthcare settings | #46 |
| ruling | #46 |
| management venous | #46 |
| standard therapy | #46 |
| pioped | #46 |
| ssc isth | #46 |
| stroke risk assessment | #46 |
| hospital outpatients | #46 |
| daily rivaroxaban | #46 |
| percent confidence | #46 |
| prothrombin fragment f1 | #46 |
| male methimazole | #47 |
| central venous lines | #47 |
| mechanical prophylaxis | #47 |
| boehringer ingelheim | #47 |
| iiia receptors | #47 |
| bristol myers squibb | #47 |
| plasma ddimer levels | #47 |
| new oral anticoagulant | #47 |
| outcome vitamin | #47 |
| mutation pregnancy | #47 |
| roccurve | #47 |
| episode vte | #47 |
| ambulatory anticoagulants | #47 |
| small studies | #48 |
| rivaroxaban compared | #48 |
| patients pulmonary | #48 |
| thromboprophylactic | #48 |
| diagnosis physicians | #48 |
| intermediate risk risk | #48 |
| fondaparinux heparin | #48 |
| travel risk | #48 |
| risk recurrent | #48 |
| patients acute dvt | #48 |
| recurrence venous thromboembolism | #48 |
| thrombotic burden | #48 |
| factors rivaroxaban | #48 |
| subcommittee | #48 |
| daiichi | #48 |
| elevated plasma levels | #48 |
| factor viii deficiency | #49 |
| levels protein | #49 |
| calf vein | #49 |
| lowmolecularweight heparin lmwh | #49 |
| women aspirin | #49 |
| enoxaparin | #49 |
| vte diagnosis | #49 |
| rivaroxaban prevention | #49 |
| treatment threshold | #50 |
| etexilate | #50 |
| atria patients | #50 |
| nonselective betablockers | #50 |
| transient risk factor | #50 |
| intensity treatment | #50 |
| thromboembolism aged | #50 |
| cardiac surgery mortality | #50 |
| buller | #50 |
| incidence venous thromboembolism | #50 |
| prospective diagnostic | #50 |
| dvt diagnosis | #50 |
| vitamink antagonists | #50 |
| acute respiratory insufficiency | #50 |
| outpatient therapy | #50 |
| acenocoumarol | #51 |
| global disease | #51 |
| tomography pulmonary | #51 |
| factor vte | #51 |
| discrimination model | #51 |
| protein deficiencies | #51 |
| normal perfusion | #51 |
| effects coagulation | #51 |
| 95 apixaban | #51 |
| patients 11 | #51 |
| strategies treatment | #51 |
| previous survey | #51 |
| 1·12 | #52 |
| apixaban vte | #52 |
| inhibitors heparin | #52 |
| pdvt | #52 |
| unnecessarily | #52 |
| lung scans | #52 |
| lmwh fondaparinux | #52 |
| free thyroxine ft4 | #52 |
| hematologic malignancies patients | #52 |
| patients comorbid conditions | #52 |
| risk venous thromboembolism | #52 |
| svt patients | #52 |
| 3 month | #52 |
| doacs vka | #52 |
| vte major bleeding | #52 |
| 40 daily | #53 |
| suspected venous thromboembolism | #53 |
| postthrombotic syndrome | #53 |
| 479 patients | #53 |
| absolute risks | #53 |
| reported incidence | #53 |
| 1522 | #53 |
| hemostatic balance | #53 |
| patients initially | #53 |
| warfarintreated patients | #53 |
| thromboembolism prevention | #53 |
| preference patients | #53 |
| thrombophilic factors | #53 |
| versus enoxaparin | #53 |
| cross study | #53 |
| 378 patients | #54 |
| bled score | #54 |
| major bleeds | #54 |
| chads2 cha2ds2vasc | #54 |
| thromboembolism death | #54 |
| pai1 levels patients | #54 |
| prethrombotic | #54 |
| 034 | #54 |
| familial thrombophilia | #54 |
| 2537 | #54 |
| vte mortality | #54 |
| male pulmonary embolism | #54 |
| antithrombotic drug | #54 |
| acquired risk factors | #54 |
| patients incidence | #54 |
| endocrine disorders | #54 |
| patients obese | #54 |
| unfractionated heparin ufh | #55 |
| rivaroxaban | #55 |
| anticoagulants arthroplasty replacement | #55 |
| compared lmwh | #55 |
| proximal extent | #55 |
| legs patients | #55 |
| long term risk | #55 |
| methods randomized | #55 |
| unfractionated heparin | #55 |
| nondeficient | #55 |
| treatment thresholds | #55 |
| insurances | #55 |
| biological pan | #55 |
| dosereduction | #55 |
| enoxaparin rivaroxaban | #56 |
| reduced capacity | #56 |
| enoxaparin patients | #56 |
| inr values | #56 |
| vasopressors | #56 |
| vte death | #56 |
| seventh accp conference | #56 |
| venous outflow obstruction | #56 |
| risk major bleeding | #56 |
| time event | #56 |
| major bleeding apixaban | #56 |
| vitamin warfarin | #56 |
| 20210a | #56 |
| tromboembólica | #56 |
| deficiency prevalence | #56 |
| physicians guidelines | #56 |
| preeclampsia hellp syndrome | #56 |
| level mortality | #56 |
| weight heparins | #56 |
| clinical models | #57 |
| risk factors vte | #57 |
| ctscan | #57 |
| inhibitors female humans | #57 |
| antithrombin iii heparin | #57 |
| calf dvt | #57 |
| levels survival | #57 |
| subsegmental pulmonary | #57 |
| fibrinolysis humans | #58 |
| thrombin activatable | #58 |
| malignancy mortality | #58 |
| unfractionated heparin patients | #58 |
| inhibitors female | #58 |
| doacs patients | #58 |
| ruled | #58 |
| pharmo | #58 |
| lowmolecular weight heparin | #58 |
| spiral computed | #58 |
| bias trial | #59 |
| aventis | #59 |
| direct oral | #59 |
| safety warfarin | #59 |
| risk periods | #59 |
| risk factors sensitivity | #59 |
| mutation prothrombin | #59 |
| factor generation | #59 |
| heterozygous factor | #59 |
| risk vte | #59 |
| warfarin treatment | #59 |
| incidence symptomatic | #59 |
| clot lysis time | #59 |
| thrombosis aged | #59 |
| acute venous thromboembolism | #59 |
| anticoagulants treatment | #60 |
| acute pulmonary embolism | #60 |
| women difference | #60 |
| atrial fibrillation metaanalysis | #60 |
| 079 95 | #60 |
| pediatric venous thromboembolism | #60 |
| pulmonary embolism 95 | #60 |
| constans | #60 |
| hemorrhage humans | #60 |
| fixeddose | #60 |
| target inr | #60 |
| awareness risk factors | #60 |
| prevalence pulmonary | #60 |
| perfusion ventilation | #61 |
| amuse | #61 |
| hypocoagulable | #61 |
| month surgery | #61 |
| rosendaal | #61 |
| free thyroxine | #61 |
| association protein | #61 |
| dvt 95 | #61 |
| benzimidazoles dabigatran | #61 |
| long‐term treatment | #61 |
| 3633 | #61 |
| tests prevalence | #61 |
| cdr score | #61 |
| ttr patients | #62 |
| 273 patients | #62 |
| activated partial | #62 |
| informatizado | #62 |
| general practitioners patients | #62 |
| post thrombotic | #62 |
| 250 patients | #62 |
| patients administration | #62 |
| human endotoxemia | #62 |
| combined contraceptives oral | #62 |
| protein fibrinogen | #62 |
| procoagulant state | #62 |
| symptoms dvt | #63 |
| management anticoagulation | #63 |
| physicians predictive | #63 |
| revised geneva score | #63 |
| smoking smoking cessation | #63 |
| women mutations | #63 |
| quantitative test | #63 |
| common odds ratio | #63 |
| cvrs | #63 |
| vte thromboprophylaxis | #63 |
| injection endotoxin | #63 |
| venous thromboembolisms | #63 |
| treatment network | #63 |
| factor leiden risk | #63 |
| rivaroxaban lmwh | #63 |
| 33 women | #63 |
| oral thrombin | #64 |
| bleeding events patients | #64 |
| patients aortic valve | #64 |
| acute pulmonary | #64 |
| decision rules | #64 |
| heparin fondaparinux | #64 |
| cancer noncancer patients | #64 |
| blinded trial | #64 |
| thrombophilic risk | #64 |
| factor inhibitors | #64 |
| superficial vein | #64 |
| postthrombotic | #64 |
| vkas treatment | #64 |
| dvts | #64 |
| prior vte | #64 |
| selfadjustment | #64 |
| treatment pad | #65 |
| fvl vte | #65 |
| accuracy diagnostic tests | #65 |
| stroke thromboembolism | #65 |
| prevalence abnormalities | #65 |
| prothrombin g20210a mutation | #65 |
| ultrasonograms | #65 |
| elfa | #66 |
| 95 bleeding | #66 |
| dvt sensitivity | #66 |
| rapid triage | #66 |
| axa | #66 |
| female heparin | #66 |
| 0 points | #66 |
| statin therapy risk | #66 |
| risk factor thrombosis | #66 |
| newer anticoagulants | #66 |
| death classification | #66 |
| atrial fibrillation stroke | #67 |
| rate major | #67 |
| standard therapy patients | #67 |
| patients tertiles | #67 |
| patients factor | #67 |
| apixaban | #67 |
| 1127 | #67 |
| academic medical centre | #68 |
| patients bnp levels | #68 |
| 05 95 | #68 |
| patients benefits | #68 |
| 3594 | #68 |
| coagulation fibrinolysis | #68 |
| 1894 | #68 |
| perioperative blood | #68 |
| ranging study | #68 |
| 20210g | #68 |
| fibrinolytic | #68 |
| enfermedad tromboembólica | #69 |
| ionis | #69 |
| suspected | #69 |
| thrombosis blood | #69 |
| certoparin | #69 |
| justify | #69 |
| plasma interleukin | #69 |
| recurrent thrombosis patients | #69 |
| postphlebitic | #69 |
| heparin ufh | #69 |
| α2ap | #70 |
| vwfrco | #70 |
| aged predictive | #70 |
| elevated cardiac | #70 |
| major bleeding complications | #70 |
| thrombosis recurrence | #70 |
| fixed dose | #70 |
| withhold | #70 |
| ischemic events patients | #70 |
| mantelhaenszel | #70 |
| cutoff levels | #70 |
| test patients | #70 |
| gramnegative sepsis | #70 |
| 8190 | #70 |
| rivaroxaban treatment | #70 |
| patients protein | #70 |
| clopidogrel placebo | #71 |
| asymptomatic atherosclerosis | #71 |
| unfractionated | #71 |
| diagnostic sensitivity specificity | #71 |
| tests prospective | #71 |
| thromboprophylaxis | #71 |
| levels vwf | #71 |
| topic costs | #71 |
| vte vka | #71 |
| plasminogen plg | #71 |
| new anticoagulant | #72 |
| pooled rate | #72 |
| trifurcation | #72 |
| overt hypothyroidism | #72 |
| antithrombin iii iii | #72 |
| elevated factor | #72 |
| patients lmwh | #72 |
| hf studies | #72 |
| viia factor | #72 |
| complications hematologic | #72 |
| versus vitamin | #72 |
| ddimer values | #72 |
| activation prothrombin | #72 |
| analysis diagnostic | #73 |
| tomography spiral | #73 |
| noacs | #73 |
| 12 months 95 | #73 |
| soluble fibrin | #73 |
| ddimer measurement | #73 |
| ingelheim | #73 |
| prolongations | #73 |
| reversal agent | #73 |
| dvt study | #74 |
| female hemorrhage | #74 |
| 5395 | #74 |
| 2550 | #74 |
| carriers | #74 |
| 2124 | #74 |
| proteins patients | #74 |
| soluble thrombomodulin | #74 |
| longterm risk | #74 |
| prethrombotic state | #74 |
| suspected dvt | #74 |
| experimental metastasis | #74 |
| study selection | #74 |
| 1732 | #74 |
| postoperative dvt | #75 |
| 1334 | #75 |
| retrospective follow | #75 |
| 2904 | #75 |
| thrombolytic therapy patients | #75 |
| incidence bleeding events | #75 |
| carotid femoral arteries | #75 |
| 8492 | #75 |
| selective factor | #75 |
| angiography ctpa | #76 |
| oral combined contraceptives | #76 |
| extended anticoagulation | #76 |
| risk thrombosis | #76 |
| duration thromboprophylaxis | #76 |
| early time | #76 |
| tests primary | #76 |
| combined contraceptives | #76 |
| factor xii deficiency | #76 |
| boehringer | #77 |
| social aspects | #77 |
| individual patient | #77 |
| p023 | #77 |
| patients secondary | #77 |
| thrombosis pregnancy | #77 |
| unprovoked | #78 |
| women thrombophilia | #78 |
| 20 daily | #78 |
| female fibrinolysis | #78 |
| elevated dimer | #78 |
| arterial thromboembolism | #78 |
| ipg | #78 |
| arterial wall thickness | #78 |
| humans pulmonary | #79 |
| vte fvl | #79 |
| factor adult | #79 |
| time therapeutic | #79 |
| efficacy agents | #79 |
| suspected acute | #79 |
| topic heparin | #79 |
| limulus test | #79 |
| 2486 | #79 |
| vkas | #79 |
| vte rate | #80 |
| bleeding mortality | #80 |
| alife | #80 |
| patient data | #80 |
| sspe patients | #80 |
| suspected cancer | #80 |
| daily bid | #80 |
| validation models | #80 |
| 95 05 | #80 |
| heterozygous deficiency | #80 |
| thromboembolism incidence | #80 |
| subhazard ratio | #80 |
| outpatient basis | #81 |
| prothrombin complex concentrate | #81 |
| vascular events | #81 |
| weitz | #81 |
| topic risk | #81 |
| lmwh vte | #81 |
| systemic inflammatory | #81 |
| walking distance | #81 |
| test evaluation | #81 |
| knee arthroplasty patients | #81 |
| symptomatic carriers | #82 |
| mammography patients | #82 |
| 50 micrograms | #82 |
| prospective validation | #82 |
| thrombosis incidence | #82 |
| thrombosis thrombophilia | #82 |
| clinical sign | #82 |
| common practice | #82 |
| heparin prevention | #82 |
| 3month followup | #82 |
| placebo women | #82 |
| thrombolytic drugs | #82 |
| crnmb | #82 |
| timeperiods | #82 |
| posthoc analysis | #82 |
| dimer patients | #83 |
| bleeding women | #83 |
| patients thrombi | #83 |
| inhibitor dabigatran | #83 |
| elective coronary | #83 |
| 287 | #83 |
| 2213 | #83 |
| bistro | #83 |
| inhibitor rivaroxaban | #84 |
| heparin treatment | #84 |
| inherited thrombophilia | #84 |
| normotensive patients | #84 |
| diagnostic outcome | #84 |
| screening humans | #84 |
| duration therapy | #84 |
| prophylactic dose | #84 |
| healthcare setting | #84 |
| asymptomatic dvt | #85 |
| endotoxins | #85 |
| normal levels | #85 |
| thrombosis svt | #85 |
| venous thrombosis patients | #85 |
| antithrombin iii protein | #85 |
| peripheral vascular diseases | #85 |
| anticoagulants antiphospholipid | #85 |
| venovenous hemofiltration | #86 |
| 4576 | #86 |
| 10⁶ | #86 |
| dabigatran vka | #86 |
| rhapc | #86 |
| elevated ddimer levels | #86 |
| major bleeding warfarin | #86 |
| 75 microg | #86 |
| clinical impact | #87 |
| contact activation | #87 |
| ≤50 | #87 |
| 95 100 | #87 |
| obstetric patients | #87 |
| acute venous | #87 |
| post‐hoc analysis | #87 |
| avws | #87 |
| patients 28 | #87 |
| vidas | #87 |
| activation factor | #88 |
| internist | #88 |
| 4 points | #88 |
| 3319 | #88 |
| treatment incidence | #88 |
| cdr | #88 |
| aged multicenter | #88 |
| lmwhs | #88 |
| washout period | #88 |
| treatment statins | #88 |
| venographic | #88 |
| unexplained recurrent | #89 |
| costs patient | #89 |
| rates major bleeding | #89 |
| safety noacs | #89 |
| smoking incidence | #89 |
| severe hf | #89 |
| beta blockers | #89 |
| anticoagulants dabigatran | #89 |
| vte venous thromboembolism | #89 |
| matisse | #89 |
| adequate treatment | #89 |
| ddimer | #89 |
| cytokine release | #89 |
| tests test | #89 |
| ventilation lung | #89 |
| reversal strategies | #89 |
| stroke bleeding | #89 |
| outweighs | #90 |
| primary thromboprophylaxis | #90 |
| popliteal vein | #90 |
| pediatric venous | #90 |
| fibrinolytic factors | #90 |
| thrombophilic risk factors | #90 |
| 2293 | #90 |
| vka dabigatran | #90 |
| new patients | #90 |
| venous thrombosis risk | #90 |
| cdrs | #91 |
| pyridines pyridones | #91 |
| 20210 | #91 |
| thromboembolism pregnancy | #91 |
| anticoagulants doacs | #91 |
| 60 95 | #91 |
| inconvenience | #91 |
| thrombosis women | #91 |
| perfusion ratio | #91 |
| agents hemorrhage | #91 |
| thrombotic disease | #92 |
| combined clinical | #92 |
| prophylaxis incidence | #92 |
| single intravenous | #92 |
| anticoagulation reversal | #93 |
| incidence knee | #93 |
| 95 years | #93 |
| direct thrombin inhibitors | #93 |
| rivaroxaban edoxaban | #93 |
| compression patients | #93 |
| scenario analyses | #93 |
| heparins | #94 |
| vte surgery | #94 |
| 125 patients | #94 |
| test result | #94 |
| hf severity | #94 |
| patients symptomatic | #94 |
| atherogenic lipid | #94 |
| children vte | #94 |
| 1027 | #94 |
| viia rfviia | #95 |
| direct oral anticoagulant | #95 |
| european consensus statement | #95 |
| 2 levels | #95 |
| efficacy rivaroxaban | #96 |
| ddimer level | #96 |
| randomised crossover study | #96 |
| symptomatic vte | #96 |
| risk symptomatic | #96 |
| fondaparinux treatment | #96 |
| xii deficiency | #96 |
| 6 12 months | #96 |
| abnormal perfusion | #97 |
| symptomatic pulmonary embolism | #97 |
| invasive testing | #97 |
| studies evaluated | #97 |
| difference rates | #97 |
| doacs risk | #97 |
| fibrin generation | #97 |
| tpa release | #97 |
| pyrazoles pyridones | #97 |
| haemophilia patients | #97 |
| simplify | #98 |
| essential thrombocythaemia | #98 |
| pregnancy postpartum period | #98 |
| 16slice | #98 |
| major bleed | #98 |
| 2875 | #98 |
| hypercoagulable | #98 |
| supervised exercise therapy | #98 |
| activated protein apc | #98 |
| hirudin | #99 |
| perfusion scintigraphy | #99 |
| probast | #99 |
| risk arterial | #99 |
| lmwh warfarin | #99 |
| 2·0 | #99 |
| acute dvt | #99 |
| unselected | #99 |
| prevention recurrent | #100 |
| patient groups | #100 |
| gbd 2010 | #100 |
| doubleblind trial | #100 |
| 1116 | #100 |
| fatty foods | #100 |
| increasing levels | #100 |
| previews | #100 |
| warfarin patients | #100 |
| 3 trials | #100 |
| morpholines | #101 |
| factor vii factor | #101 |
| aptts | #101 |
| factor viia | #101 |
| 40 microg | #102 |
| low pretest probability | #102 |
| alternative diagnosis | #102 |
| pts patients | #102 |
| 265 patients | #102 |
| enoxaparin fondaparinux | #102 |
| venous thromboembolism women | #102 |
| adjudicated | #103 |
| cteph patients | #103 |
| endogenous thrombin | #103 |
| arthroscopic anterior | #103 |
| pregnancy puerperium | #103 |
| doppler method | #103 |
| 338 | #103 |
| therapeutic consequences | #103 |
| fibrin degradation products | #104 |
| recurrence women | #104 |
| separate analyses | #104 |
| diagnostic imaging humans | #104 |
| apparent increase | #104 |
| antithrombin iii | #104 |
| term treatment | #104 |
| absolute increase | #104 |
| heparin pregnancy | #104 |
| partial restoration | #104 |
| oral factor | #104 |
| assay variation | #104 |
| embryo loss | #105 |
| 1089 | #105 |
| 7 children | #105 |
| conventional therapy patients | #105 |
| hospitalized patients hf | #106 |
| fibrinolytic systems | #106 |
| elevated levels | #106 |
| thrombosis age | #106 |
| 314 | #106 |
| study total | #106 |
| thromboprophylaxis patients | #106 |
| chest ray | #106 |
| 2479 | #106 |
| thrombophilia | #106 |
| blind double | #106 |
| essentials | #106 |
| definition classification | #107 |
| topic recurrence | #107 |
| ddimer levels | #107 |
| vte risk | #107 |
| survival cancer patients | #107 |
| thromboembolic | #107 |
| simplified version | #107 |
| cardiovascular death stroke | #108 |
| post thrombotic syndrome | #108 |
| specific subgroups | #108 |
| noncancer patients | #108 |
| patients cancer | #108 |
| human volunteers | #108 |
| grade 1c | #108 |
| evaluation studies | #109 |
| 1235 | #109 |
| embolism treatment | #109 |
| viia | #109 |
| 500μg | #109 |
| 039 | #109 |
| routine coagulation | #109 |
| synthetic pentasaccharide | #109 |
| anticoagulants cohort | #109 |
| factor mutation | #109 |
| thrombin antithrombin | #109 |
| thrombosis treated | #110 |
| subsequent pregnancy | #110 |
| antiplasmin | #110 |
| inferiority trial | #110 |
| embolism quality | #110 |
| primary safety | #110 |
| cancer activity | #110 |
| vka doac | #110 |
| predefined | #111 |
| siset | #111 |
| obstetric complications | #111 |
| anticoagulants biomarkers | #111 |
| negative predictive 100 | #111 |
| treatment risk factors | #111 |
| comparison control | #111 |
| humans intermittent | #111 |
| recurrence treatment | #112 |
| publication anticoagulants | #112 |
| risk rivaroxaban | #112 |
| topic guidelines | #112 |
| emergency situations | #112 |
| chromogenic | #112 |
| thromboembolic diseases | #112 |
| patients ventricular dysfunction | #112 |
| efficacy prevention | #112 |
| patients 70 | #112 |
| epidemiology risk factors | #112 |
| rivaroxaban enoxaparin | #112 |
| heterozygous carriers | #113 |
| metabolic response | #113 |
| lmwh risk | #113 |
| nonionic contrast | #113 |
| patients nephrotoxicity | #113 |
| inappropriate treatment | #113 |
| study centre | #114 |
| 0·0 | #114 |
| cancerassociated vte | #114 |
| patients intermediate | #114 |
| dialysers | #114 |
| postphlebitic syndrome | #114 |
| total knee replacement | #114 |
| fibrinogen vwf | #115 |
| patients recurrent | #115 |
| 393 | #115 |
| global public | #115 |
| hyperhomocysteinaemia | #115 |
| positive predictive values | #115 |
| heparin warfarin | #116 |
| computed tomography patients | #116 |
| effects tnf | #116 |
| anticoagulants arthroplasty | #116 |
| major bleeding 95 | #116 |
| vte data | #116 |
| life treatment | #116 |
| women severe preeclampsia | #116 |
| agents heparin | #116 |
| reference standard | #116 |
| topic dabigatran | #116 |
| vte complications | #117 |
| protein resistance | #117 |
| arthroscopies | #117 |
| protein inhibitor pci | #117 |
| 2460 | #117 |
| vte children | #117 |
| fibrinolytic parameters | #117 |
| women caesarean | #117 |
| proximal dvt | #118 |
| 2744 | #118 |
| arterial thrombosis patients | #118 |
| patients extensive | #118 |
| 4118 | #118 |
| autopsyconfirmed | #118 |
| humans leg | #119 |
| compression stockings | #119 |
| compared warfarin | #119 |
| patients doac | #119 |
| incidence pulmonary embolism | #119 |
| dabigatran factor | #120 |
| acquired deficiency | #120 |
| healthy humans | #120 |
| thrombosis study | #120 |
| previous vte | #120 |
| lactoferrin leukocyte | #120 |
| months follow | #120 |
| rivaroxaban patients | #120 |
| risk thromboembolism | #120 |
| mortality diseases | #120 |
| patients prostatic cancer | #121 |
| thrombocytopenia thrombosis | #121 |
| fatal pulmonary embolism | #122 |
| anti factor | #122 |
| patients 6 | #122 |
| oral hormonal | #122 |
| studies venous | #122 |
| early dynamics | #123 |
| placebo standard | #123 |
| 100 patients | #123 |
| heparin | #123 |
| minor bleeding | #123 |
| venous thromboembolism pregnancy | #123 |
| factor xia | #123 |
| acute infection | #123 |
| heparin hirudin | #123 |
| ft4 levels | #124 |
| thrombophilia pregnancy | #124 |
| atherogenic lipid profile | #124 |
| association level | #124 |
| vte lmwh | #124 |
| statin risk | #124 |
| treatment data | #124 |
| elevated liver enzymes | #125 |
| intravenous heparin | #125 |
| puerperal disorders | #125 |
| treatment indication | #125 |
| skin perfusion | #125 |
| thromboembolism recurrence | #125 |
| fibrinolysis inhibitor | #125 |
| bayer | #125 |
| incidence thrombosis | #125 |
| nonsignificantly | #125 |
| peripheral arterial disease | #125 |
| diseases mortality | #125 |
| doacs treatment | #126 |
| distal dvt | #126 |
| upper extremity | #126 |
| thromboprophylaxis lmwh | #127 |
| marder | #127 |
| occurrence vte | #127 |
| patients ventilation | #127 |
| patients permanent | #127 |
| performance scores | #127 |
| unacceptably | #127 |
| prevention | #128 |
| resistance apc | #128 |
| treatment months | #128 |
| direct factor | #128 |
| 50 age | #128 |
| patients conventional therapy | #128 |
| development vte | #128 |
| venous thromboembolism risk | #128 |
| 1041 | #129 |
| elevated biomarkers | #129 |
| riete registry | #129 |
| ctrough | #129 |
| mortality cancer patients | #129 |
| 060 | #129 |
| anticoagulants antithrombins | #130 |
| hospital discharge records | #130 |
| 220 | #130 |
| plaster cast | #130 |
| 194 patients | #130 |
| patients episode | #130 |
| day 10 | #130 |
| internists | #130 |
| pooled incidence | #131 |
| obviating | #131 |
| long‐term clinical outcomes | #131 |
| linear interpolation | #131 |
| 05 patients | #131 |
| tests specificity | #131 |
| hypocoagulability | #132 |
| postpartum period women | #132 |
| rivaroxaban versus | #132 |
| hoc analysis | #132 |
| direct inhibitors | #133 |
| cha2ds2vasc | #133 |
| avidin | #133 |
| enoxaparin treatment | #133 |
| fxa inhibitors | #133 |
| started | #133 |
| 80 anticoagulants | #133 |
| rco vwf | #134 |
| embolism acute | #134 |
| instituted | #134 |
| pulmonary angiography patients | #134 |
| selectin levels | #134 |
| risk pad | #134 |
| activator plasminogen | #135 |
| prevalence dvt | #135 |
| anticoagulant prophylaxis | #135 |
| bnp concentration | #135 |
| clinical prediction | #136 |
| thrombotic syndrome | #136 |
| apixaban edoxaban | #136 |
| followup patients | #136 |
| east asian patients | #136 |
| months anticoagulation | #136 |
| severe pph | #136 |
| 0056 | #136 |
| diagnostic work | #137 |
| factor prothrombin | #137 |
| acquired thrombophilia | #137 |
| 99 patients | #137 |
| phase 3 trials | #137 |
| 2283 | #137 |
| point‐of‐care | #137 |
| sequential application | #137 |
| national guidelines | #138 |
| intravascular coagulation dic | #138 |
| studies mortality | #138 |
| complete inhibition | #138 |
| antidote | #138 |
| bleeding warfarin | #138 |
| enhanced factor | #138 |
| patients comparison | #139 |
| 95 major bleeding | #139 |
| factor viii factor | #139 |
| 3 weeks | #139 |
| oral anticoagulant treatment | #139 |
| 2465 | #139 |
| risk fatal | #139 |
| direct inhibitor | #139 |
| reproducibility risk | #139 |
| ottawa | #140 |
| 80 cohort | #140 |
| distal deep | #140 |
| 0114 | #140 |
| dvt incidence | #140 |
| 12 95 | #140 |
| human activated | #140 |
| 20 iu | #140 |
| vwf rco | #140 |
| antidotes | #141 |
| thromboembolic disorders | #141 |
| pharmacy records | #141 |
| thrombin potential | #142 |
| carriership | #142 |
| warfarin administration | #143 |
| treatment pulmonary | #143 |
| escherichia humans | #143 |
| points 95 | #143 |
| ischaemic events | #143 |
| active malignancy | #143 |
| geneva | #143 |
| jugular veins | #143 |
| fatal pulmonary | #144 |
| postoperative venous | #144 |
| pregnancy female humans | #144 |
| compared treatment | #144 |
| management vte | #144 |
| topic practice patterns | #144 |
| doac treatment | #144 |
| serial testing | #145 |
| referred patients | #145 |
| thrombosis model | #145 |
| patient populations | #145 |
| filters venous | #145 |
| dose rivaroxaban | #145 |
| hyperthyroxinemia | #145 |
| months treatment | #146 |
| protein factor | #146 |
| derived microvesicles | #146 |
| death cancer patients | #146 |
| personal fees | #147 |
| tissue factor pathway | #147 |
| partial thromboplastin | #148 |
| intention treat | #148 |
| 2076 | #148 |
| long‐acting | #148 |
| acute medical illness | #148 |
| embolism diagnosis | #148 |
| rebuttal | #148 |
| antithrombotic drugs | #148 |
| 10 years patients | #148 |
| procoagulant | #149 |
| risk subgroups | #149 |
| thrombocyte | #149 |
| 0·45 | #149 |
| vte hospitalization | #149 |
| diagnostic score | #149 |
| individual patient data | #149 |
| relevant publications | #149 |
| dimer level | #150 |
| additional imaging | #151 |
| enoxaparin unfractionated heparin | #151 |
| coagulation dic | #151 |
| humans injections | #151 |
| patients primary outcome | #152 |
| continuous venovenous | #152 |
| longterm treatment | #152 |
| patient eligibility | #152 |
| bleeding patients | #152 |
| hypercoagulable state | #153 |
| extracorporeal circuit | #153 |
| cardiopulmonary bypass surgery | #153 |
| point systems | #153 |
| thrombosis prevention | #153 |
| thrombosis factor | #154 |
| direct thrombin | #154 |
| dimer levels | #154 |
| bleeding scores | #154 |
| active cancer | #154 |
| angioplasty patients | #154 |
| activity mortality | #154 |
| thromboembolic event | #155 |
| tomography patients | #155 |
| states venous | #155 |
| warfarin apixaban | #155 |
| drug factor | #155 |
| curve sensitivity | #155 |
| fiia | #155 |
| patients gastrointestinal | #156 |
| 09 | #156 |
| vte treatment | #156 |
| recurrent symptoms | #156 |
| daily oral | #156 |
| stockings | #156 |
| coagulant activity | #156 |
| enoxaparin dose | #156 |
| fvl | #156 |
| hemodynamically | #157 |
| prophylaxis patients | #157 |
| cross‐sectional survey | #157 |
| increased thrombin | #157 |
| months chemotherapy | #158 |
| 2126 | #158 |
| duration anticoagulation | #158 |
| 97 | #158 |
| underlying malignancy | #158 |
| dfl | #158 |
| increased risk thrombosis | #159 |
| adjusted relative risk | #159 |
| plasma dimer | #160 |
| guidelines prevention | #160 |
| antithrombotic efficacy | #160 |
| thrombotic disorders | #160 |
| 120 minutes | #160 |
| children fh | #160 |
| schering | #160 |
| 145 patients | #160 |
| antagonists patients | #161 |
| prophylactics | #161 |
| pvo | #161 |
| lysine analogues | #162 |
| 2206 | #162 |
| incidence vte | #162 |
| women time | #162 |
| patients imaging | #162 |
| venous thrombus | #163 |
| 198 patients | #163 |
| lmwh therapy | #163 |
| coagulation blood | #163 |
| rates vte | #163 |
| imaging test | #163 |
| increased plasma levels | #163 |
| strain gauge | #163 |
| factors bleeding | #163 |
| justified | #164 |
| age comorbidity | #164 |
| 028 | #164 |
| observer variability | #164 |
| inborn humans | #164 |
| relatives patients | #165 |
| subhazard | #165 |
| patients enoxaparin | #165 |
| mutation factor | #165 |
| stockings compression | #166 |
| phlebography | #166 |
| viii factor | #166 |
| management venous thromboembolism | #166 |
| pravastatin therapy | #166 |
| microvascular thrombosis | #166 |
| strategies patients | #166 |
| recurrent thrombosis | #167 |
| thrombin venous | #167 |
| ankle brachial abi | #167 |
| 3658 | #167 |
| double heterozygosity | #168 |
| current clinical practice | #168 |
| cvcs | #168 |
| syndrome pts | #168 |
| treatment 3 months | #168 |
| cstatistics | #168 |
| warfarin | #168 |
| recurrent acute | #168 |
| patients infections | #169 |
| postthrombotic syndrome pts | #169 |
| risk profile | #169 |
| 3 12 | #169 |
| fold increased | #169 |
| preexistent | #169 |
| therapeutic range | #169 |
| interobserver agreement | #170 |
| heavy menstrual bleeding | #170 |
| cart patients | #170 |
| postoperative blood loss | #170 |
| thrombosis cancer | #170 |
| recombinant factor | #171 |
| aged algorithms | #171 |
| 57 years | #171 |
| adamts‐13 | #171 |
| venous thrombotic events | #171 |
| antifibrinolytic | #172 |
| patients blood transfusion | #172 |
| clinical trials patients | #172 |
| pulmonology | #172 |
| lmw heparin | #172 |
| vaginal bleeding | #172 |
| risk factors patients | #172 |
| hospitalized medical patients | #173 |
| pulmonary | #173 |
| bleeds | #173 |
| inr | #173 |
| bleeding tendency | #174 |
| laboratory monitoring | #174 |
| patients initial | #174 |
| arterial occlusions | #174 |
| clinically bleeding | #174 |
| vte common | #175 |
| data control | #175 |
| reocclusion | #175 |
| arterial venous | #175 |
| fragment 1 | #175 |
| picotamide | #177 |
| mitsubishi | #177 |
| prothrombin | #177 |
| aspirin ticlopidine | #178 |
| intention analysis | #178 |
| short‐ | #178 |
| hyperthyroidism hypothyroidism | #178 |
| 122 | #178 |
| oral female humans | #179 |
| concomitance | #179 |
| vte event | #179 |
| baseline day | #179 |
| noninferior | #179 |
| additional risk factors | #180 |
| isth | #180 |
| patients deficiency | #180 |
| ventilation perfusion | #180 |
| thromboplastin time | #180 |
| referral bias | #180 |
| aged partial | #181 |
| testing patients | #182 |
| antithrombin | #182 |
| painkillers | #182 |
| acute episode | #182 |
| hyperhomocysteinemic | #183 |
| 2–4 | #183 |
| biological variation | #183 |
| patients major | #183 |
| subsequent diagnosis | #184 |
| treat analysis | #184 |
| thromboinflammation | #184 |
| risk bleeding | #184 |
| n110 | #184 |
| prognosis pulmonary | #184 |
| pregnancy vte | #184 |
| 4150 | #184 |
| incidental | #184 |
| antithrombin iii atiii | #184 |
| coagulation factors | #184 |
| vte age | #185 |
| deficient patients | #185 |
| symptomatic | #186 |
| live birth rate | #186 |
| studies heparin | #186 |
| patients thromboprophylaxis | #186 |
| hemostatic effects | #186 |
| patients intensive units | #186 |
| brain natriuretic | #186 |
| anticoagulated | #186 |
| patients haemophilia | #187 |
| antifibrinolytic agents | #187 |
| safety apixaban | #187 |
| risk composite | #187 |
| cutoff level | #187 |
| humans international | #188 |
| absolute rate | #188 |
| doacs vkas | #188 |
| ratio inr | #188 |
| spontaneous rupture | #188 |
| 926 | #188 |
| prevalence cancer | #188 |
| riete | #189 |
| heparin administration | #189 |
| fibrinolysis | #189 |
| viia female | #189 |
| clinical validity | #189 |
| 64slice | #189 |
| patients netherlands | #189 |
| blood loss patients | #189 |
| willebrand factor antigen | #189 |
| anticoagulant drugs | #190 |
| current views | #190 |
| thrombosis patients | #190 |
| ccus | #190 |
| ischemic event | #190 |
| attending physicians | #191 |
| 07 | #191 |
| score patients | #191 |
| venous outflow | #191 |
| gogh | #191 |
| acute thrombosis | #191 |
| stroke systemic | #192 |
| 1495 | #192 |
| 058 | #192 |
| endothelial cell activation | #193 |
| coagulation assays | #193 |
| prothrombin activation | #194 |
| blood coagulation | #194 |
| 070 | #194 |
| heparin patients | #194 |
| anticoagulation | #194 |
| target range | #195 |
| antixa levels | #195 |
| antagonist treatment | #195 |
| recurrent ischemic events | #195 |
| risk major | #195 |
| 65 months | #195 |
| abnormal test | #196 |
| complications cardiovascular | #196 |
| coagulation status | #196 |
| 29 95 | #196 |
| vwf adamts13 | #198 |
| treatment groups patients | #198 |
| difference treatment | #198 |
| ate | #198 |
| sew2871 | #198 |
| vii rfviia | #198 |
| cachectin | #199 |
| coagulation monitoring | #199 |
| patient diagnosis | #199 |
| obese controls | #200 |
| incidence cardiovascular events | #200 |
| screening patients | #200 |
| patients 12 months | #200 |
| vte incidence | #201 |
| patients abnormal | #201 |
| thrombin factor | #201 |
| validation sets | #201 |
| thromboembolic disease | #201 |
| peritoneovenous | #202 |
| arterial thrombosis | #202 |
| johnson | #202 |
| 17 95 | #202 |
| induced activation | #203 |
| symptomatic pad | #203 |
| invitees | #203 |
| worldwide survey | #203 |
| heparin dose | #203 |
| levonorgestrel | #204 |
| antithrombotic agents | #204 |
| 0 95 | #205 |
| low incidence | #205 |
| thrombophilia risk | #205 |
| stroke systemic embolism | #205 |
| period time | #205 |
| extended thromboprophylaxis | #205 |
| patients anticoagulant therapy | #206 |
| data synthesis | #206 |
| varese | #206 |
| fgt | #206 |
| venous ultrasonography | #206 |
| objectively | #207 |
| systematic review studies | #207 |
| 06 | #207 |
| imt patients | #207 |
| death female humans | #207 |
| methods consecutive | #207 |
| platelet activation patients | #207 |
| fviii | #207 |
| desogestrel | #207 |
| cardiologist | #207 |
| algorithms anticoagulants | #207 |
| bleeding compared | #208 |
| thrombocythaemia | #208 |
| patients hypothyroidism | #208 |
| deficiency risk | #209 |
| free protein | #209 |
| hirudins | #210 |
| tgt | #210 |
| antixa activity | #210 |
| women frequency | #210 |
| toxaemia | #211 |
| stocking | #211 |
| ioxaglate | #211 |
| systemic embolism patients | #211 |
| atrial fibrillation study | #212 |
| anticoagulation management | #212 |
| plasminogen activator activity | #213 |
| heparitin sulfate | #213 |
| dabigatran dose | #214 |
| topic practice | #214 |
| correct interpretation | #214 |
| studies rivaroxaban | #215 |
| standard duration | #215 |
| thrombin inhibition | #215 |
| current developments | #215 |
| factors vte | #215 |
| community hospital | #216 |
| betatg | #216 |
| deamino | #216 |
| warfarin stroke | #216 |
| duplex venous | #216 |
| undergoing total | #217 |
| mildest | #217 |
| studies difference | #217 |
| diagnostic algorithm | #217 |
| obviates | #217 |
| npv 100 | #218 |
| conclusive evidence | #218 |
| g20210a | #218 |
| cstatistic | #218 |
| plasminogen activator inhibitor | #218 |
| 077 95 | #219 |
| deamino arginine | #219 |
| cancer | #219 |
| patients cart | #219 |
| hip replacement surgery | #220 |
| data extraction | #220 |
| vii factor | #220 |
| viii female | #220 |
| techniques female | #220 |
| healthy human subjects | #221 |
| preventive measures | #221 |
| postoperative vte | #221 |
| heparin humans | #221 |
| hmvec | #221 |
| proximally | #222 |
| apc resistance | #222 |
| vte events | #222 |
| engl | #223 |
| 1541 | #223 |
| substantial proportion | #223 |
| pulmonologists | #223 |
| 1 january | #223 |
| thromboendarterectomy | #224 |
| protein pathway | #224 |
| subsequent cancer | #224 |
| topic factor | #224 |
| kruskalwallis | #225 |
| neoplasms prospective | #225 |
| org | #225 |
| balloon coronary anticoagulants | #225 |
| thrombosis warfarin | #225 |
| 0·67 | #226 |
| vascular events patients | #226 |
| extremity amputation | #226 |
| 16 95 | #226 |
| inr monitoring | #226 |
| 35 ± | #227 |
| tests diagnosis | #227 |
| haemostasis | #227 |
| acute medical | #227 |
| ipe | #228 |
| mild hyperhomocysteinemia | #228 |
| scant | #229 |
| residual thrombus | #229 |
| dalteparin | #229 |
| cgp | #229 |
| advocated | #230 |
| 037 | #230 |
| thiazoles | #231 |
| patients discontinuation | #231 |
| major orthopaedic surgery | #231 |
| 6 studies | #231 |
| habitual abortion | #231 |
| urosepsis | #231 |
| severe preeclampsia | #231 |
| ft4 | #231 |
| resource utilisation | #231 |
| equinox | #231 |
| patients warfarin | #232 |
| aspirin dipyridamole | #232 |
| endogenous thrombin potential | #233 |
| surgical embolectomy | #233 |
| recurrence risk factors | #233 |
| humans netherlands | #233 |
| anticoagulant effects | #233 |
| dimer | #233 |
| cancer prevalence | #233 |
| effective alternative | #234 |
| graduated compression | #235 |
| doac | #235 |
| prothrombotic state | #235 |
| venous thromboembolic events | #236 |
| brain natriuretic peptide | #236 |
| humans meta | #236 |
| oral anticoagulants | #237 |
| myocardial infarction 95 | #237 |
| treatment continuation | #237 |
| patients vkas | #238 |
| 6500 | #238 |
| 009 | #238 |
| predictive tests | #238 |
| crossover study | #239 |
| anticoagulants aspirin | #239 |
| rational approach | #239 |
| factor tnf | #239 |
| factor viii fviii | #239 |
| arterial venous thrombosis | #240 |
| patients initial treatment | #240 |
| 045 | #241 |
| hip knee arthroplasty | #241 |
| aspirin heparin | #241 |
| time therapeutic range | #242 |
| bleeding incidence | #242 |
| patients intermittent claudication | #243 |
| prothrombin fragment | #243 |
| pivotal trials | #243 |
| iohexol | #244 |
| n89 | #245 |
| vte risk factors | #245 |
| vte cases | #246 |
| casecontrol | #246 |
| children neonates | #246 |
| thrombogenesis | #246 |
| antithrombotic | #247 |
| warfarin aged | #247 |
| lipoproteina levels | #247 |
| 23 95 | #247 |
| coronary anticoagulants | #248 |
| committees | #248 |
| anti activity | #248 |
| treatment compared | #248 |
| patients solid tumours | #248 |
| score risk | #249 |
| diagnostic models | #249 |
| bleeding rates | #249 |
| multiple comorbidities | #249 |
| fv leiden | #250 |
| ioxaglic | #250 |
| protein risk | #250 |
| ischemic strokes | #250 |
| finalized | #251 |
| microthrombosis | #251 |
| 8595 | #251 |
| patients contraindications | #251 |
| simplification | #252 |
| somit | #252 |
| vkas doacs | #252 |
| incidence | #253 |
| thrombin thrombosis | #253 |
| treatment duration | #254 |
| agents anticoagulants | #254 |
| palga | #255 |
| fibrinolytic activity | #255 |
| medea | #256 |
| activation humans | #256 |
| haul | #256 |
| bleeding risk | #257 |
| continuous intravenous | #257 |
| activity assay | #257 |
| cost‐effectiveness | #257 |
| clinical utility | #257 |
| q24h | #257 |
| fibrin degradation | #258 |
| ctpa | #258 |
| patient subgroups | #258 |
| unpublished data | #259 |
| 30 50 | #259 |
| dvt risk | #260 |
| sspe | #260 |
| noncarriers | #261 |
| thrombus size | #261 |
| toxicosis | #261 |
| heparin dosing | #261 |
| patients hospitalization | #262 |
| optimal duration | #263 |
| risk pulmonary | #263 |
| blind study | #264 |
| graft type | #265 |
| 400 patients | #266 |
| pbac | #267 |
| einstein | #267 |
| endotoxaemia | #268 |
| statins risk | #268 |
| versus aspirin | #269 |
| propeptide | #269 |
| randomised cross | #269 |
| lysis time | #269 |
| malignancy patients | #269 |
| relation time | #269 |
| discontinuing | #270 |
| single test | #270 |
| protein patients | #270 |
| exclusion | #270 |
| hormonal replacement therapy | #271 |
| thrombosis inflammation | #271 |
| protein apc | #271 |
| orthopaedic patients | #271 |
| platelet serotonin | #271 |
| 3·0 | #271 |
| clopidogrel ticlopidine | #272 |
| vte recurrence | #272 |
| bleeding patient | #272 |
| patients combination | #272 |
| groups levels | #272 |
| efficacy analysis | #273 |
| ankle brachial | #273 |
| prevalence pad | #274 |
| risk levels | #274 |
| cleavage sites | #274 |
| months 12 | #274 |
| international normalized | #275 |
| performance score | #275 |
| parenteral nutrition patients | #275 |
| fourth quartile | #276 |
| antithrombotic agent | #276 |
| time aptt | #277 |
| smoking hypertension | #277 |
| normalized ratio | #278 |
| dose reduction | #278 |
| imaging sensitivity | #278 |
| rco | #279 |
| aptt | #279 |
| blood test | #279 |
| exclusion criteria | #280 |
| propositi | #280 |
| partial thromboplastin time | #280 |
| intracranial hemorrhage patients | #280 |
| hospitalized medical | #280 |
| obviate | #280 |
| patients presence | #281 |
| thromboplastin | #282 |
| diagnostic test | #282 |
| thyroid diseases | #283 |
| diagnostic sensitivity | #283 |
| presentation patients | #283 |
| puerperal | #283 |
| neutrophil degranulation | #283 |
| noninferiority margin | #284 |
| animals anticoagulants | #284 |
| departments | #284 |
| favor | #284 |
| test characteristics | #284 |
| outpatient treatment | #284 |
| major orthopaedic | #285 |
| gentamicin treatment | #286 |
| plasma bnp | #286 |
| patients apixaban | #286 |
| 2630 | #286 |
| disseminated intravascular | #287 |
| levels measured | #287 |
| subdistribution | #287 |
| patients pancreatic cancer | #287 |
| clinically | #287 |
| md patients | #288 |
| 227 | #288 |
| oral combined | #288 |
| premature atherosclerosis | #288 |
| substantiation | #289 |
| vte rates | #289 |
| vte women | #289 |
| clot lysis | #289 |
| cvt patients | #289 |
| thrombin time | #290 |
| n59 | #290 |
| 0·50 | #290 |
| extracted data | #291 |
| carriers mutation | #291 |
| oral contraceptives | #291 |
| 016 | #291 |
| current clinical | #291 |
| activator inhibitor | #292 |
| 2 studies | #292 |
| 1603 | #292 |
| willebrand disease vwd | #292 |
| plasmin activity | #293 |
| 1000 personyears | #293 |
| pentasaccharide | #293 |
| patients dabigatran | #293 |
| adverse outcome patients | #293 |
| tissuetype plasminogen activator | #294 |
| patients rivaroxaban | #294 |
| lower extremities | #294 |
| cardiac troponin ctnt | #294 |
| scenario analysis | #295 |
| extremity dvt | #295 |
| 1025 | #295 |
| coagulation factor viii | #296 |
| peripheral vascular | #296 |
| classified | #296 |
| observer agreement | #297 |
| routine monitoring | #297 |
| specificity npv | #298 |
| episode patients | #298 |
| thrombocytes | #298 |
| recurrent miscarriage | #298 |
| patients inr | #299 |
| inferiority | #300 |
| 041 | #301 |
| heparitin | #301 |
| subclinical thyroid dysfunction | #302 |
| aged neoplasms | #302 |
| 155 patients | #302 |
| thromboglobulin | #302 |
| toxemia | #302 |
| absolute difference | #304 |
| 1214 | #304 |
| rivaroxaban dabigatran | #305 |
| prophylactic administration | #306 |
| medline embase | #306 |
| chimpanzees | #307 |
| noninvasive testing | #308 |
| complex concentrate | #309 |
| surgery day | #310 |
| vte pregnancy | #310 |
| thrombotic | #310 |
| hematologic pregnancy | #310 |
| 105 patients | #311 |
| percentage points | #311 |
| antithrombins blood | #311 |
| patients 100 | #311 |
| clinical presentation | #311 |
| 598 | #312 |
| leg male | #312 |
| negative reactions | #313 |
| hereditary thrombophilia | #313 |
| obesity risk factor | #313 |
| vte 95 | #313 |
| diagnosis | #314 |
| puerperium | #315 |
| postpartum haemorrhage | #315 |
| funding | #315 |
| cardiologists | #315 |
| heparin aspirin | #315 |
| therapeutic dose | #316 |
| apixaban versus | #316 |
| adjudicators | #317 |
| patients followup | #317 |
| deciding | #318 |
| 0·92 | #318 |
| decision model | #319 |
| safety outcomes | #319 |
| failure rates | #319 |
| 1731 | #320 |
| influenza infections | #320 |
| catheter thrombosis | #320 |
| patients pregnancy | #320 |
| combined administration | #320 |
| bnp levels | #320 |
| ventricular dysfunction patients | #321 |
| difference risk | #322 |
| intermediate phenotype | #322 |
| additional data | #322 |
| patients noacs | #322 |
| peripheral arterial | #324 |
| glaxosmithkline | #324 |
| inrs | #324 |
| convincing evidence | #325 |
| mortality odds ratio | #325 |
| pulmonary embolus | #326 |
| mechanical heart valves | #326 |
| blood coagulation factor | #326 |
| 122 patients | #326 |
| surgery trauma | #327 |
| clinical | #327 |
| association vte | #329 |
| vitamin administration | #331 |
| pregnancy outcome women | #331 |
| incidence bleeding | #331 |
| thrombotic event | #331 |
| new oral | #332 |
| analysis trials | #333 |
| 95 percent | #333 |
| embase databases | #333 |
| n69 | #333 |
| 95 confidence limits | #334 |
| minor effects | #334 |
| complicate | #334 |
| incidences | #334 |
| patients healthy volunteers | #335 |
| rationale design | #335 |
| fibrillation benzimidazoles | #335 |
| pulmonary perfusion | #336 |
| septicaemia | #336 |
| central venous catheter | #336 |
| 035 | #337 |
| plethysmographic | #337 |
| recurrent | #337 |
| 2 points | #337 |
| total hip replacement | #337 |
| 065 | #337 |
| outpatient management | #338 |
| fatal bleeding | #338 |
| aged netherlands | #338 |
| coagulation abnormalities | #338 |
| prospective clinical study | #339 |
| noacs warfarin | #339 |
| placebo trials | #339 |
| antithrombotic effects | #340 |
| patients 12 | #340 |
| 024 | #340 |
| 217 | #341 |
| coagulation markers | #341 |
| activatable | #341 |
| knee arthroscopy | #342 |
| noac patients | #342 |
| patients covid19 infection | #344 |
| pretest | #344 |
| rfviia | #345 |
| vte prevention | #345 |
| antithrombotic strategies | #345 |
| splanchnic vein thrombosis | #345 |
| diagnosis vte | #346 |
| embolisms | #346 |
| 073 | #347 |
| activated protein resistance | #347 |
| patients thrombosis | #347 |
| cochrane central | #348 |
| 044 | #348 |
| 2575 | #349 |
| chads2 | #349 |
| bsf | #349 |
| brain predictive | #350 |
| tafia | #350 |
| trousseau | #350 |
| randomized studies | #350 |
| factor viii | #351 |
| versus warfarin | #351 |
| 013 | #351 |
| selection bias | #352 |
| anticoagulants noacs | #352 |
| dermatan sulphate | #352 |
| factor activation | #352 |
| relative efficacy | #353 |
| vein | #353 |
| 5075 | #353 |
| 1590 | #353 |
| oral anticoagulant therapy | #353 |
| international normalized ratio | #354 |
| aged pulmonary | #354 |
| studies diagnostic accuracy | #355 |
| patients gp | #355 |
| protein deficiency | #356 |
| categorised | #357 |
| tests prospective studies | #357 |
| intestinal microbiome | #357 |
| post hoc | #357 |
| 127 patients | #358 |
| pilots | #360 |
| sucra | #360 |
| intermittent claudication | #361 |
| treatment risk | #362 |
| consensus agreement | #362 |
| anticoagulation patients | #364 |
| conventional therapy | #365 |
| humans risk | #365 |
| topic female | #366 |
| bleeding rate | #366 |
| prediction models | #367 |
| infrainguinal | #368 |
| patients 3 | #368 |
| time recurrence | #368 |
| thrombin inhibitor | #369 |
| influenza infection | #370 |
| patients acl reconstruction | #370 |
| 6week | #370 |
| endotoxin infusion | #371 |
| venous stasis | #371 |
| 055 | #372 |
| 803 | #372 |
| recombinant activated | #373 |
| aprotinin blood | #373 |
| patients svt | #373 |
| knee surgery | #373 |
| clinical suspicion | #373 |
| patients scores | #374 |
| helical computed tomography | #374 |
| human cytomegalovirus infection | #374 |
| hmb | #375 |
| subcutaneous | #375 |
| lyg | #377 |
| subclinical hyperthyroidism | #378 |
| contraceptives oral | #380 |
| stroke venous | #380 |
| ethinyloestradiol | #381 |
| tafi | #381 |
| antitnf | #382 |
| prefilter | #383 |
| thromboembolic complications | #384 |
| standardized questionnaire | #384 |
| reassessed | #384 |
| multivariate regression analysis | #384 |
| 0·8 | #384 |
| alpha2m | #385 |
| systemic activation | #385 |
| conference proceedings | #386 |
| surrogate outcome | #386 |
| bleeding events | #386 |
| antithrombins | #387 |
| cumulative incidences | #387 |
| sensitivity npv | #387 |
| delegates | #388 |
| major orthopedic | #388 |
| systemic embolism | #389 |
| 880 | #389 |
| referred | #389 |
| safety rivaroxaban | #389 |
| apixaban warfarin | #390 |
| tinzaparin | #390 |
| vitt | #390 |
| postop | #391 |
| comparison patients | #391 |
| abi | #391 |
| increased bleeding | #391 |
| drug prescription | #391 |
| biosis | #391 |
| time presentation | #392 |
| topic female humans | #392 |
| patients chest | #392 |
| factors thrombosis | #393 |
| kappa values | #393 |
| background patients | #394 |
| pulmonary emboli | #394 |
| injections intravenous | #394 |
| clinical score | #394 |
| 007 | #395 |
| bleeding event | #396 |
| popliteal | #396 |
| 95 12 | #396 |
| hirudins humans | #397 |
| replacement surgery | #397 |
| factors factor | #397 |
| embolic events | #397 |
| 665 | #397 |
| risk score patients | #399 |
| heparin induced | #400 |
| patients risk | #400 |
| echography | #400 |
| risk factors asthma | #400 |
| hemostatic parameters | #401 |
| fibrinolytic agents | #402 |
| dabigatran | #403 |
| increased risk vte | #403 |
| controversy | #403 |
| massive pulmonary embolism | #405 |
| 2215 | #406 |
| 075 | #406 |
| treatment patient | #406 |
| thrombolytic agents | #406 |
| factor levels | #408 |
| oral anticoagulant | #408 |
| biologic effects | #410 |
| safety combination | #411 |
| fviii levels | #411 |
| noacs patients | #411 |
| patients assigned | #411 |
| major risk factor | #412 |
| transfusion patients | #412 |
| 20 microg | #412 |
| coagulation patients | #414 |
| maastricht | #414 |
| euthyroidism | #414 |
| xii | #415 |
| aged odds | #415 |
| hypocortisolism | #415 |
| intravascular coagulation | #416 |
| deserve | #416 |
| pai1 levels | #416 |
| dose heparin | #416 |
| data risk | #417 |
| comparable | #417 |
| 95 10 | #417 |
| pretest probability | #418 |
| carotid femoral | #418 |
| 95 | #418 |
| dermatan | #419 |
| risk factors thrombosis | #419 |
| 269 | #419 |
| xia | #420 |
| ototoxicity | #420 |
| fibrillation risk | #421 |
| tests radiography | #422 |
| 1989 | #422 |
| 2850 | #422 |
| fibrillation clinical | #422 |
| fibrinolysin | #423 |
| fviia | #424 |
| subanalysis | #424 |
| prevalence patients | #425 |
| cancer cohort | #426 |
| fii | #426 |
| adjunct | #426 |
| randomised double | #426 |
| consecutive | #427 |
| activated factor | #427 |
| excessive bleeding | #428 |
| daily practice | #428 |
| plg | #428 |
| conferences | #428 |
| daily clinical practice | #429 |
| undergoing elective | #429 |
| idiopathic myelofibrosis | #429 |
| prolactin levels | #429 |
| patients testing | #429 |
| 1904 | #430 |
| bleeding complications | #431 |
| heparinoids | #431 |
| rule | #431 |
| 04 | #432 |
| outpatients | #433 |
| incidence length | #433 |
| ncb | #434 |
| patients systematic review | #434 |
| blood cultures | #436 |
| firstdegree relatives patients | #436 |
| bolus injection | #437 |
| 059 | #437 |
| proven | #439 |
| women compared | #439 |
| dose adjustment | #439 |
| composite point | #439 |
| prostatic cancer | #439 |
| highrisk populations | #441 |
| concomitant medications | #441 |
| 074 | #442 |
| rate vte | #442 |
| –control study | #444 |
| standard therapies | #444 |
| prespecified | #445 |
| patients atrial fibrillation | #446 |
| febrile patients | #446 |
| female fibrinolytic | #447 |
| 58 | #449 |
| utrecht | #449 |
| hellp | #449 |
| patients parenteral nutrition | #449 |
| prevalence distribution | #450 |
| 3 12 months | #450 |
| category | #451 |
| stigmatisation | #451 |
| pipecolic | #452 |
| noninvasive tests | #453 |
| thrombin generation | #453 |
| fatal disease | #453 |
| aspirin risk | #453 |
| factor xii | #454 |
| 30 40 | #454 |
| portal blood | #454 |
| placebo day | #454 |
| 026 | #455 |
| microthrombi | #455 |
| 12week | #455 |
| dichotomized | #456 |
| fviii vwf | #456 |
| squibb | #457 |
| dicumarol | #457 |
| onwards | #457 |
| hazard ratio 95 | #458 |
| anti levels | #458 |
| iii complexes | #458 |
| plasma lipoprotein | #460 |
| recommend | #460 |
| svt | #460 |
| factor fxa | #461 |
| gastrointestinal cancer | #461 |
| expert consensus document | #462 |
| hip arthroplasty replacement | #462 |
| curve biomarkers | #462 |
| guidelines patients | #463 |
| haemolysis | #463 |
| studies ultrasonography | #464 |
| gp iib | #464 |
| patients values | #464 |
| month follow | #465 |
| cancerassociated thrombosis | #466 |
| diabetes stroke | #466 |
| thrombin formation | #467 |
| accuracy detection | #467 |
| patients nsaids | #468 |
| intimamedia thickness | #468 |
| prophylaxis | #468 |
| teaching hospitals | #469 |
| eligible studies | #469 |
| bmi≥30 | #469 |
| roc analysis | #470 |
| 077 | #470 |
| test probability | #470 |
| hemihepatectomy | #470 |
| inr patients | #470 |
| placebo recipients | #471 |
| case control study | #472 |
| hypercoagulability | #472 |
| prophylactic anticoagulation | #472 |
| cardiovascular risk assessment | #473 |
| thrombophilia testing | #474 |
| plethysmograph | #475 |
| patients heparin | #475 |
| heterozygote humans | #475 |
| intermittent pneumatic | #475 |
| 15 95 | #475 |
| endotoxemia | #475 |
| atria | #477 |
| haemophiliacs | #479 |
| patients score | #479 |
| 08 | #479 |
| versus standard | #480 |
| hit patients | #481 |
| acutely | #481 |
| thrombosis cvt | #481 |
| transportability | #482 |
| postoperative blood | #482 |
| advisory | #482 |
| 1162 | #482 |
| thrombin inhibitors | #483 |
| events mortality | #484 |
| patients hematologic malignancies | #485 |
| diagnostic efficacy | #485 |
| awaited | #486 |
| composite scores | #487 |
| secondary prophylaxis | #487 |
| silent | #488 |
| travel | #488 |
| activity patients | #489 |
| 98 | #490 |
| blinded | #491 |
| treatment period | #493 |
| new therapy | #493 |
| residual risk | #493 |
| pan troglodytes | #493 |
| hemophilic | #493 |
| p00007 | #493 |
| vcf | #494 |
| activated protein | #495 |
| favour | #496 |
| dose oral | #496 |
| replacement hip arthroplasty | #496 |
| heterozygote | #496 |
| 271 | #497 |
| topic risk factors | #497 |
| discriminative ability | #498 |
| blockages | #498 |
| risk factors stroke | #498 |
| willebrand disease | #498 |
| hip knee | #501 |
| nri | #502 |
| ptp | #502 |
| deficiencies | #503 |
| ft4 tsh | #503 |
| subcategories | #503 |
| rapid decrease | #504 |
| complications pulmonary | #505 |
| patients referred | #505 |
| 1107 | #505 |
| nondiagnostic | #505 |
| 310 | #506 |
| net clinical | #506 |
| nonionic | #507 |
| day surgery | #507 |
| oftentimes | #507 |
| inhibitors rivaroxaban | #508 |
| 13 95 | #509 |
| contraceptives | #509 |
| aminocaproates | #509 |
| guidelines diagnosis | #509 |
| coagulation tests | #509 |
| angiography patients | #510 |
| new oral anticoagulants | #510 |
| thrombosis animals | #510 |
| degradation products | #510 |
| viii fviii | #511 |
| 019 | #512 |
| epiphenomenon | #512 |
| serial | #513 |
| 056 | #514 |
| highintensity | #514 |
| interim analysis | #514 |
| daycare | #515 |
| safety | #516 |
| crcl | #517 |
| bleeding outcomes | #518 |
| protein antithrombin | #518 |
| sensitivity diagnosis | #518 |
| thrombotic diseases | #518 |
| thrombophilia thrombosis | #518 |
| groups treatment | #519 |
| treatment cancer patients | #519 |
| study sensitivity | #520 |
| duration intensity | #521 |
| 8090 | #521 |
| 1599 | #521 |
| warfarin therapy | #524 |
| fixed doses | #525 |
| general practitioner | #525 |
| 062 | #527 |
| cancer age | #528 |
| cindices | #528 |
| 051 | #529 |
| convincing | #529 |
| 923 | #529 |
| 378 | #529 |
| fatal | #530 |
| health female | #530 |
| medically patients | #531 |
| thrombosis hemostasis | #531 |
| betaalanine | #531 |
| humans postoperative | #531 |
| thrombosis risk | #532 |
| ≥50 years | #532 |
| 068 | #532 |
| intensive units icu | #532 |
| therapy cancer | #534 |
| factor thrombin | #534 |
| 730 | #536 |
| factor pathway | #537 |
| 449 | #538 |
| patients idiopathic | #538 |
| humans neoplasms | #538 |
| cbo | #539 |
| comprehensive search | #539 |
| ddavp | #539 |
| concise | #539 |
| diagnostic accuracy studies | #540 |
| clinical review | #540 |
| diagnosis acute | #540 |
| conventional treatment | #543 |
| thrombotic risk | #543 |
| patients eligible | #543 |
| bleeding episodes | #543 |
| 234 | #543 |
| vascular obstruction | #543 |
| coagulative | #544 |
| 00 | #544 |
| jak2 mutation | #544 |
| pad abi | #544 |
| hellp syndrome | #545 |
| perc | #545 |
| v617f | #545 |
| prospective cohort study | #545 |
| association statin | #546 |
| screening strategies | #546 |
| bureau | #547 |
| prothrombin complex | #547 |
| primary | #548 |
| overt | #549 |
| adequate | #549 |
| 95 difference | #549 |
| cancer type | #550 |
| reviewers | #550 |
| percent patients | #550 |
| conduction anesthesia | #550 |
| 1103 | #550 |
| platelet inhibitors | #550 |
| studies sensitivity | #552 |
| day patients | #552 |
| careful | #552 |
| 500 patients | #552 |
| management bleeding | #552 |
| amsterdam | #552 |
| femoral arteries | #553 |
| general population patients | #554 |
| ttr | #556 |
| humans infusions | #557 |
| 66 patients | #558 |
| factor vii | #558 |
| vivo treatment | #558 |
| bleeding time | #559 |
| orthopedic surgery | #559 |
| limulus | #561 |
| female humans tests | #563 |
| risk development | #563 |
| board directors | #563 |
| patients transfusion | #563 |
| appears | #564 |
| anamnesis | #564 |
| hip replacement | #564 |
| increasing risk | #565 |
| hyperfibrinolysis | #565 |
| solid tumours | #566 |
| withholding | #566 |
| cardiac troponins | #566 |
| roc curves | #568 |
| n46 | #568 |
| patients 2 years | #568 |
| alpha1antitrypsin | #571 |
| levothyroxine | #571 |
| aggravation | #572 |
| ctnt | #573 |
| menstrual bleeding | #574 |
| cutoff point | #574 |
| revascularization procedures | #574 |
| women proportion | #575 |
| subcutaneously | #575 |
| major bleedings | #575 |
| progression cancer | #577 |
| endothelial barrier | #578 |
| patients vka | #578 |
| pharma | #579 |
| thiophenes | #579 |
| endotoxin | #579 |
| notice | #580 |
| 99 | #580 |
| diagnostic tools | #580 |
| cancer thrombosis | #581 |
| subgroups patients | #583 |
| unselected patients | #584 |
| dummy | #584 |
| 094 | #585 |
| coagulation disorders | #585 |
| chondroitin sulfates | #586 |
| major orthopedic surgery | #588 |
| feasibility safety | #588 |
| helminth proteins | #589 |
| healthy human | #590 |
| beta alanine | #590 |
| malignancy | #590 |
| thrombophilias | #590 |
| reversal agents | #590 |
| doppler ultrasound | #592 |
| conventional management | #592 |
| massive pulmonary | #592 |
| bmi30 | #594 |
| factor fv | #595 |
| severe bleeding | #597 |
| replacement knee | #597 |
| ldf | #597 |
| patency rates | #597 |
| major hemorrhage | #597 |
| infusions intravenous | #598 |
| analysis topic | #599 |
| loss surgical | #600 |
| tests sensitivity | #600 |
| 046 | #601 |
| association patients | #602 |
| vwd | #603 |
| events occurred | #604 |
| clinical characteristics patients | #604 |
| comorbid conditions | #604 |
| diagnostic studies | #606 |
| 0·3 | #607 |
| activated coagulation | #607 |
| patients antibodies | #607 |
| initial increase | #607 |
| treatment acute | #608 |
| pfizer | #609 |
| tissue factor | #609 |
| arbitrage | #609 |
| patients death | #610 |
| benefit risk | #610 |
| airline | #610 |
| 100 years | #610 |
| clinical evaluation | #611 |
| ultrasonography | #613 |
| coagulation inflammation | #614 |
| reluctant | #615 |
| patients bariatric surgery | #615 |
| leg | #615 |
| complications risk | #616 |
| treatment rivaroxaban | #617 |
| arterial disease | #617 |
| occurred | #618 |
| 467 | #618 |
| stroke atrial fibrillation | #618 |
| compared placebo | #620 |
| fh patients | #620 |
| patients elevated | #621 |
| advisory committees | #621 |
| 1002 | #622 |
| sgs | #623 |
| thyrotoxic | #623 |
| thrombocytopenia hit | #623 |
| peptide bnp | #625 |
| cochrane central register | #625 |
| topic practice guidelines | #626 |
| stopped | #626 |
| stroke warfarin | #627 |
| women risk factors | #628 |
| 5000 | #628 |
| warfarin risk | #628 |
| 66 | #628 |
| human subjects | #629 |
| physical training | #629 |
| diagnostic algorithms | #629 |
| referral patients | #629 |
| absolute | #630 |
| sanofi | #630 |
| atiii | #632 |
| risk treatment | #633 |
| screening strategy | #634 |
| outweigh | #635 |
| uneventful | #635 |
| pentoxifylline | #637 |
| travelling | #638 |
| 14 95 | #640 |
| 95 allcause mortality | #640 |
| study quality | #641 |
| proceedings | #641 |
| 3050 | #642 |
| predictive performance | #642 |
| threatening bleeding | #643 |
| neutrophilia | #643 |
| primary outcome measure | #647 |
| association mortality | #647 |
| studies efficacy | #648 |
| necessitating | #648 |
| statin treatment | #648 |
| thrombolysis patients | #651 |
| fixed | #651 |
| 036 | #651 |
| organisations | #652 |
| troglodytes | #652 |
| hemorrhagic stroke | #653 |
| fxa | #653 |
| 127 | #655 |
| patients review | #657 |
| bleeding death | #659 |
| 69 | #659 |
| coronary stent implantation | #659 |
| haematoma | #660 |
| physical examination | #661 |
| tertiles | #661 |
| coagulation proteins | #661 |
| haemophilia | #662 |
| clinical presentations | #662 |
| 1028 | #663 |
| 95 studies | #663 |
| long term treatment | #664 |
| provoked | #664 |
| sepsis shock | #665 |
| deep | #666 |
| phase iii studies | #666 |
| patients completed | #667 |
| onethird | #667 |
| presence patients | #667 |
| guideline adherence | #667 |
| male medical | #668 |
| 8 wk | #669 |
| 1110 | #671 |
| phenprocoumon | #672 |
| patients cteph | #673 |
| elevated plasma | #673 |
| hospitalization hf | #674 |
| managing | #674 |
| il6 levels | #675 |
| inhibitor 1 | #675 |
| clotting factors | #675 |
| prothrombotic | #676 |
| highincome countries | #676 |
| asymptomatic subjects | #677 |
| favourably | #678 |
| jugular | #679 |
| medicine humans | #681 |
| pulmonary endarterectomy | #681 |
| suspicion | #682 |
| conclude | #687 |
| apolipoproteina | #688 |
| efficacy safety | #690 |
| ambulatory patients | #692 |
| patients bleeding | #692 |
| activator pa | #693 |
| myocardial infarctions | #693 |
| graduated | #693 |
| precise mechanisms | #694 |
| intracranial bleeding | #694 |
| administer | #694 |
| composite outcome | #694 |
| 1718 | #695 |
| stroke prevention patients | #696 |
| combined oral contraceptives | #696 |
| moyamoya | #696 |
| ratio male | #698 |
| participant data | #698 |
| difference 95 | #698 |
| compression devices | #700 |
| episode | #700 |
| diagnostic errors | #702 |
| prothrombin gene | #702 |
| therapeutic management | #702 |
| veins venous | #703 |
| patients confirmed | #703 |
| surgery risk | #703 |
| willebrand | #704 |
| data incidence | #706 |
| subclinical hypothyroidism | #708 |
| clinical expression | #709 |
| directors | #709 |
| starters | #711 |
| 048 | #712 |
| gastrointestinal bleeding | #712 |
| medical patients | #712 |
| gynaecology | #712 |
| radionuclide imaging | #713 |
| neurosurgical patients | #714 |
| 1098 | #714 |
| rate death | #714 |
| intravenous bolus | #715 |
| rivaroxaban stroke | #716 |
| menstrual period | #716 |
| cancer groups | #717 |
| adequately | #717 |
| solid cancer | #718 |
| 10 30 | #718 |
| falsely | #718 |
| plasminogen | #719 |
| reagent kits | #719 |
| pulmonary medicine | #720 |
| clinical judgment | #721 |
| pyrazoles pyridines | #721 |
| nordisk | #721 |
| accp | #721 |
| s1p1 | #722 |
| 95 hazard ratio | #724 |
| abnormal | #726 |
| follow period | #726 |
| gentamicins | #727 |
| 59 patients | #727 |
| orthopaedic surgery | #728 |
| diagnostic therapeutic | #728 |
| diagnostic tests | #730 |
| gentamicin | #732 |
| leeches | #732 |
| tumor necrosis factor | #733 |
| oral contraception | #733 |
| relative risk 95 | #734 |
| disease pad | #735 |
| hull | #735 |
| patients levels | #735 |
| clinical prediction rule | #736 |
| atrial fibrillation risk | #736 |
| tests retrospective studies | #736 |
| post hoc analysis | #739 |
| 6 12 | #739 |
| anti tnf | #740 |
| evaluable patients | #741 |
| unclear | #742 |
| early pregnancy loss | #742 |
| 040 | #742 |
| topic predictive | #743 |
| illness time factors | #744 |
| molecular weight | #744 |
| betathromboglobulin | #744 |
| antithrombin activity | #746 |
| 285 | #746 |
| etp | #746 |
| patients 50 years | #746 |
| leukocyte activation | #748 |
| thrombolytic therapy | #749 |
| hospitalization heart failure | #750 |
| indication | #752 |
| advisable | #754 |
| fibrin formation | #754 |
| primary patients | #755 |
| 95 combination | #756 |
| pneumatic compression | #756 |
| 95 risk factors | #756 |
| answer | #756 |
| hf risk | #756 |
| venovenous | #757 |
| 1·7 | #758 |
| 85 | #759 |
| loe | #759 |
| inflammation coagulation | #760 |
| patients peripheral | #761 |
| proportion women | #763 |
| 435 | #763 |
| cprs | #764 |
| start treatment | #764 |
| hip surgery | #765 |
| 689 | #767 |
| risk pregnancy | #767 |
| aspirin clopidogrel | #767 |
| 732 | #768 |
| method drug | #769 |
| relevant | #770 |
| groups patients | #770 |
| 566 | #770 |
| baseline values | #772 |
| graft patency | #772 |
| patients criteria | #773 |
| subcutaneous injections | #774 |
| bmi patients | #774 |
| 1·5 | #776 |
| 992 | #777 |
| dose intravenous | #778 |
| patients 65 years | #778 |
| dose warfarin | #778 |
| study groups | #778 |
| miscarriage | #779 |
| patients hyperthyroidism | #780 |
| plasmin generation | #780 |
| thromboembolism prophylaxis | #780 |
| 066 | #780 |
| age ≥ | #782 |
| factor ixa | #785 |
| onefifth | #785 |
| abnormalities patients | #786 |
| topic disease models | #787 |
| cteph | #787 |
| 100 personyears | #787 |
| general practitioners | #787 |
| polypharmacy | #787 |
| preferable | #788 |
| secondary outcome | #791 |
| mechanical heart | #793 |
| recombinant tissue | #793 |
| risk factors risk | #795 |
| 047 | #795 |
| inactivators | #795 |
| patency | #796 |
| patient years | #796 |
| studies prevalence | #797 |
| eligible | #797 |
| netherlands | #797 |
| femoropopliteal | #798 |
| lupus anticoagulant | #798 |
| patients lower | #799 |
| theme | #799 |
| estrogen therapy | #799 |
| hemophilia patients | #800 |
| willebrand factor | #802 |
| randomized patients | #804 |
| subclinical | #804 |
| anticoagulant agents | #805 |
| microvesicles | #805 |
| adverse outcomes patients | #806 |
| fibrillation blood | #806 |
| stroke risk factors | #807 |
| ventricular dysfunction | #808 |
| hypertension cteph | #809 |
| efficacy patients | #809 |
| activator inhibitor1 | #810 |
| 069 | #811 |
| model patients | #813 |
| primary aim | #814 |
| flights | #816 |
| factor vwf | #816 |
| 0·4 | #818 |
| vehicle control | #820 |
| irrespective | #820 |
| health predictive | #820 |
| abruptio | #821 |
| neuroradiologist | #822 |
| prevention patients | #823 |
| reduction mortality | #823 |
| single administration | #824 |
| coc | #824 |
| risk benefit | #825 |
| study incidence | #827 |
| cardioembolic stroke | #828 |
| gp | #828 |
| patients anticoagulants | #830 |
| cava filters | #832 |
| 93 | #833 |
| myers | #833 |
| antithrombotic treatment | #833 |
| abortion habitual | #835 |
| oral adult | #836 |
| plough | #836 |
| noac | #837 |
| versus placebo | #837 |
| 87 | #838 |
| 057 | #839 |
| genetic defect | #841 |
| risk scores | #844 |
| 49 | #846 |
| antithrombotic therapy | #846 |
| 072 | #847 |
| multidetector row | #847 |
| advise | #848 |
| recurrence risk | #849 |
| caesarean | #850 |
| patients diagnosis | #850 |
| area roc curve | #852 |
| 30 patients | #853 |
| pre‐eclampsia | #853 |
| reference method | #853 |
| advanced prostate | #854 |
| fibrin | #855 |
| clopidogrel aspirin | #855 |
| patients mutation | #859 |
| ultrafiltrate | #860 |
| dutch population | #861 |
| microg | #862 |
| cardiometabolic disease | #863 |
| 090 | #865 |
| placebo study | #866 |
| diagnostic methods | #868 |
| 1046 | #869 |
| 6 month | #870 |
| pyridones | #870 |
| longterm clinical outcomes | #872 |
| individual participant | #872 |
| favoring | #873 |
| tasman | #873 |
| targeted inhibition | #874 |
| imaging reproducibility | #874 |
| thromboembolic pulmonary | #874 |
| titles | #875 |
| plasminogen activation | #875 |
| n15 | #876 |
| cha2ds2 | #877 |
| dabigatran rivaroxaban | #878 |
| risk thromboembolic | #878 |
| 57 | #879 |
| anticoagulants atrial | #879 |
| oral | #881 |
| angiograms | #882 |
| control trial | #883 |
| 92 | #884 |
| imaging tests | #885 |
| prostate turp | #888 |
| handbook | #890 |
| 084 | #894 |
| male mexico | #894 |
| domiciliary | #894 |
| loading dose | #896 |
| p011 | #896 |
| repeatedly | #897 |
| uln | #901 |
| indefinite | #902 |
| bleedings | #904 |
| vkorc1 | #905 |
| wml | #906 |
| 064 | #908 |
| factor activity | #908 |
| subcutaneous administration | #909 |
| patients clinical trials | #911 |
| documented | #911 |
| haemostatic | #912 |
| initially | #912 |
| impedance | #913 |
| specificity sensitivity | #914 |
| combined approach | #916 |
| haemodialysis patients | #916 |
| 317 | #917 |
| thromboembolic events | #918 |
| 022 | #918 |
| chronic thromboembolic | #919 |
| standard patients | #920 |
| randomeffects model | #920 |
| antagonist oral | #920 |
| loss patients | #921 |
| ultrasound examination | #921 |
| optimal dose | #921 |
| practise | #923 |
| estimate male | #923 |
| multifactorial disease | #925 |
| study medication | #925 |
| total hip | #926 |
| safer | #928 |
| 902 | #928 |
| 004 | #929 |
| recurrent events | #930 |
| fxi | #931 |
| treatment placebo | #934 |
| wording | #934 |
| 84 | #936 |
| publication clinical trials | #937 |
| 60 patients | #938 |
| subgroup patients | #938 |
| rrr | #940 |
| families patients | #941 |
| teaching hospital | #943 |
| women preeclampsia | #944 |
| stroke atrial | #944 |
| echocardiographically | #944 |
| emboli | #945 |
| ssc | #946 |
| predictive values | #946 |
| anticoagulation treatment | #947 |
| knee replacement | #948 |
| extensive disease | #948 |
| diagnostic | #948 |
| previous diagnosis | #951 |
| adjudication | #954 |
| registro | #956 |
| dic | #956 |
| cancer humans | #956 |
| network metaanalysis | #956 |
| venous insufficiency | #957 |
| reassuring | #957 |
| day1 | #958 |
| efficacy | #958 |
| retropubic | #961 |
| combined oral | #961 |
| guidelines recommend | #962 |
| 3 months | #963 |
| blood product | #964 |
| travellers | #965 |
| inhibitor1 | #966 |
| reference lists | #966 |
| peaking | #969 |
| greater risk | #970 |
| allogeneic blood | #971 |
| hoc | #973 |
| prevalence characteristics | #973 |
| antiplatelet | #973 |
| risk allcause mortality | #973 |
| segmental | #974 |
| patients anticoagulation | #975 |
| vascular humans | #976 |
| female fibrinogen | #976 |
| fvii | #978 |
| false negative | #979 |
| onset aged aged | #980 |
| 071 | #980 |
| 50 100 | #980 |
| early gestation | #984 |
| 426 | #986 |
| prophylactic treatment | #987 |
| randomised trials | #987 |
| patients safety | #988 |
| vascular patency | #989 |
| study treatment | #990 |
| rises | #991 |
| missed | #991 |
| seminar | #992 |
| academic medical center | #992 |
| counteracted | #993 |
| normal lung | #993 |
| treatment bleeding | #994 |
| 226 | #999 |
| aged | #999 |
| thromboembolic risk | #1000 |
| lower extremity | #1000 |
| justification | #1000 |
| tissue type | #1001 |
| parenteral administration | #1002 |
| rivaroxaban apixaban | #1002 |
| eclamptic | #1003 |
| interleukin 6 | #1005 |
| extended | #1005 |
| hyperprolactinaemia | #1005 |
| pyridines | #1006 |
| easier | #1007 |
| orthosis | #1007 |
| 50 patients | #1007 |
| valsalva maneuver | #1009 |
| venous catheter | #1011 |
| individual participant data | #1012 |
| weighing | #1014 |
| pounds | #1018 |
| ticlopidine | #1018 |
| clotting time | #1019 |
| prostatic carcinoma | #1020 |
| 200 patients | #1022 |
| years risk | #1023 |
| cha2ds2 vasc | #1023 |
| humans randomized | #1024 |
| international prospective | #1024 |
| 076 | #1025 |
| diagnostic challenge | #1026 |
| prothrombin time | #1027 |
| decision analysis | #1030 |
| firstdegree relatives | #1030 |
| ixa | #1031 |
| prolactin | #1032 |
| cardiovascular event | #1033 |
| risk hemorrhage | #1033 |
| relatives | #1033 |
| 052 | #1035 |
| male netherlands | #1037 |
| graft occlusion | #1037 |
| 2 hours | #1039 |
| detect | #1040 |
| 025 | #1041 |
| 3 6 months | #1046 |
| vwf levels | #1047 |
| patients severe asthma | #1047 |
| patients massive | #1050 |
| examiner | #1050 |
| continuation | #1052 |
| patients analysis | #1053 |
| 221 | #1054 |
| mean±sd | #1054 |
| free triiodothyronine | #1056 |
| diseases liver | #1057 |
| 179 | #1060 |
| coagulant | #1060 |
| birth rate | #1060 |
| pad | #1061 |
| 610 | #1061 |
| published literature | #1062 |
| primary data | #1062 |
| false | #1064 |
| prekallikrein | #1065 |
| 150 | #1065 |
| live birth | #1066 |
| 00008 | #1066 |
| 101 | #1066 |
| lysosphingolipid | #1067 |
| cut | #1067 |
| pmol | #1068 |
| register controlled | #1070 |
| 95 increased risk | #1070 |
| observer variation | #1071 |
| specialties | #1072 |
| continued | #1073 |
| laboratory diagnosis | #1074 |
| thorax | #1074 |
| systematic search | #1078 |
| 063 | #1080 |
| advocate | #1080 |
| drawbacks | #1082 |
| f1 | #1087 |
| longterm therapy | #1087 |
| bandages | #1089 |
| clarifications | #1095 |
| stopping | #1095 |
| mandated | #1096 |
| idarucizumab | #1096 |
| diagnostic utility | #1096 |
| 083 | #1099 |
| 1223 | #1099 |
| 62 | #1102 |
| 96 | #1104 |
| fourfold | #1105 |
| blueprint | #1105 |
| peptide brain | #1107 |
| clinical protocols | #1107 |
| pending | #1111 |
| incidence pulmonary | #1112 |
| assigned | #1113 |
| diagnostic approach | #1115 |
| bypass grafts | #1116 |
| haemodialysis | #1116 |
| 252 | #1117 |
| qualified | #1118 |
| sensitivity specificity | #1119 |
| critical appraisal | #1120 |
| randomized controlled trials | #1122 |
| resistance factor | #1123 |
| probands | #1123 |
| new developments | #1124 |
| advised | #1125 |
| new perspectives | #1126 |
| 445 | #1126 |
| cip | #1127 |
| heparininduced thrombocytopenia | #1127 |
| patients pad | #1128 |
| judged | #1132 |
| discretion | #1132 |
| statistic | #1133 |
| ≤10 | #1133 |
| 95 confidence interval | #1134 |
| pulse rate | #1135 |
| gram negative | #1137 |
| 1043 | #1139 |
| disseminated | #1140 |
| 635 | #1141 |
| superior efficacy | #1141 |
| 86 | #1143 |
| 734 | #1145 |
| 844 | #1147 |
| roc curve | #1150 |
| refusal | #1150 |
| medline | #1151 |
| medical records | #1151 |
| embolectomy | #1153 |
| longterm complications | #1154 |
| risk recurrence | #1155 |
| blood loss | #1156 |
| anticoagulation therapy | #1156 |
| patients influenza | #1156 |
| prophylaxis treatment | #1157 |
| 3040 | #1158 |
| patients increased | #1159 |
| extension study | #1161 |
| cvc | #1162 |
| published guidelines | #1163 |
| bristol | #1163 |
| safety concerns | #1164 |
| intermittent | #1164 |
| hyperhomocysteinemia | #1164 |
| viii | #1164 |
| stable angina | #1164 |
| thromboembolism risk | #1165 |
| age 65 years | #1165 |
| angiogram | #1167 |
| atherosclerotic disease | #1172 |
| crossover design | #1172 |
| perioperative bleeding | #1172 |
| glucocorticoid treatment | #1172 |
| occlusive diseases | #1173 |
| practice guideline | #1173 |
| 5 years patients | #1176 |
| macroglobulin | #1176 |
| findings patients | #1178 |
| analysis studies | #1178 |
| 79 | #1179 |
| conceive | #1181 |
| concealed | #1181 |
| unaware | #1182 |
| hospitalized patients | #1182 |
| patients obesity | #1182 |
| combined therapy | #1186 |
| conclusive | #1186 |
| occult | #1189 |
| degree relatives | #1189 |
| adult analysis | #1191 |
| cus | #1194 |
| administration oral | #1195 |
| 21 patients | #1197 |
| mandate | #1199 |
| international society | #1199 |
| cardiotonic agents | #1199 |
| hypercortisolism | #1200 |
| 83 | #1203 |
| categorized | #1204 |
| 015 | #1204 |
| quantitative trait locus | #1204 |
| increase plasma | #1205 |
| 31 | #1207 |
| biomarkers blood | #1210 |
| 56 patients | #1212 |
| multicenter randomized | #1214 |
| pph | #1214 |
| 103 | #1218 |
| scores patients | #1221 |
| patient treatment | #1221 |
| warranted | #1221 |
| ultrasound screening | #1222 |
| 6months | #1223 |
| peak levels | #1224 |
| 64 patients | #1224 |
| vasc | #1225 |
| 16 patients | #1226 |
| blind | #1227 |
| sixfold | #1227 |
| consensus guidelines | #1228 |
| metabolic syndrome patients | #1228 |
| trial background | #1229 |
| peptide hydrolases | #1229 |
| radionuclide | #1229 |
| 65 patients | #1230 |
| rules | #1232 |
| doubles | #1232 |
| aspirin | #1234 |
| postoperative hemorrhage | #1238 |
| milliliter | #1238 |
| coronary angiography patients | #1238 |
| humans length | #1240 |
| clinical criteria | #1241 |
| patients fh | #1242 |
| vte prophylaxis | #1244 |
| neurohormone | #1245 |
| multinational | #1246 |
| thrombolytic | #1247 |
| knee arthroplasty | #1248 |
| intermediate risk | #1250 |
| matter lesions | #1252 |
| ml1 | #1252 |
| subgroups | #1252 |
| artery pulmonary | #1254 |
| search strategy | #1257 |
| extensive | #1257 |
| oral vitamin | #1257 |
| prospective cohort | #1258 |
| symptomatic patients | #1259 |
| major surgery | #1262 |
| entity | #1266 |
| troponins | #1266 |
| visiting | #1266 |
| macroglobulins | #1267 |
| 172 | #1270 |
| amputations | #1273 |
| equally | #1274 |
| intensive patients | #1274 |
| design study | #1276 |
| antiplatelet agents | #1278 |
| proportionally | #1279 |
| routine screening | #1281 |
| 75 years | #1281 |
| statin users | #1281 |
| factors ultrasonography | #1285 |
| thyroxine | #1287 |
| 050 | #1288 |
| blockers | #1290 |
| dermatan sulfate | #1292 |
| perfusion defects | #1295 |
| janssen | #1295 |
| scan | #1295 |
| hemofiltration | #1297 |
| predictive | #1297 |
| insufficiently | #1298 |
| low prevalence | #1299 |
| cardiovascular complications | #1299 |
| dutch | #1300 |
| prolong | #1302 |
| 61 | #1303 |
| pf4 | #1303 |
| pulmonary circulation | #1304 |
| scores | #1305 |
| 95 mortality | #1307 |
| risk difference | #1312 |
| 1st | #1312 |
| apoa | #1312 |
| cyproterone | #1312 |
| adamts13 activity | #1313 |
| 0·7 | #1314 |
| current strategies | #1314 |
| tests severity | #1314 |
| claudication | #1316 |
| atrial fibrillation | #1316 |
| carotid imt | #1317 |
| international guidelines | #1318 |
| replacement hip | #1320 |
| study time | #1321 |
| coagulation factor | #1322 |
| vienna | #1323 |
| increases risk | #1324 |
| lipoproteina | #1325 |
| glycoprotein gpiib | #1325 |
| patients coronavirus disease | #1326 |
| vascular diseases | #1329 |
| beneficial | #1329 |
| antibodies monoclonal antibodies | #1329 |
| low moderate | #1330 |
| plasminogen activators | #1330 |
| thyroid disorders | #1330 |
| 77 | #1331 |
| 6 months patients | #1331 |
| coagulation cascade | #1331 |
| 126 | #1332 |
| frequent complication | #1333 |
| adjusted age | #1335 |
| transurethral resection | #1336 |
| likelihood ratio | #1342 |
| venous catheters | #1342 |
| 91 | #1342 |
| blood sample | #1343 |
| daily patients | #1344 |
| surgical trauma | #1347 |
| antitrypsin | #1347 |
| patients relatives | #1351 |
| neurosurgery | #1355 |
| arthroplasty patients | #1356 |
| patients stable angina | #1357 |
| allcause mortality 95 | #1359 |
| experimental model | #1359 |
| 15 patients | #1359 |
| vwf | #1363 |
| arsenal | #1363 |
| limb salvage | #1363 |
| vtes | #1365 |
| 95 patients | #1366 |
| operatively | #1367 |
| 12 month | #1369 |
| heart valves | #1370 |
| starting | #1372 |
| ethinyl | #1373 |
| acetylsalicylic | #1375 |
| costeffectiveness analysis | #1376 |
| utmost | #1378 |
| consented | #1382 |
| management patients | #1383 |
| gps | #1384 |
| 224 | #1385 |
| dl1 | #1385 |
| noninferiority | #1385 |
| disorders blood | #1386 |
| ivt | #1389 |
| patients cvd | #1392 |
| substitute | #1394 |
| screening tests | #1399 |
| patients control subjects | #1400 |
| record linkage | #1400 |
| antisense oligonucleotide | #1402 |
| equipoise | #1402 |
| 82 | #1402 |
| mandatory | #1403 |
| clinical challenges | #1404 |
| patients advanced cancer | #1405 |
| 1886 | #1405 |
| pregnancy loss | #1406 |
| obese patients | #1406 |
| 515 | #1408 |
| categories | #1408 |
| 994 | #1409 |
| reflected | #1410 |
| inception | #1411 |
| tranexamic | #1413 |
| adamts13 | #1417 |
| 0·1 | #1418 |
| 7 weeks | #1419 |
| 3 6 | #1419 |
| thrombotic complications | #1419 |
| 6 weeks | #1419 |
| total knee | #1420 |
| 95 0 | #1421 |
| followup data | #1422 |
| university hospitals | #1422 |
| ≥55 | #1424 |
| 061 | #1424 |
| daily | #1424 |
| eightfold | #1425 |
| 080 | #1427 |
| randomised controlled trials | #1427 |
| rgs | #1430 |
| casecontrol study | #1430 |
| outcome pregnancy | #1438 |
| imaging radiopharmaceuticals | #1439 |
| 096 | #1439 |
| 78 | #1443 |
| principal | #1443 |
| 1123 | #1445 |
| weight bmi | #1446 |
| drug levels | #1446 |
| outcome studies | #1446 |
| underreporting | #1451 |
| support systems | #1452 |
| confusion | #1454 |
| population patients | #1454 |
| platelet factor | #1455 |
| aged blood | #1455 |
| dip | #1456 |
| mbe | #1457 |
| conclusions patients | #1459 |
| prospectively | #1460 |
| multicenter studies | #1461 |
| humans | #1463 |
| inaccuracy | #1464 |
| actual | #1466 |
| funded | #1466 |
| avoided | #1468 |
| 0·9 | #1468 |
| 26 patients | #1469 |
| heart failure hf | #1469 |
| groin | #1471 |
| risk factors mortality | #1472 |
| prevalences | #1473 |
| 1215 | #1473 |
| centrally | #1474 |
| probability | #1477 |
| systemic infection | #1477 |
| lowest tertile | #1478 |
| remained | #1480 |
| atherothrombotic | #1481 |
| undetermined | #1482 |
| dysfunction patients | #1483 |
| cushing syndrome | #1485 |
| analysis randomized | #1485 |
| methodologic | #1486 |
| phase iii trials | #1486 |
| general practice | #1491 |
| patients control | #1495 |
| procoagulant activity | #1495 |
| randomly | #1496 |
| 64 | #1498 |
| aged natriuretic | #1499 |
| exposing | #1501 |
| imt | #1507 |
| fracture surgery | #1510 |
| specificity 100 | #1512 |
| odds ratio 95 | #1513 |
| adverse outcome | #1514 |
| growing body | #1514 |
| proximal | #1516 |
| ganz | #1520 |
| patients 10 | #1520 |
| pregnancy postpartum | #1520 |
| subgroup | #1521 |
| factor deficiency | #1522 |
| gsk | #1524 |
| chills | #1526 |
| contraindicated | #1527 |
| thrombotic events | #1527 |
| time study | #1529 |
| score | #1529 |
| oral contraceptive | #1534 |
| mechanical compression | #1536 |
| immobilisation | #1539 |
| comparator | #1540 |
| patients life | #1541 |
| humans neoplasm | #1542 |
| hemostatics humans | #1545 |
| 089 | #1548 |
| tsh levels | #1551 |
| patients severe sepsis | #1552 |
| live births | #1552 |
| 23 | #1554 |
| vascular thrombosis | #1555 |
| fees | #1556 |
| neonatal period | #1558 |
| patients year | #1559 |
| discriminatory | #1562 |
| hypothyroidism | #1563 |
| enfermedad | #1564 |
| pfa | #1564 |
| iii topic | #1565 |
| treatment prevention | #1566 |
| topic | #1566 |
| 95ci | #1568 |
| deficient | #1568 |
| hyperlipoproteinemia type | #1568 |
| cushings syndrome | #1568 |
| aged biomarkers | #1571 |
| plasminogen activator | #1575 |
| 36 | #1575 |
| humans platelet | #1576 |
| 012 | #1577 |
| hyperlipoproteinemia | #1580 |
| risk myocardial infarction | #1584 |
| cocs | #1586 |
| activation markers | #1586 |
| thyroid dysfunction | #1586 |
| study entry | #1586 |
| studies association | #1587 |
| adjusted hazard ratio | #1589 |
| volunteers | #1591 |
| 1·1 | #1594 |
| total mortality | #1594 |
| translates | #1597 |
| noncancer | #1598 |
| placebo | #1598 |
| exclude | #1599 |
| lmw | #1601 |
| figures | #1604 |
| paroxetine | #1606 |
| abdominal surgery | #1607 |
| complement pathway | #1609 |
| curability | #1610 |
| 162 | #1613 |
| general surgery | #1613 |
| ethinylestradiol | #1614 |
| recommending | #1615 |
| tests reproducibility | #1616 |
| prospective cohort studies | #1616 |
| factors tomography | #1616 |
| postpartum period | #1616 |
| positive effects | #1616 |
| perinatal outcome | #1618 |
| 155 | #1618 |
| cvd patients | #1619 |
| female hemostasis | #1619 |
| imaging tomography | #1619 |
| proportion | #1620 |
| uncertain | #1621 |
| 12month followup | #1621 |
| 079 | #1623 |
| competing risk | #1628 |
| isis | #1630 |
| major | #1631 |
| incidentally | #1632 |
| venous disease | #1632 |
| pa patients | #1632 |
| clinical patients | #1633 |
| fresh frozen plasma | #1633 |
| study outcomes | #1639 |
| double | #1639 |
| 029 | #1642 |
| 181 | #1643 |
| stroke prevention | #1644 |
| ctni | #1644 |
| patients hospitalized | #1647 |
| mismatched | #1648 |
| 997 | #1651 |
| dorsiflexion | #1651 |
| ≤4 | #1652 |
| 35 years | #1652 |
| studies data | #1653 |
| thrombin activity | #1653 |
| clotting | #1656 |
| remaining | #1660 |
| plasma concentration | #1661 |
| outcome data | #1663 |
| spiral | #1669 |
| homocysteine levels | #1670 |
| disease adult | #1670 |
| thrombi | #1674 |
| daily dosing | #1676 |
| inpatient treatment | #1676 |
| deficiency | #1677 |
| plasma level | #1677 |
| warfarin dose | #1680 |
| arthroscopy | #1684 |
| steroidal anti | #1686 |
| unreliable | #1686 |
| patients acs | #1687 |
| thrombin | #1690 |
| severe renal | #1694 |
| patients brain metastases | #1695 |
| prospective | #1702 |
| necrosis factor | #1705 |
| highest risk | #1707 |
| cancer screening | #1708 |
| awaiting | #1710 |
| 033 | #1712 |
| yielded | #1712 |
| hemorheology | #1715 |
| intravenous | #1715 |
| bronchospasm | #1720 |
| hematologic malignancies | #1720 |
| diagnostic evaluation | #1721 |
| female femoral | #1721 |
| mb | #1721 |
| cardioembolic | #1722 |
| cumulative incidence | #1723 |
| laser doppler | #1724 |
| 107 | #1726 |
| conference | #1726 |
| derived microparticles | #1729 |
| volunteer | #1730 |
| 021 | #1730 |
| 161 | #1733 |
| percentage patients | #1734 |
| clinical scores | #1735 |
| east asian | #1735 |
| patients icu | #1736 |
| rico | #1737 |
| 500 | #1738 |
| minor | #1739 |
| revised | #1744 |
| patients ventricular | #1745 |
| 691 | #1745 |
| table | #1745 |
| profession | #1746 |
| hyperinsulinaemia | #1747 |
| risk cardiovascular events | #1747 |
| turp | #1749 |
| apc | #1749 |
| replacement | #1750 |
| homozygosity | #1750 |
| pselectin | #1750 |
| 128 | #1752 |
| 133 | #1753 |
| intracranial hemorrhages | #1753 |
| 3 studies | #1755 |
| spontaneous | #1756 |
| arterial occlusive | #1758 |
| patients randomized | #1759 |
| treatment recommendations | #1760 |
| assessor | #1760 |
| audiometry | #1760 |
| current treatment | #1761 |
| primary setting | #1762 |
| long‐term | #1763 |
| fx | #1764 |
| human insulin | #1764 |
| duplicate | #1769 |
| initial management | #1770 |
| arteriosclerosis | #1770 |
| hemorrhage | #1770 |
| 2 6 | #1774 |
| allcause death | #1774 |
| 28 weeks | #1781 |
| hemostasis humans | #1782 |
| trough levels | #1785 |
| infusions | #1787 |
| ethinyl estradiol | #1789 |
| selfmanagement | #1790 |
| clinical consequences | #1790 |
| microparticle | #1793 |
| reid | #1793 |
| vascular surgical | #1794 |
| cardiac troponin | #1794 |
| healthy male volunteers | #1799 |
| 042 | #1800 |
| aggregation inhibitors | #1802 |
| 020 | #1802 |
| retrospective analysis | #1805 |
| hemophilia humans | #1808 |
| unpublished | #1810 |
| 95 specificity | #1812 |
| slc6a4 | #1812 |
| tumor necrosis | #1812 |
| overlapped | #1814 |
| 51 | #1815 |
| 078 | #1818 |
| economic evaluation | #1819 |
| conjoint | #1819 |
| interobserver | #1823 |
| awareness | #1824 |
| screening middle | #1825 |
| preference | #1825 |
| 303 | #1828 |
| placebo 95 | #1832 |
| undergoing coronary | #1834 |
| compressibility | #1837 |
| definite | #1837 |
| kaplanmeier estimate | #1838 |
| cushing | #1838 |
| severe sepsis | #1839 |
| central venous | #1842 |
| 1 week | #1842 |
| workup | #1848 |
| orthopaedic | #1849 |
| explanations | #1852 |
| hydroxyethyl starch | #1852 |
| 160 | #1854 |
| fibrinopeptide | #1862 |
| cancer therapies | #1865 |
| alpha 2 | #1867 |
| gramnegative | #1869 |
| serially | #1870 |
| humans pregnancy | #1874 |
| separately | #1876 |
| oral anticoagulation | #1880 |
| thromboses | #1892 |
| shrs | #1892 |
| diagnostic techniques | #1892 |
| lower incidence | #1893 |
| stable patients | #1895 |
| 5 10 | #1897 |
| 067 | #1897 |
| contraindications | #1900 |
| diagnostic testing | #1901 |
| extremity | #1901 |
| tnf | #1901 |
| clt | #1905 |
| induced thrombocytopenia | #1906 |
| hazard ratio | #1906 |
| plaster | #1906 |
| differential effects | #1907 |
| 95 year | #1909 |
| efficacy treatment | #1910 |
| referral | #1910 |
| random | #1911 |
| plato | #1913 |
| experimental mice mice | #1916 |
| 238 | #1918 |
| randomized | #1919 |
| 13 patients | #1920 |
| 793 | #1920 |
| administration | #1921 |
| pregnancy treatment | #1922 |
| stroke 95 | #1923 |
| 868 | #1923 |
| 55 years | #1924 |
| biotin | #1924 |
| venous pressure | #1926 |
| trials patients | #1926 |
| intracranial hemorrhage | #1927 |
| μg | #1927 |
| coronary syndromes | #1928 |
| 272 | #1929 |
| cardiovascular events patients | #1930 |
| chimpanzee | #1931 |
| adjusted | #1932 |
| glucocorticoid | #1934 |
| nonfatal | #1934 |
| relative risks | #1935 |
| 3months | #1935 |
| acute | #1936 |
| 17 | #1936 |
| thrombolytic treatment | #1937 |
| 27 | #1938 |
| randomized placebo | #1947 |
| safety effectiveness | #1950 |
| femoral vein | #1950 |
| 0·5 | #1952 |
| medical illness | #1954 |
| overtreatment | #1955 |
| prolongation | #1958 |
| intravascular | #1959 |
| major risk | #1960 |
| advanced age | #1961 |
| observer | #1962 |
| investigators | #1962 |
| 1050 | #1965 |
| permanent | #1966 |
| 80 female | #1967 |
| hyperglycaemia | #1970 |
| coronary angioplasty | #1971 |
| fibrin clot | #1973 |
| surgical blood | #1973 |
| 48 hours | #1973 |
| renewed | #1976 |
| potent inhibitor | #1976 |
| topic clinical trials | #1978 |
| 771 | #1981 |
| specificity ultrasonography | #1981 |
| hyperaldosteronism | #1981 |
| computerised | #1982 |
| patients pancreatic | #1985 |
| 1·0 | #1986 |
| treatment cancer | #1986 |
| randomized controlled | #1988 |
| coumarins | #1990 |
| 177 | #1991 |
| prospero | #1992 |
| 018 | #1992 |
| cmax | #1994 |
| drug drug therapy | #1994 |
| computerized | #1995 |
| cvt | #1995 |
| hemorrhage patients | #1996 |
| ors | #1998 |
| 602 | #1999 |
| autopsy | #2000 |
| 3 months patients | #2000 |
| transient increase | #2000 |
| clinical severity | #2000 |
| 53 | #2003 |
| pneumonia patients | #2006 |
| 7 patients | #2006 |
| pih | #2011 |
| mantel | #2013 |
| catheterization central | #2014 |
| angina unstable | #2017 |
| mongrel | #2017 |
| poc | #2019 |
| 225 | #2020 |
| type plasminogen | #2023 |
| pathophysiologic | #2024 |
| 35 | #2025 |
| patients statins | #2026 |
| annual | #2028 |
| 15th | #2031 |
| atheroma | #2032 |
| patients lung | #2033 |
| 097 | #2033 |
| pertechnetate | #2036 |
| costs cost | #2041 |
| medical record | #2041 |
| undergoing major | #2042 |
| abstracts | #2042 |
| questioned | #2043 |
| thrice | #2045 |
| prediction rule | #2045 |
| dichotomous | #2046 |
| normal | #2048 |
| quartiles | #2051 |
| superior vena cava | #2051 |
| inadequately | #2052 |
| 277 | #2053 |
| pregnancy trimester | #2053 |
| controversial | #2055 |
| adherence guidelines | #2056 |
| stent implantation | #2056 |
| hospitalized | #2057 |
| randomized comparison | #2060 |
| outpatient | #2061 |
| interobserver variability | #2062 |
| requested | #2063 |
| varies | #2063 |
| biological neoplasms | #2064 |
| clinical indications | #2064 |
| hemostatics | #2070 |
| national institute | #2074 |
| 188 | #2074 |
| mcnemar | #2074 |
| familial hypercholesterolemia | #2077 |
| unavailable | #2079 |
| searched | #2082 |
| disseminate | #2083 |
| ristocetin | #2086 |
| media thickness | #2087 |
| bypasses | #2087 |
| 03 | #2089 |
| versions | #2091 |
| square distribution | #2092 |
| 114 | #2092 |
| tissue plasminogen | #2093 |
| preformed | #2099 |
| reference range | #2099 |
| 038 | #2100 |
| 59 | #2101 |
| lifetime risk | #2101 |
| desmopressin | #2101 |
| placebos | #2102 |
| concealment | #2104 |
| hospital treatment | #2106 |
| fibrin deposition | #2107 |
| argatroban | #2108 |
| 1966 | #2109 |
| 031 | #2109 |
| substantial | #2109 |
| aged 80 | #2111 |
| debated | #2116 |
| jugular vein | #2117 |
| independently | #2118 |
| unnecessary | #2118 |
| exists | #2119 |
| initial | #2119 |
| development validation | #2120 |
| clinicaltrialsgov | #2122 |
| coronary stent | #2122 |
| 11 | #2122 |
| original | #2125 |
| acl reconstruction | #2125 |
| patients cardiovascular disease | #2127 |
| topic surveys | #2127 |
| controlled | #2129 |
| chose | #2129 |
| current recommendations | #2131 |
| odds ratios | #2132 |
| congress | #2134 |
| protamines | #2134 |
| 190 | #2136 |
| 788 | #2137 |
| hip arthroplasty | #2139 |
| heterozygous | #2141 |
| antagonists | #2142 |
| clot | #2145 |
| live | #2145 |
| bodyweight | #2146 |
| professionals | #2146 |
| pancreatic cancer patients | #2157 |
| oestrogens | #2160 |
| committee | #2160 |
| lowdose aspirin | #2163 |
| academic medical | #2167 |
| drains | #2170 |
| embase | #2171 |
| fibrinogen | #2175 |
| 1998 | #2178 |
| trimesters | #2179 |
| reproductive age | #2182 |
| advanced cancer | #2183 |
| 674 | #2183 |
| fifty | #2185 |
| 2 × | #2185 |
| giant cell arteritis | #2185 |
| patients diagnosed | #2187 |
| 631 | #2188 |
| controlled study | #2192 |
| superficial | #2194 |
| difference incidence | #2198 |
| adjust | #2202 |
| diagnostic performance | #2204 |
| increased patients | #2205 |
| pravastatin | #2205 |
| antagonist | #2206 |
| clinical implications | #2208 |
| lower limbs | #2209 |
| neutrophil elastase | #2212 |
| diagnosis differential | #2212 |
| doubled | #2213 |
| pao2 | #2219 |
| 364 | #2219 |
| insufficient | #2221 |
| comparing | #2222 |
| differential female | #2225 |
| 94 | #2225 |
| lung perfusion | #2226 |
| italian society | #2227 |
| 76 | #2233 |
| takeda | #2236 |
| nationwide cohort study | #2245 |
| clot formation | #2247 |
| congenital heart disease | #2252 |
| hemorrhages | #2253 |
| clots | #2257 |
| hivinfected patients | #2257 |
| kilogram | #2259 |
| aprotinin | #2261 |
| 8000 | #2264 |
| stroke aged | #2265 |
| hyperthyroidism | #2265 |
| 12 | #2266 |
| 6 months | #2267 |
| metaanalysis | #2267 |
| reverses | #2273 |
| patients developed | #2273 |
| arterial | #2274 |
| intrinsic pathway | #2275 |
| famine | #2278 |
| 656 | #2279 |
| ultrasonographic | #2281 |
| based case | #2284 |
| setting | #2284 |
| 14 patients | #2286 |
| ft3 | #2288 |
| case control | #2291 |
| patients heart failure | #2293 |
| aged molecular | #2295 |
| daily dose | #2296 |
| sole | #2298 |
| strategy | #2303 |
| 88 | #2308 |
| 0047 | #2310 |
| normalised | #2312 |
| metaanalysis studies | #2314 |
| tests | #2314 |
| initial therapy | #2316 |
| nephelometry | #2316 |
| obstetrics | #2317 |
| adjustments | #2319 |
| humans myocardial | #2324 |
| method female | #2324 |
| methodological | #2325 |
| 60 | #2327 |
| normalized | #2329 |
| brachial | #2332 |
| gradually | #2335 |
| random sample | #2336 |
| positive predictive | #2337 |
| transfusion requirements | #2340 |
| ultrasonography doppler | #2341 |
| 543 | #2343 |
| lacked | #2344 |
| inhibitor | #2344 |
| prescribe | #2347 |
| illness severity | #2350 |
| 20 weeks | #2351 |
| thr | #2353 |
| prefer | #2354 |
| cancer progression | #2364 |
| 053 | #2371 |
| 118 | #2372 |
| receiving | #2374 |
| risk bias | #2375 |
| 099 | #2375 |
| patients active | #2376 |
| hemostasis | #2377 |
| predictable | #2377 |
| acute coronary syndromes | #2379 |
| enrolling | #2379 |
| 187 | #2381 |
| dosing regimen | #2382 |
| anticardiolipin | #2382 |
| 145 | #2387 |
| scintigraphy | #2389 |
| 140 | #2391 |
| 244 | #2393 |
| complication rate | #2400 |
| patients liver cirrhosis | #2401 |
| 757 | #2401 |
| 086 | #2402 |
| letters | #2405 |
| curable | #2406 |
| protein | #2413 |
| periodicals | #2413 |
| postinjection | #2413 |
| risk estimates | #2414 |
| 22 | #2415 |
| sphingosine1 | #2415 |
| study drug | #2424 |
| internal medicine | #2424 |
| 32 | #2425 |
| sensitivity 100 | #2426 |
| guidelines | #2426 |
| coagulants | #2430 |
| 0048 | #2430 |
| legs | #2430 |
| 002 | #2430 |
| patients adult | #2431 |
| ci95 | #2432 |
| normal range | #2433 |
| prolonging | #2434 |
| ptca | #2434 |
| aminoglycoside | #2435 |
| cindex | #2437 |
| 030 | #2438 |
| cumulative | #2439 |
| 166 | #2441 |
| endogenous | #2445 |
| microplate | #2446 |
| 719 | #2448 |
| turbidimetry | #2448 |
| administration schedule | #2449 |
| transmigration | #2453 |
| homocysteine | #2454 |
| anticoagulant activity | #2455 |
| ≥75 | #2459 |
| extensively | #2463 |
| prognostic patients | #2464 |
| watchful | #2464 |
| potential benefits | #2466 |
| nephrotoxic | #2468 |
| therapy acute | #2468 |
| 477 | #2469 |
| comprised | #2469 |
| pharmacologic | #2473 |
| consisted | #2474 |
| current review | #2476 |
| cancer population | #2476 |
| 05 | #2481 |
| 50 | #2482 |
| pathway inhibitor | #2485 |
| 648 | #2485 |
| treatment efficacy | #2489 |
| 1015 | #2490 |
| 829 | #2490 |
| duration | #2493 |
| chest | #2493 |
| 25 | #2495 |
| 616 | #2503 |
| illness tomography | #2503 |
| bnp | #2504 |
| subsequent pregnancies | #2505 |
| 522 | #2507 |
| movie | #2508 |
| recurrence retrospective | #2509 |
| unstable angina | #2510 |
| presentation | #2512 |
| superinfection | #2513 |
| comprising | #2515 |
| 479 | #2516 |
| drug female humans | #2516 |
| sulfates | #2519 |
| 750 | #2520 |
| 463 | #2521 |
| neutrophil extracellular traps | #2521 |
| accurate diagnosis | #2523 |
| 152 | #2523 |
| treatment arms | #2524 |
| scientific | #2529 |
| establish | #2534 |
| 0046 | #2537 |
| 874 | #2537 |
| 164 | #2537 |
| nematode | #2540 |
| 67 | #2542 |
| pyrazoles | #2547 |
| arrive | #2549 |
| decided | #2552 |
| effectiveness analysis | #2553 |
| haematology | #2560 |
| hours | #2560 |
| hydroxyethyl | #2560 |
| 928 | #2565 |
| radiologist | #2566 |
| roc | #2568 |
| biologic | #2569 |
| clinical settings | #2570 |
| infrequent | #2572 |
| 73 | #2574 |
| kits | #2574 |
| humans logistic | #2574 |
| prevalence | #2575 |
| pill | #2575 |
| translate | #2577 |
| patients total | #2577 |
| 973 | #2578 |
| specificity | #2580 |
| cancer chemotherapy | #2581 |
| 374 | #2582 |
| 591 | #2585 |
| efficacious | #2585 |
| pivotal | #2588 |
| analysed | #2589 |
| bolus | #2595 |
| 657 | #2596 |
| multiple organ failure | #2599 |
| hypercholesterolaemia | #2600 |
| doppler duplex | #2602 |
| laboratory investigation | #2603 |
| manifest | #2605 |
| burden disease | #2605 |
| metaregression | #2606 |
| parenteral | #2606 |
| fatal outcome | #2608 |
| patients 2 | #2608 |
| 098 | #2610 |
| p0001 patients | #2613 |
| died | #2615 |
| 886 | #2618 |
| percent | #2619 |
| aviation | #2620 |
| cost analysis | #2620 |
| concentrate | #2621 |
| occlusive | #2622 |
| presenting | #2625 |
| assess | #2626 |
| prescribed | #2631 |
| agents steroidal | #2633 |
| coincided | #2635 |
| chondroitin | #2635 |
| trials rcts | #2635 |
| 10 day | #2637 |
| attractive | #2641 |
| 345 | #2641 |
| mutation patients | #2642 |
| greatest risk | #2643 |
| 23 patients | #2645 |
| decision | #2649 |
| risk cardiovascular disease | #2656 |
| 134 | #2659 |
| recurrence | #2660 |
| hamilton | #2661 |
| benzimidazoles | #2662 |
| c677 | #2662 |
| 679 | #2663 |
| shr | #2667 |
| quartile | #2674 |
| receive | #2675 |
| 439 | #2677 |
| valsalva | #2680 |
| trials | #2682 |
| 516 | #2683 |
| outcome ultrasonography | #2683 |
| initial dose | #2685 |
| iii | #2685 |
| inconclusive | #2686 |
| tmax | #2687 |
| mortality 95 | #2688 |
| tissue plasminogen activator | #2690 |
| aso | #2691 |
| 594 | #2691 |
| bleed | #2692 |
| schedule female | #2694 |
| stillbirth | #2698 |
| patients risk factors | #2702 |
| early discharge | #2703 |
| 14 | #2706 |
| previous stroke | #2720 |
| prematurely | #2725 |
| 897 | #2727 |
| txb2 | #2729 |
| management strategies | #2732 |
| dose low | #2732 |
| cart | #2736 |
| 595 | #2737 |
| classifications | #2739 |
| 427 | #2739 |
| therapeutic options | #2744 |
| risk ratio | #2745 |
| 848 | #2746 |
| predetermined | #2746 |
| baseline characteristics | #2747 |
| patients asthma | #2747 |
| direct comparison | #2752 |
| pan | #2755 |
| nephrotoxicity | #2758 |
| randomised trial | #2764 |
| contusions | #2765 |
| management acute | #2768 |
| 143 | #2768 |
| confounded | #2769 |
| alpha animals | #2772 |
| antithyroid | #2772 |
| expert consensus | #2772 |
| active control | #2775 |
| thrombomodulin | #2776 |
| inpatient | #2776 |
| 563 | #2777 |
| compression | #2778 |
| dosages | #2779 |
| leukocyte count | #2781 |
| mass screening | #2782 |
| 466 | #2783 |
| hemostatic | #2784 |
| primary outcomes | #2785 |
| percentiles | #2788 |
| 90th | #2789 |
| nadph2 | #2791 |
| consecutive series | #2802 |
| 402 | #2802 |
| reaching | #2805 |
| cirrhosis patients | #2805 |
| international | #2809 |
| standardized | #2811 |
| secondary | #2811 |
| embolic | #2812 |
| follow studies | #2813 |
| 406 | #2813 |
| prevalence risk factors | #2814 |
| httlpr | #2816 |
| discriminant analysis | #2817 |
| selectins | #2819 |
| consisting | #2823 |
| equivalency | #2825 |
| antiplatelet drugs | #2826 |
| bid | #2826 |
| genetic variations | #2830 |
| 557 | #2833 |
| male mass | #2834 |
| contacting | #2835 |
| recurrence rate | #2835 |
| helminth | #2836 |
| ketoprostaglandin | #2836 |
| crossover | #2839 |
| kruskal | #2839 |
| 554 | #2843 |
| partum | #2847 |
| anterior cruciate ligament | #2850 |
| carboxypeptidase | #2851 |
| iii trials | #2852 |
| doppler ultrasonography | #2852 |
| ≤2 | #2853 |
| postoperative patients | #2854 |
| new treatment | #2857 |
| post discharge | #2857 |
| specialised | #2858 |
| methods prospective | #2862 |
| 497 | #2870 |
| discontinuation | #2871 |
| 264 | #2876 |
| 628 | #2877 |
| 52 | #2879 |
| excessive | #2880 |
| trimester pregnancy | #2880 |
| hit | #2884 |
| mdct | #2885 |
| balloon angioplasty | #2886 |
| anterior cruciate | #2887 |
| 670 | #2895 |
| eligibility | #2896 |
| 21 | #2897 |
| systematic review metaanalysis | #2897 |
| central venous catheters | #2900 |
| statin | #2902 |
| severe asthma | #2903 |
| feasible | #2903 |
| slight | #2903 |
| 12 patients | #2908 |
| concomitantly | #2910 |
| supposed | #2911 |
| insulin receptors | #2914 |
| leading death | #2917 |
| lowrisk patients | #2917 |
| 39 | #2919 |
| routine clinical practice | #2920 |
| referrals | #2921 |
| older children | #2922 |
| 993 | #2928 |
| proportions | #2928 |
| clear | #2932 |
| 2400 | #2934 |
| risk stratification patients | #2934 |
| aggregation platelet | #2941 |
| control subjects patients | #2945 |
| meier estimate | #2946 |
| addison | #2952 |
| portal | #2954 |
| 100 | #2956 |
| returned | #2957 |
| 270 | #2960 |
| 010 | #2960 |
| 20 | #2961 |
| followup | #2962 |
| exercise therapy | #2962 |
| transabdominal | #2963 |
| 132 | #2974 |
| echocardiography patients | #2975 |
| 123 | #2978 |
| risk myocardial | #2981 |
| declare | #2984 |
| lecture | #2984 |
| eclampsia pregnancy | #2986 |
| glucose levels | #2987 |
| preoperatively | #2988 |
| adult blood | #2990 |
| pneumatic | #2991 |
| point | #2991 |
| n4 | #2992 |
| undefined | #2993 |
| treatable | #2996 |
| cvr | #2997 |
| microvessels | #2998 |
| 499 | #3004 |
| prostacyclin | #3012 |
| dipyridamole | #3013 |
| antigen levels | #3015 |
| factors surveys | #3015 |
| 2 patients | #3016 |
| 081 | #3019 |
| double‐blind | #3022 |
| 35 patients | #3023 |
| early recognition | #3025 |
| nested case | #3025 |
| comorbidity | #3026 |
| contraindication | #3028 |
| intention | #3035 |
| extremities | #3038 |
| 50 years | #3040 |
| 419 | #3040 |
| patients hf | #3041 |
| lymphopenia | #3043 |
| relevant articles | #3044 |
| 095 | #3045 |
| prenatal exposure | #3047 |
| summarize | #3050 |
| respondents | #3052 |
| respects | #3060 |
| subcutaneous injection | #3062 |
| nomogram | #3063 |
| 80 | #3063 |
| fourteen | #3065 |
| 95 p0001 | #3066 |
| patients data | #3067 |
| study prevalence | #3071 |
| 2 4 | #3076 |
| subsequently | #3076 |
| disease aged | #3077 |
| 524 | #3082 |
| 342 | #3083 |
| chronic renal failure | #3088 |
| angioplasty | #3088 |
| independent risk factors | #3089 |
| healthy | #3090 |
| clinical risk factors | #3098 |
| lancet | #3102 |
| reviewer | #3104 |
| practice guidelines | #3109 |
| trimester | #3110 |
| benchmark | #3110 |
| npv | #3115 |
| pregnant woman | #3119 |
| neutrophil activation | #3120 |
| lifelong | #3122 |
| oac | #3122 |
| wallis | #3122 |
| inadequacy | #3123 |
| intravenously | #3129 |
| claimed | #3132 |
| 136 | #3134 |
| 12 months | #3134 |
| meta‐analysis | #3137 |
| levels risk | #3142 |
| 082 | #3142 |
| placentae | #3143 |
| randomized clinical trial | #3145 |
| time interval | #3147 |
| arthroscopic | #3149 |
| 507 | #3153 |
| idiopathic | #3153 |
| marathon | #3155 |
| mega | #3156 |
| avoiding | #3158 |
| radiologists | #3165 |
| initial presentation | #3172 |
| seventh | #3173 |
| cornerstone | #3182 |
| test | #3184 |
| 494 | #3188 |
| revascularisation | #3191 |
| 409 | #3193 |
| diethylstilbestrol | #3194 |
| pregnancy women | #3194 |
| pacientes | #3197 |
| 945 | #3198 |
| plasmin | #3198 |
| tenth | #3199 |
| therapy risk | #3199 |
| gold standard | #3200 |
| vivo model | #3205 |
| res | #3207 |
| patient preference | #3211 |
| catheter | #3212 |
| suggested | #3219 |
| cancer types | #3219 |
| 153 | #3223 |
| intravenous infusion | #3223 |
| 72 hours | #3225 |
| 605 | #3227 |
| methodological quality | #3238 |
| observers | #3239 |
| recombinant | #3241 |
| meetings | #3241 |
| intravenous administration | #3242 |
| risk stroke | #3246 |
| alternative | #3249 |
| 198 | #3251 |
| bivalirudin | #3251 |
| 29 | #3253 |
| hypothyroid | #3253 |
| judgement | #3255 |
| scoring | #3255 |
| normotensive | #3256 |
| 054 | #3257 |
| patient preferences | #3261 |
| glargine | #3265 |
| validated | #3266 |
| patients evidence | #3267 |
| 116 | #3268 |
| immunoassay | #3271 |
| 414 | #3275 |
| 6 | #3277 |
| tranexamic acid | #3279 |
| gbd | #3280 |
| contraceptive | #3281 |
| inclusion | #3284 |
| arthroplasty replacement | #3288 |
| tumor markers | #3289 |
| coumarin | #3289 |
| replace | #3290 |
| 65 years | #3291 |
| swan | #3292 |
| recurrence rates | #3294 |
| efficacy outcomes | #3299 |
| 812 | #3314 |
| rtpa | #3315 |
| reversibility | #3316 |
| anticardiolipin antibodies | #3319 |
| discriminant | #3321 |
| vascular risk | #3322 |
| 104 | #3325 |
| hemophilia | #3328 |
| 972 | #3329 |
| 465 | #3330 |
| reduces | #3330 |
| cruciate ligament | #3331 |
| patients symptoms | #3334 |
| 74 | #3337 |
| meta | #3338 |
| acute coronary syndrome | #3339 |
| inpatients | #3344 |
| cerebrovascular disease | #3344 |
| 362 | #3349 |
| evaluating | #3349 |
| diagnosing | #3354 |
| spontaneous abortion | #3354 |
| 273 | #3355 |
| diagnosis cancer | #3356 |
| common complication | #3356 |
| 15 | #3357 |
| lysate | #3358 |
| 581 | #3359 |
| 092 | #3361 |
| miscarriages | #3365 |
| prevalent | #3371 |
| thrombolysis | #3376 |
| treatment modalities | #3377 |
| 363 | #3378 |
| 301 | #3379 |
| concluded | #3379 |
| humans lower | #3379 |
| intima media | #3380 |
| computed tomography | #3382 |
| hematomas | #3387 |
| function patients | #3389 |
| calf | #3389 |
| contraception | #3390 |
| repeated | #3394 |
| 413 | #3395 |
| p0002 | #3397 |
| cava | #3399 |
| 311 | #3400 |
| tunica | #3403 |
| acute treatment | #3403 |
| 553 | #3403 |
| humans kaplan | #3408 |
| saved | #3415 |
| differs | #3418 |
| randomisation | #3419 |
| preventive | #3419 |
| study risk | #3420 |
| hypothesised | #3420 |
| surgical patients | #3420 |
| thrombocythemia | #3422 |
| odds | #3424 |
| confirm | #3425 |
| testimony | #3430 |
| competing | #3434 |
| natriuretic | #3437 |
| 70 | #3439 |
| ease | #3443 |
| asian patients | #3444 |
| 124 | #3445 |
| 519 | #3447 |
| 487 | #3451 |
| prevalence incidence | #3452 |
| 168 | #3452 |
| evening | #3458 |
| covid19 infection | #3464 |
| differ | #3470 |
| 34 | #3470 |
| intensive chemotherapy | #3471 |
| patients receive | #3472 |
| pregnancy complications | #3472 |
| worsened | #3476 |
| induced platelet | #3479 |
| undiagnosed | #3482 |
| antiphospholipid | #3485 |
| cancer metastasis | #3485 |
| increased morbidity | #3486 |
| lower leg | #3487 |
| asymptomatic | #3487 |
| personyears | #3490 |
| paradox | #3490 |
| pacemaker | #3493 |
| statistical methods | #3494 |
| convergent validity | #3496 |
| failure hf | #3497 |
| 201 | #3504 |
| hemorrhagic complications | #3506 |
| treat | #3506 |
| inhibitors | #3506 |
| 938 | #3513 |
| tomography angiography | #3521 |
| confirmed | #3522 |
| discusses | #3522 |
| 291 | #3527 |
| quintiles | #3529 |
| 95 confidence intervals | #3530 |
| lupus | #3533 |
| human cytomegalovirus | #3533 |
| areas covered | #3537 |
| guidance | #3541 |
| societies | #3541 |
| 113 | #3544 |
| current practice | #3551 |
| gastro | #3551 |
| 10 | #3552 |
| stroke risk | #3559 |
| baboons | #3560 |
| 344 | #3562 |
| benefits risks | #3564 |
| neutralize | #3565 |
| nsaids | #3566 |
| bibliographic | #3567 |
| depends | #3571 |
| patients recurrence | #3573 |
| inconsistent | #3575 |
| safety profiles | #3580 |
| 508 | #3584 |
| evaluates | #3592 |
| prognosis prospective | #3596 |
| necessity | #3596 |
| patient management | #3598 |
| prognostic significance | #3604 |
| vitamin | #3605 |
| risk stratification | #3606 |
| consensus document | #3617 |
| treated | #3619 |
| platelet function | #3619 |
| platelet activation | #3622 |
| interval | #3622 |
| mutation | #3624 |
| lipid profiles | #3626 |
| kappa | #3629 |
| q3 | #3629 |
| organ damage | #3635 |
| analysis performed | #3640 |
| 75 | #3641 |
| homozygote | #3642 |
| undergo | #3642 |
| bypass surgery | #3642 |
| p006 | #3645 |
| externally | #3645 |
| occlusions | #3646 |
| 30 | #3649 |
| 1960 | #3649 |
| interindividual variability | #3651 |
| fibrillation | #3651 |
| coronary events | #3656 |
| atherogenic | #3658 |
| newer | #3662 |
| patients 95 | #3667 |
| optimal management | #3671 |
| outcome administration | #3671 |
| endovascular treatment | #3678 |
| blinding | #3679 |
| treatment complications | #3680 |
| limited data | #3683 |
| 68 | #3684 |
| clopidogrel | #3685 |
| mammography | #3693 |
| myalgia | #3703 |
| 478 | #3706 |
| rationale | #3707 |
| 813 | #3708 |
| rebound | #3720 |
| diagnostic process | #3721 |
| drug monitoring | #3721 |
| inhibitors humans | #3725 |
| pharmacodynamics | #3725 |
| 130 | #3729 |
| unknown | #3731 |
| patient population | #3733 |
| serine proteases | #3736 |
| 349 | #3738 |
| effective | #3739 |
| humans intracranial | #3739 |
| factor 4 | #3741 |
| 585 | #3743 |
| 299 | #3744 |
| network meta | #3746 |
| homozygous | #3747 |
| 495 | #3750 |
| practitioner | #3752 |
| randomised | #3754 |
| deterioration | #3754 |
| objectives | #3759 |
| subgroup analyses | #3762 |
| 8 patients | #3762 |
| 00001 | #3765 |
| host defense | #3769 |
| statin therapy | #3772 |
| scarce | #3773 |
| computed ultrasonography | #3774 |
| clinicians patients | #3774 |
| inherited | #3775 |
| interpretable | #3778 |
| 517 | #3778 |
| 483 | #3782 |
| thyroid hormones | #3789 |
| total knee arthroplasty | #3789 |
| aminoglycosides | #3789 |
| 525 | #3791 |
| 412 | #3795 |
| 441 | #3797 |
| life illness | #3801 |
| 333 | #3802 |
| versus | #3803 |
| vessel wall | #3804 |
| compelling | #3804 |
| preexisting | #3808 |
| outcome measure | #3814 |
| patients lung cancer | #3815 |
| 330 | #3815 |
| valid | #3816 |
| iu | #3818 |
| 55 patients | #3821 |
| fv | #3823 |
| stasis | #3824 |
| lost | #3825 |
| compares | #3830 |
| itching | #3831 |
| proved | #3834 |
| osmolar | #3837 |
| elective | #3838 |
| hydrolases | #3839 |
| patient education | #3843 |
| 197 | #3849 |
| irs | #3856 |
| meeting | #3856 |
| anaesthesia | #3857 |
| 4 patients | #3858 |
| congresses | #3859 |
| review data | #3860 |
| acquired resistance | #3860 |
| male neoplasms | #3862 |
| preferred | #3864 |
| occurring | #3867 |
| death | #3880 |
| optimisation | #3884 |
| cancer survival | #3884 |
| record | #3885 |
| sensitivity | #3885 |
| avoids | #3887 |
| calculated | #3888 |
| 184 | #3890 |
| difference | #3890 |
| 351 | #3890 |
| 10000 | #3902 |
| halflives | #3903 |
| methylamines | #3903 |
| methimazole | #3904 |
| patients time | #3905 |
| incidence prevalence | #3908 |
| angiography | #3915 |
| specificity tomography | #3915 |
| coronary thrombosis | #3918 |
| decide | #3927 |
| 474 | #3931 |
| ankle | #3932 |
| 955 | #3935 |
| 458 | #3938 |
| jak2 | #3939 |
| extravasation | #3945 |
| case fatality | #3946 |
| 405 | #3946 |
| preeclampsia | #3952 |
| neurology | #3953 |
| 56 | #3956 |
| p004 | #3961 |
| dichotomy | #3961 |
| randomized clinical trials | #3963 |
| women | #3964 |
| carboxypeptidases | #3965 |
| postoperatively | #3966 |
| clinical effectiveness | #3968 |
| risk cancer | #3970 |
| uncontrolled | #3970 |
| austrian | #3971 |
| behalf | #3971 |
| cardiovascular events | #3972 |
| 2nd | #3975 |
| data studies | #3975 |
| quality assurance | #3980 |
| pregnancy | #3982 |
| 986 | #3982 |
| continuous infusion | #3983 |
| unstable | #3986 |
| flying | #3986 |
| month | #3987 |
| 488 | #3990 |
| systematic analysis | #3994 |
| sequentially | #4006 |
| calculate | #4010 |
| lower risk | #4011 |
| limited evidence | #4014 |
| patients evaluated | #4016 |
| scored | #4023 |
| secondary prevention | #4026 |
| 538 | #4028 |
| equivalence | #4029 |
| gln | #4031 |
| meyer | #4032 |
| cerebral venous | #4041 |
| 296 | #4045 |
| introduction | #4045 |
| 423 | #4047 |
| 262 | #4051 |
| ended | #4052 |
| validating | #4058 |
| received | #4062 |
| recurrent disease | #4066 |
| cruciate | #4073 |
| elevated | #4074 |
| compare | #4075 |
| bariatric | #4077 |
| pcc | #4077 |
| avoid | #4080 |
| 429 | #4081 |
| 326 | #4083 |
| hour | #4088 |
| oligosaccharides | #4089 |
| natriuretic peptide | #4089 |
| angioplasty balloon | #4091 |
| maneuver | #4092 |
| 3000 | #4093 |
| 16 | #4098 |
| activation | #4099 |
| cutoff | #4099 |
| indications | #4099 |
| contact | #4102 |
| pharmacological | #4106 |
| infusion rate | #4109 |
| 392 | #4113 |
| 335 | #4117 |
| 6 months treatment | #4119 |
| ptm | #4120 |
| completing | #4125 |
| patients low risk | #4133 |
| 008 | #4137 |
| withdrawn | #4137 |
| 41 | #4138 |
| bms | #4146 |
| patients died | #4149 |
| medical students | #4152 |
| haemorrhagic | #4154 |
| continue | #4158 |
| study control | #4161 |
| nulliparous | #4167 |
| patients prostate cancer | #4171 |
| 2030 | #4171 |
| antitumour | #4177 |
| steroidal | #4178 |
| multidisciplinary approach | #4189 |
| direct | #4192 |
| therapy combination | #4198 |
| casts | #4200 |
| 485 | #4212 |
| 411 | #4212 |
| medical center | #4214 |
| 408 | #4215 |
| weighted | #4221 |
| additional | #4222 |
| 452 | #4223 |
| 121 | #4226 |
| 289 | #4226 |
| trough | #4229 |
| p0005 | #4230 |
| crosssectional analysis | #4230 |
| hormonal | #4234 |
| veins | #4235 |
| patients mortality | #4242 |
| cox regression | #4242 |
| 178 | #4246 |
| nsaid | #4261 |
| 263 | #4263 |
| abbreviated | #4267 |
| encountered | #4268 |
| atrial fibrillation patients | #4274 |
| fab | #4279 |
| late pregnancy | #4285 |
| pai1 | #4286 |
| rise | #4287 |
| oral aged | #4294 |
| q4 | #4296 |
| 228 | #4303 |
| share | #4304 |
| 10 patients | #4306 |
| 105 | #4310 |
| rehospitalization | #4314 |
| patients increased risk | #4315 |
| 185 | #4316 |
| tat | #4319 |
| separate | #4322 |
| concentrates | #4328 |
| intima | #4329 |
| devised | #4331 |
| 294 | #4339 |
| 455 | #4340 |
| 102 | #4340 |
| pronounced | #4342 |
| incidental findings | #4345 |
| potential risk factors | #4350 |
| managed | #4350 |
| detrimental | #4356 |
| 253 | #4359 |
| agreed | #4360 |
| young age | #4363 |
| specialist | #4379 |
| minutes | #4383 |
| rapid | #4383 |
| retrospective studies | #4384 |
| 447 | #4385 |
| cd11b | #4387 |
| 288 | #4391 |
| 170 | #4392 |
| slice | #4394 |
| concurrently | #4394 |
| risk cardiovascular | #4396 |
| steadily | #4402 |
| 239 | #4406 |
| general | #4407 |
| bowel diseases | #4407 |
| negative | #4407 |
| 71 | #4407 |
| guideline recommendations | #4408 |
| postoperative day | #4409 |
| ventilation | #4413 |
| lacking | #4417 |
| splanchnic | #4417 |
| dose aspirin | #4419 |
| immunoassays | #4419 |
| recombinant proteins | #4423 |
| 3 patients | #4426 |
| author | #4427 |
| 148 | #4428 |
| 281 | #4429 |
| primary myelofibrosis | #4430 |
| appropriateness | #4433 |
| profoundly | #4436 |
| completed | #4438 |
| platelet | #4440 |
| cellulitis | #4441 |
| sixteen | #4442 |
| concomitant | #4445 |
| assays | #4453 |
| 334 | #4458 |
| 192 | #4459 |
| vascular surgery | #4459 |
| cytomegalovirus infection | #4461 |
| proband | #4461 |
| total costs | #4474 |
| 377 | #4479 |
| 443 | #4482 |
| cd18 | #4486 |
| clinical manifestations | #4486 |
| inadequate | #4487 |
| pancreatic cancer | #4487 |
| coronavirus disease covid19 | #4489 |
| smr | #4492 |
| risk prediction | #4493 |
| bus | #4497 |
| current management | #4498 |
| 476 | #4499 |
| doubling | #4500 |
| infected patients | #4502 |
| activation platelet | #4503 |
| comprises | #4503 |
| 54 | #4513 |
| primary diagnosis | #4515 |
| alpha2 | #4516 |
| therapeutic | #4532 |
| septic | #4534 |
| 3 groups | #4535 |
| male pulmonary | #4541 |
| 526 | #4542 |
| elastase | #4544 |
| hitherto | #4546 |
| fairly | #4552 |
| cardiovascular death | #4559 |
| 985 | #4564 |
| 1250 | #4567 |
| calculating | #4571 |
| cerebrovascular disorders | #4571 |
| multicenter trial | #4574 |
| 2c | #4585 |
| debate | #4586 |
| disadvantage | #4588 |
| plasma concentrations | #4591 |
| 283 | #4592 |
| preserves | #4594 |
| attenuating | #4594 |
| eventually | #4595 |
| gradual | #4595 |
| simplified | #4596 |
| 204 | #4596 |
| 4 | #4601 |
| 4000 | #4601 |
| encouraged | #4603 |
| icer | #4610 |
| frequently | #4611 |
| acetylsalicylic acid | #4613 |
| vii | #4613 |
| vaginal | #4614 |
| 917 | #4619 |
| assay | #4634 |
| subclinical atherosclerosis | #4636 |
| hospital costs | #4640 |
| risks benefits | #4640 |
| 242 | #4642 |
| genetic risk factors | #4644 |
| escalating | #4648 |
| priori | #4654 |
| 003 | #4658 |
| habitual | #4658 |
| survey | #4659 |
| transurethral | #4663 |
| myelofibrosis | #4670 |
| 171 | #4670 |
| thyroid hormone | #4673 |
| 40 | #4675 |
| 407 | #4679 |
| fh | #4680 |
| day | #4680 |
| recurrent stroke | #4681 |
| wheezing | #4693 |
| unchanged | #4698 |
| ranging | #4698 |
| 5 patients | #4701 |
| complicated | #4703 |
| truncated | #4709 |
| therapeutic intervention | #4715 |
| differential humans | #4719 |
| immobilization | #4725 |
| 129 | #4727 |
| orthopedic | #4735 |
| cardiovascular morbidity | #4738 |
| current guidelines | #4739 |
| therapeutic strategies | #4744 |
| ranged | #4769 |
| 027 | #4774 |
| baseline patients | #4775 |
| chronic renal | #4775 |
| acute coronary | #4784 |
| scheduled | #4785 |
| 44 | #4785 |
| molecular | #4792 |
| knee | #4800 |
| insulin glargine | #4801 |
| prophylactic | #4802 |
| arthroplasty | #4803 |
| alternatively | #4810 |
| extracranial | #4813 |
| courses | #4819 |
| diagnostic imaging | #4825 |
| therapy humans | #4836 |
| echocardiography | #4846 |
| 174 | #4848 |
| cholesterol levels | #4853 |
| acl | #4861 |
| definition | #4861 |
| efficiency | #4869 |
| gpiib | #4870 |
| nonvalvular atrial fibrillation | #4870 |
| increased plasma | #4875 |
| unexposed | #4876 |
| gynecological | #4880 |
| antiphospholipid syndrome | #4881 |
| screening tool | #4884 |
| 322 | #4886 |
| total | #4891 |
| antiplatelet therapy | #4891 |
| treating | #4896 |
| abstracted | #4897 |
| doses | #4902 |
| ischemic heart disease | #4905 |
| preparations | #4906 |
| tests prognosis | #4906 |
| served | #4910 |
| fmd | #4913 |
| chlamydophila | #4913 |
| 560 | #4914 |
| recommendation | #4918 |
| geriatrics | #4920 |
| acute ischemic | #4923 |
| renal dysfunction | #4929 |
| 556 | #4932 |
| 154 | #4933 |
| 870 | #4934 |
| cpb | #4939 |
| 325 | #4951 |
| 26 | #4952 |
| satisfied | #4957 |
| appeared | #4959 |
| fund | #4972 |
| manufacturers | #4976 |
| dose | #4976 |
| orthopedics | #4982 |
| albeit | #4982 |
| recommended | #4987 |
| cardiology | #5000 |
| references | #5006 |
| 389 | #5006 |
| reminder | #5009 |
| epoprostenol | #5009 |
| probnp | #5014 |
| point mutation | #5018 |
| risk women | #5023 |
| syndrome patients | #5033 |
| 156 | #5040 |
| screening test | #5040 |
| proposal | #5042 |
| global burden | #5044 |
| primary health | #5045 |
| analytic | #5047 |
| obstetrical | #5048 |
| lasted | #5049 |
| patients sepsis | #5051 |
| limitations | #5055 |
| diagnosis management | #5058 |
| patients myocardial infarction | #5062 |
| spinal surgery | #5065 |
| 255 | #5068 |
| conflicting | #5070 |
| saphenous | #5075 |
| inaccessible | #5078 |
| 1a | #5079 |
| switched | #5084 |
| evaluable | #5089 |
| regarded | #5089 |
| relation | #5090 |
| hip fractures | #5090 |
| transluminal | #5093 |
| menstrual | #5094 |
| fashion | #5098 |
| amputation | #5102 |
| external validation | #5103 |
| arteritis | #5107 |
| inflammatory responses | #5109 |
| oxadiazoles | #5110 |
| dalys | #5112 |
| tailor | #5115 |
| admission patients | #5118 |
| composite | #5120 |
| discriminative | #5123 |
| vivo studies | #5124 |
| bay | #5124 |
| 108 | #5125 |
| 282 | #5129 |
| 0018 | #5130 |
| ischaemic stroke | #5130 |
| 131 | #5131 |
| female | #5131 |
| transfused | #5134 |
| balancing | #5136 |
| contrast media | #5136 |
| fetal death | #5138 |
| activator | #5139 |
| scans | #5143 |
| 341 | #5146 |
| n6 | #5150 |
| kg1 | #5151 |
| shortly | #5157 |
| disagreement | #5157 |
| preclinical studies | #5160 |
| doppler | #5165 |
| 11 patients | #5170 |
| predispose | #5170 |
| hazard | #5171 |
| readers | #5173 |
| prescriptions | #5174 |
| graft failure | #5178 |
| weaknesses | #5185 |
| renal impairment | #5186 |
| 70 patients | #5190 |
| infarctions | #5191 |
| screening | #5193 |
| threefold | #5198 |
| highest | #5202 |
| extracellular vesicles | #5204 |
| acs | #5205 |
| 144 | #5206 |
| hospital patients | #5208 |
| remains | #5209 |
| excess mortality | #5210 |
| doppler color | #5221 |
| polysaccharides | #5223 |
| heparan | #5229 |
| articles | #5233 |
| emergencies | #5233 |
| indwelling | #5241 |
| flowmetry | #5242 |
| gram | #5244 |
| 3 | #5248 |
| platelet aggregation | #5252 |
| considerably | #5253 |
| comparison | #5262 |
| testing | #5264 |
| plasma levels | #5265 |
| estimate | #5288 |
| 365 | #5289 |
| pooling | #5289 |
| aware | #5300 |
| 36 patients | #5301 |
| thrombus | #5301 |
| urokinase | #5302 |
| atherogenesis | #5302 |
| triage | #5303 |
| case reports | #5305 |
| benefit | #5308 |
| reversal | #5310 |
| stroke treatment | #5314 |
| contrasted | #5316 |
| orthomyxoviridae | #5319 |
| openlabel | #5320 |
| 70 years | #5325 |
| aged postoperative | #5330 |
| animal drug evaluation | #5332 |
| dizziness | #5334 |
| absent | #5335 |
| factor humans | #5336 |
| stratify | #5340 |
| acute ischemic stroke | #5341 |
| reagent | #5341 |
| blood vessel | #5343 |
| ultrasound imaging | #5344 |
| fatality | #5347 |
| contrast agents | #5355 |
| arose | #5361 |
| male | #5363 |
| schedule drug | #5363 |
| based guidelines | #5370 |
| hyper | #5372 |
| obstetric | #5376 |
| accepted | #5383 |
| thyrotropin | #5401 |
| informed consent | #5402 |
| blood products | #5405 |
| selected patients | #5406 |
| adult | #5407 |
| heart valve | #5409 |
| intracranial | #5411 |
| questionnaire | #5414 |
| register | #5415 |
| summarized | #5416 |
| 19 | #5417 |
| noninvasive | #5421 |
| clinical risk | #5424 |
| nonsignificant | #5429 |
| protein levels | #5430 |
| concerns | #5439 |
| charts | #5440 |
| hyperprolactinemia | #5441 |
| familiarity | #5442 |
| 37 | #5445 |
| 630 | #5448 |
| retrieved | #5450 |
| cancer growth | #5455 |
| presently | #5456 |
| congenital heart | #5465 |
| registered | #5470 |
| recombinant human | #5474 |
| intermediate | #5475 |
| 340 | #5476 |
| 395 | #5484 |
| allocation | #5488 |
| 247 | #5490 |
| occurrences | #5490 |
| moyamoya disease | #5491 |
| ntprobnp | #5493 |
| kaplan meier | #5496 |
| patient risk | #5497 |
| 260 | #5497 |
| continuing | #5499 |
| discomfort | #5499 |
| 9 patients | #5500 |
| postal | #5503 |
| ssris | #5515 |
| correctly | #5517 |
| weight | #5524 |
| 309 | #5530 |
| period | #5533 |
| limitation | #5539 |
| erythema | #5539 |
| suggestions | #5541 |
| survival benefit | #5542 |
| imputed | #5545 |
| established | #5563 |
| receptor1 | #5563 |
| 175 | #5565 |
| 545 | #5566 |
| management | #5569 |
| reduce risk | #5573 |
| 46 | #5573 |
| 324 | #5595 |
| excludes | #5597 |
| circulating levels | #5598 |
| equivalent | #5598 |
| categorical | #5600 |
| stm | #5607 |
| grounds | #5617 |
| expert | #5620 |
| 02 | #5624 |
| microgram | #5626 |
| minus | #5627 |
| premenopausal women | #5629 |
| retrieve | #5633 |
| food preferences | #5637 |
| drug administration | #5641 |
| platelet count | #5643 |
| reclassification | #5644 |
| 80 years | #5644 |
| 65 | #5651 |
| trial | #5653 |
| 087 | #5667 |
| published data | #5671 |
| 48 | #5676 |
| seventy | #5684 |
| 214 | #5689 |
| latex | #5690 |
| platelet glycoprotein | #5692 |
| reproducible | #5696 |
| 1997 | #5698 |
| meier | #5714 |
| 370 | #5718 |
| return | #5721 |
| 40 years | #5729 |
| atherosclerotic | #5730 |
| 89 | #5732 |
| perform | #5734 |
| 995 | #5748 |
| 091 | #5755 |
| stand | #5756 |
| 0014 | #5761 |
| metabolic effects | #5764 |
| milder | #5771 |
| semiquantitative | #5771 |
| 241 | #5777 |
| recurrence patients | #5781 |
| varied | #5784 |
| creatinine clearance | #5788 |
| 3rd | #5791 |
| incidence rates | #5804 |
| mpo | #5804 |
| 95 women | #5809 |
| orthopedic procedures | #5810 |
| male middle aged | #5811 |
| url | #5812 |
| aircraft | #5819 |
| 1000 | #5819 |
| income countries | #5828 |
| diagnosed | #5840 |
| undergoing surgery | #5843 |
| true | #5852 |
| atrial | #5852 |
| 088 | #5854 |
| attending | #5856 |
| 290 | #5857 |
| women pregnancy | #5857 |
| hip | #5866 |
| advantageous | #5875 |
| complete resolution | #5878 |
| occurrence | #5894 |
| reliable | #5894 |
| excluded | #5899 |
| aged models | #5919 |
| adding | #5923 |
| safety patients | #5927 |
| 22 patients | #5928 |
| aged platelet | #5928 |
| graded | #5934 |
| revision | #5938 |
| premenopause | #5938 |
| 353 | #5945 |
| prodrugs | #5946 |
| rrs | #5949 |
| 141 | #5952 |
| gastrointestinal hemorrhage | #5954 |
| janus kinase | #5959 |
| 43 | #5962 |
| rcts | #5962 |
| families | #5967 |
| 328 | #5971 |
| deemed | #5977 |
| savings | #5980 |
| counseling | #5985 |
| blood platelets | #5987 |
| blood | #5990 |
| receiver operating | #5996 |
| guideline | #5998 |
| cancer incidence | #6006 |
| current standard | #6013 |
| therapeutic interventions | #6028 |
| nadir | #6034 |
| registries risk | #6039 |
| patients experience | #6042 |
| allocated | #6044 |
| ≥3 | #6052 |
| wash | #6059 |
| advance | #6062 |
| quarter | #6065 |
| spect | #6068 |
| glycosaminoglycans | #6069 |
| decompensated | #6074 |
| 24 | #6076 |
| bacteremia | #6090 |
| topics | #6101 |
| type iii | #6101 |
| suggestive | #6105 |
| emerging evidence | #6113 |
| prevent | #6117 |
| safety data | #6120 |
| directly | #6133 |
| 72 | #6135 |
| 267 | #6136 |
| lipid profile | #6140 |
| ≥2 | #6144 |
| normalization | #6151 |
| centuries | #6153 |
| 47 | #6157 |
| ffa | #6160 |
| generation | #6160 |
| lobar | #6161 |
| agents blood | #6164 |
| 292 | #6165 |
| informed | #6173 |
| pharmacodynamic | #6188 |
| lung male | #6190 |
| updating | #6192 |
| advantages disadvantages | #6194 |
| lower | #6195 |
| bilateral | #6198 |
| cyclosporine | #6208 |
| tumour growth | #6212 |
| pathogenetic | #6221 |
| femoral artery | #6224 |
| terminated | #6228 |
| mortality morbidity | #6228 |
| new drugs | #6229 |
| 312 | #6230 |
| evidence base | #6232 |
| vitro studies | #6234 |
| crp | #6235 |
| discontinued | #6236 |
| 111 | #6240 |
| abdomen | #6248 |
| denmark | #6254 |
| proportional | #6268 |
| colleagues | #6273 |
| practitioners | #6273 |
| administered | #6277 |
| 1978 | #6283 |
| screened | #6293 |
| infused | #6297 |
| 840 | #6318 |
| prostatectomy | #6330 |
| 017 | #6334 |
| saphenous vein | #6339 |
| 135 | #6340 |
| 63 | #6340 |
| percentile | #6344 |
| higher doses | #6345 |
| adequacy | #6347 |
| divided | #6348 |
| apache | #6351 |
| screen | #6357 |
| opinions | #6360 |
| opposed | #6362 |
| percentage | #6370 |
| longterm followup | #6372 |
| risk mortality | #6386 |
| dyslipidemias | #6390 |
| kaplan | #6391 |
| consensus | #6392 |
| 208 | #6397 |
| potential mechanisms | #6404 |
| roche | #6405 |
| factor gene | #6405 |
| initiated | #6408 |
| compensated | #6411 |
| investigating | #6427 |
| ultrasound | #6441 |
| restenosis | #6442 |
| bootstrap | #6452 |
| collection | #6457 |
| post operative | #6464 |
| enzyme linked | #6467 |
| bariatric surgery | #6468 |
| coronary syndrome | #6469 |
| decreased risk | #6471 |
| 218 | #6472 |
| perfusion | #6475 |
| imbalance | #6484 |
| angina pectoris | #6493 |
| calendar | #6498 |
| peripheral artery disease | #6501 |
| accuracy | #6501 |
| cancer cell | #6502 |
| incidence risk | #6502 |
| complement activation | #6505 |
| pregnancies | #6519 |
| surgical procedure | #6520 |
| supervised | #6521 |
| models male | #6522 |
| 138 | #6523 |
| 318 | #6524 |
| triiodothyronine | #6524 |
| washout | #6524 |
| peripheral | #6525 |
| vena | #6527 |
| increased incidence | #6532 |
| highrisk patients | #6532 |
| cochrane | #6532 |
| placebo patients | #6536 |
| replaced | #6537 |
| exogenous | #6538 |
| bowel | #6538 |
| aspirin patients | #6540 |
| thirteen | #6540 |
| year | #6546 |
| superior | #6549 |
| clinical assessment | #6550 |
| cohorts | #6555 |
| dilemma | #6560 |
| crt | #6561 |
| dosing | #6576 |
| tertile | #6581 |
| 231 | #6586 |
| limited | #6589 |
| md | #6592 |
| prediction | #6596 |
| treatment choice | #6600 |
| pooled | #6601 |
| occurs | #6610 |
| 510 | #6611 |
| belgium | #6620 |
| crude | #6621 |
| injections | #6638 |
| genetic testing | #6641 |
| pancreatic neoplasms | #6641 |
| complications | #6650 |
| individual | #6650 |
| complaints | #6652 |
| degranulation | #6663 |
| methylenetetrahydrofolate | #6665 |
| liver diseases | #6674 |
| patents | #6680 |
| smoking cessation | #6696 |
| 17 patients | #6704 |
| routinely | #6706 |
| tumour progression | #6708 |
| saline | #6709 |
| 194 | #6713 |
| approval | #6727 |
| hazard ratios | #6729 |
| recognised | #6729 |
| thromboxane | #6734 |
| allcause mortality | #6744 |
| multicenter | #6747 |
| appropriately | #6748 |
| increasing age | #6751 |
| body temperature | #6766 |
| 385 | #6766 |
| q1 | #6768 |
| clinical signs | #6771 |
| age patients | #6774 |
| defined | #6780 |
| 2 groups | #6780 |
| expense | #6781 |
| 42 patients | #6791 |
| train | #6796 |
| hyperglycemia | #6801 |
| premedication | #6803 |
| reached | #6803 |
| plasma proteins | #6807 |
| response relationship | #6807 |
| benefits | #6810 |
| cardiovascular risk | #6821 |
| 256 | #6831 |
| 280 | #6838 |
| iqr | #6839 |
| glucocorticoids | #6840 |
| summary | #6850 |
| 279 | #6854 |
| cancer diagnosis | #6856 |
| systematic | #6870 |
| points | #6877 |
| ambulatory | #6883 |
| weekly | #6884 |
| reviews | #6891 |
| physicians | #6893 |
| fibrillation patients | #6898 |
| disturbances | #6912 |
| adverse event | #6912 |
| sought | #6918 |
| 112 | #6923 |
| 251 | #6940 |
| complications patients | #6948 |
| vasopressin | #6957 |
| failure | #6965 |
| subsequent | #6971 |
| hematologic | #6974 |
| 246 | #6976 |
| intensity | #6976 |
| humans hydroxymethylglutaryl | #6982 |
| papers | #6983 |
| tpa | #6986 |
| intervals | #6987 |
| addressed | #6989 |
| 259 | #6992 |
| 222 | #6995 |
| shock septic | #6995 |
| adapted | #6998 |
| disclosed | #7001 |
| incidence risk factors | #7008 |
| hazards models | #7015 |
| cardiovascular disease | #7019 |
| myeloperoxidase | #7020 |
| lung cancer patients | #7023 |
| stenting | #7024 |
| responded | #7026 |
| cohort | #7037 |
| 1 patient | #7038 |
| unacceptable | #7039 |
| interleukin8 | #7042 |
| reductases | #7045 |
| preventing | #7056 |
| curve | #7058 |
| patients baseline | #7065 |
| animal doseresponse relationship | #7071 |
| reduced risk | #7075 |
| written | #7080 |
| applicability | #7084 |
| asymptomatic patients | #7086 |
| monoclonal antibody | #7098 |
| hospitalization humans | #7101 |
| computed | #7104 |
| betacoronavirus covid19 | #7104 |
| novartis | #7108 |
| complications pregnancy | #7111 |
| infarction stroke | #7114 |
| superiority | #7116 |
| interquartile range | #7120 |
| select | #7122 |
| carotid intima | #7141 |
| internationality | #7146 |
| surveys questionnaires | #7160 |
| 163 | #7166 |
| pharmacy | #7167 |
| patients renal | #7171 |
| physicians patients | #7177 |
| randomization | #7184 |
| liver cirrhosis | #7187 |
| 211 | #7188 |
| brain metastases | #7190 |
| oral animals | #7192 |
| walking | #7195 |
| drawn | #7196 |
| combination | #7197 |
| 5year | #7204 |
| withdrawal | #7204 |
| acting | #7210 |
| cardiovascular disease cvd | #7210 |
| disposition | #7212 |
| paucity | #7218 |
| humans lung | #7221 |
| 20 patients | #7225 |
| sulfate | #7240 |
| operating characteristic | #7244 |
| vldl | #7250 |
| treatment children | #7250 |
| hematocrit | #7255 |
| 199 | #7257 |
| retrospective cohort study | #7257 |
| alongside | #7258 |
| clinical benefit | #7265 |
| controls | #7267 |
| diagnostics | #7270 |
| option | #7273 |
| grouped | #7275 |
| young women | #7278 |
| products | #7282 |
| likelihood | #7284 |
| sensitivity analysis | #7290 |
| modest | #7290 |
| atrium | #7291 |
| 360 | #7303 |
| types | #7304 |
| factors stroke | #7305 |
| undergoing | #7327 |
| partial | #7330 |
| patients isolated | #7332 |
| pectoris | #7338 |
| ischemic stroke | #7338 |
| interleukin6 | #7352 |
| 1c | #7352 |
| standardised | #7356 |
| myocardial infarction | #7356 |
| p0001 | #7356 |
| betacoronavirus | #7357 |
| simple | #7360 |
| radiology | #7379 |
| pap | #7392 |
| patients aspirin | #7400 |
| angiopathies | #7401 |
| regimens | #7405 |
| 109 | #7409 |
| bias | #7411 |
| peptide fragments | #7413 |
| iiia | #7424 |
| intravenous injection | #7429 |
| 420 | #7431 |
| propranolol | #7438 |
| favourable | #7440 |
| hypercholesterolemia | #7441 |
| respective | #7444 |
| dose dependent | #7447 |
| infusion | #7448 |
| clinical setting | #7454 |
| ways | #7465 |
| risk adverse | #7497 |
| il6 | #7510 |
| mortality rates | #7515 |
| 209 | #7516 |
| considerations | #7517 |
| exclusions | #7518 |
| patient safety | #7520 |
| angina | #7522 |
| urgently | #7522 |
| cmv infection | #7541 |
| phase iii | #7555 |
| 257 | #7558 |
| € | #7559 |
| interim | #7561 |
| injection | #7564 |
| cinahl | #7578 |
| comorbid | #7578 |
| 191 | #7578 |
| pheochromocytoma | #7585 |
| ischaemic | #7598 |
| antibodies monoclonal | #7601 |
| reasons | #7602 |
| tended | #7608 |
| pooled analysis | #7609 |
| azathioprine | #7615 |
| 13 | #7616 |
| predictor | #7620 |
| femoral | #7640 |
| random allocation | #7646 |
| epidemiological studies | #7647 |
| 29 patients | #7647 |
| abrupt | #7655 |
| derivation | #7662 |
| interquartile | #7675 |
| manifestation | #7676 |
| temporary | #7679 |
| positive patients | #7687 |
| 18 | #7705 |
| medical conditions | #7705 |
| seventeen | #7710 |
| 304 | #7719 |
| ligament | #7732 |
| consent | #7733 |
| study association | #7735 |
| cytomegalovirus | #7736 |
| severe | #7742 |
| adverse outcomes | #7745 |
| costs | #7753 |
| cardiac surgical | #7760 |
| 189 | #7770 |
| cochrane library | #7771 |
| pregnancy outcome | #7787 |
| manufacturer | #7802 |
| 110 | #7802 |
| ≤ | #7803 |
| 9 | #7811 |
| oxygenases | #7813 |
| male gender | #7815 |
| interleukin | #7816 |
| pts | #7819 |
| 31 patients | #7828 |
| hormone replacement | #7828 |
| label | #7828 |
| cpr | #7829 |
| 5 | #7833 |
| abortion | #7838 |
| influenza | #7845 |
| radiation exposure | #7850 |
| regular | #7877 |
| academic | #7878 |
| tramadol | #7878 |
| septic patients | #7880 |
| 95 confidence | #7884 |
| replacing | #7886 |
| patients chemotherapy | #7888 |
| iib | #7908 |
| journals | #7922 |
| strict | #7927 |
| expertise | #7928 |
| bioavailability | #7930 |
| adoption | #7934 |
| urogenital | #7939 |
| highrisk | #7939 |
| diseased | #7944 |
| increasing evidence | #7947 |
| disadvantages | #7949 |
| 243 | #7965 |
| patients 1 | #7972 |
| human blood | #7973 |
| fragment | #7975 |
| new class | #7976 |
| 28 | #7989 |
| individualized | #7990 |
| aim | #7992 |
| premenopausal | #7995 |
| advice | #8016 |
| qol | #8022 |
| malignant disease | #8026 |
| pulmonary disease | #8031 |
| 99mtc | #8034 |
| oligonucleotides | #8040 |
| vascular disease | #8049 |
| preventable | #8051 |
| medical | #8051 |
| 600 | #8051 |
| list | #8059 |
| selective | #8062 |
| routine clinical | #8068 |
| fact | #8078 |
| lasting | #8080 |
| helpful | #8084 |
| 36 months | #8086 |
| outcome acute | #8092 |
| extracorporeal | #8095 |
| 248 | #8113 |
| 90 | #8114 |
| patients heart | #8120 |
| training | #8120 |
| 2004 | #8122 |
| initiating | #8123 |
| tsh | #8125 |
| cholesterol ldl | #8138 |
| sensorineural | #8140 |
| investigational | #8141 |
| imaging studies | #8141 |
| mild | #8156 |
| nosocomial | #8164 |
| multiple organ | #8175 |
| stroke | #8176 |
| 237 | #8183 |
| 158 | #8184 |
| arteries | #8190 |
| confidence | #8204 |
| parenteral nutrition | #8204 |
| renal dialysis | #8209 |
| 33 | #8223 |
| impairment | #8228 |
| renal function | #8228 |
| 81 | #8233 |
| therapy | #8235 |
| quantitative | #8240 |
| smoking | #8243 |
| lowest | #8250 |
| lists | #8250 |
| version | #8260 |
| 125i | #8264 |
| activated | #8264 |
| minimum | #8270 |
| mortality | #8280 |
| leukopenia | #8281 |
| 0008 | #8284 |
| agents | #8286 |
| 119 | #8290 |
| utilisation | #8298 |
| practice | #8310 |
| suffered | #8316 |
| schedule | #8320 |
| thrombectomy | #8322 |
| endothelium vascular | #8338 |
| postulated | #8338 |
| immunosorbent assay | #8339 |
| elimination | #8341 |
| linked immunosorbent | #8345 |
| hematology | #8351 |
| 2 years | #8382 |
| absence presence | #8382 |
| cell derived | #8384 |
| 229 | #8394 |
| draw | #8405 |
| 28 patients | #8415 |
| occur | #8415 |
| ≥50 | #8416 |
| reports | #8427 |
| 137 | #8433 |
| mentioned | #8436 |
| covid19 coronavirus | #8447 |
| 265 | #8452 |
| glucuronidase | #8458 |
| patient characteristics | #8459 |
| transient ischemic | #8463 |
| procedures operative | #8463 |
| 295 | #8466 |
| exceed | #8486 |
| knowledge | #8493 |
| 27 patients | #8496 |
| evaluate | #8501 |
| covariate | #8501 |
| criterion | #8504 |
| inborn | #8519 |
| validate | #8528 |
| rabbits | #8537 |
| atherosclerosis | #8557 |
| large cohort | #8558 |
| menstrual cycle | #8563 |
| 193 | #8565 |
| 250 | #8568 |
| adjusted life | #8574 |
| leukocytes | #8581 |
| 146 | #8582 |
| adolescent | #8582 |
| row | #8590 |
| carotid arteries | #8596 |
| thirty | #8596 |
| safety profile | #8602 |
| cox | #8604 |
| intensities | #8605 |
| risks | #8606 |
| 15 years | #8624 |
| fish oil | #8624 |
| attenuates | #8625 |
| entry | #8639 |
| thresholds | #8646 |
| presumed | #8652 |
| emissioncomputed | #8654 |
| 223 | #8655 |
| hydroxymethylglutaryl coa | #8656 |
| valves | #8658 |
| syndrome | #8664 |
| factors patients | #8666 |
| evaluations | #8679 |
| certainty | #8687 |
| markers | #8689 |
| renal failure | #8690 |
| biomarkers | #8693 |
| polytetrafluoroethylene | #8698 |
| publication aged aged | #8706 |
| portal vein | #8708 |
| 1 2 | #8723 |
| hold | #8723 |
| additional studies | #8726 |
| cardiotonic | #8729 |
| definitions | #8731 |
| address | #8733 |
| judgment | #8744 |
| platelet counts | #8754 |
| requiring | #8755 |
| practical | #8756 |
| endovascular | #8756 |
| cardiovascular | #8756 |
| vasoactive | #8762 |
| 236 | #8763 |
| interpret | #8766 |
| undetected | #8778 |
| subpopulation | #8789 |
| medical treatment | #8792 |
| illnesses | #8798 |
| cardiovascular mortality | #8802 |
| 249 | #8834 |
| internship | #8836 |
| convenient | #8837 |
| hydroxymethylglutaryl | #8837 |
| resolving | #8863 |
| representative | #8864 |
| 2 | #8872 |
| cesarean | #8876 |
| merits | #8887 |
| endarterectomy | #8896 |
| chronic liver disease | #8902 |
| mimics | #8903 |
| early treatment | #8910 |
| surgical intervention | #8911 |
| planned | #8914 |
| micrograms | #8914 |
| epoxide | #8916 |
| aged myocardial | #8919 |
| influenced | #8934 |
| normal subjects | #8936 |
| signs symptoms | #8945 |
| proportional hazards | #8945 |
| clinicians | #8956 |
| cessation | #8958 |
| experienced | #8960 |
| heparan sulfate | #8962 |
| leads | #8973 |
| 24 hours | #8977 |
| rct | #8980 |
| options | #9002 |
| patients placebo | #9002 |
| comprise | #9005 |
| chemoprevention | #9005 |
| societies medical | #9007 |
| clinical events | #9007 |
| reply | #9017 |
| receiver | #9026 |
| rank | #9043 |
| 7 | #9061 |
| databases factual | #9064 |
| early mortality | #9075 |
| diagnose | #9080 |
| mps | #9080 |
| frequency | #9083 |
| jan | #9088 |
| statins | #9090 |
| alpha1 | #9115 |
| blood proteins | #9116 |
| prone | #9142 |
| time points | #9147 |
| valve prosthesis | #9147 |
| patient patients | #9150 |
| pelvis | #9158 |
| square | #9165 |
| life threatening | #9170 |
| molecular mechanisms | #9179 |
| 75 patients | #9183 |
| advanced stage | #9184 |
| lysis | #9190 |
| editor | #9193 |
| consensus statement | #9209 |
| 361 | #9213 |
| considerable | #9225 |
| platelets | #9226 |
| 1 month | #9227 |
| pci | #9230 |
| dyspnea | #9230 |
| performs | #9233 |
| contrast | #9238 |
| 4 hours | #9259 |
| extrinsic | #9263 |
| hazards | #9264 |
| illness surveys | #9264 |
| experts | #9266 |
| uncomplicated | #9267 |
| mumol | #9278 |
| attenuation | #9283 |
| positive | #9286 |
| rabbit | #9286 |
| trial registration | #9297 |
| corresponded | #9298 |
| dialysis | #9319 |
| feasibility | #9320 |
| earlier | #9339 |
| suboptimal | #9342 |
| patients negative | #9355 |
| p0004 | #9355 |
| preceded | #9376 |
| loss | #9378 |
| 014 | #9380 |
| higher incidence | #9380 |
| purposes | #9383 |
| invited | #9384 |
| single center | #9385 |
| death patients | #9391 |
| radioactivity | #9394 |
| bacterial infections | #9401 |
| fourth | #9402 |
| 2b | #9412 |
| ascending | #9415 |
| haemorrhage | #9425 |
| 167 | #9436 |
| properly | #9442 |
| rheumatic | #9446 |
| hospitalised | #9448 |
| dysfunction | #9460 |
| belonged | #9480 |
| secondary analysis | #9483 |
| respiratory tract | #9486 |
| 169 | #9490 |
| 240 | #9493 |
| ipd | #9502 |
| factual | #9503 |
| valvular | #9505 |
| thyroid function | #9507 |
| selectin | #9509 |
| hrs | #9524 |
| inflammatory agents | #9529 |
| confirms | #9530 |
| designed | #9535 |
| cardiopulmonary bypass | #9540 |
| swelling | #9542 |
| 3 4 | #9544 |
| insight | #9557 |
| cooperation | #9561 |
| requirements | #9566 |
| hemoglobins | #9573 |
| rose | #9592 |
| il10 | #9597 |
| observational cohort | #9598 |
| lpa | #9600 |
| rates | #9617 |
| comparative effectiveness | #9630 |
| kidney failure | #9638 |
| primary point | #9638 |
| successful treatment | #9639 |
| laboratories | #9644 |
| cardiogenic | #9645 |
| optimal treatment | #9650 |
| 2008 | #9656 |
| hf | #9670 |
| published | #9674 |
| congestive | #9695 |
| pathophysiological | #9704 |
| patients hospital | #9713 |
| spontaneously | #9720 |
| modalities | #9721 |
| inappropriate | #9724 |
| reuptake | #9727 |
| acts | #9729 |
| identifier | #9730 |
| 2007 | #9732 |
| lactoferrin | #9734 |
| 42 | #9744 |
| substitutes | #9747 |
| hypothetical | #9754 |
| nested | #9764 |
| nonesterified | #9768 |
| 90 patients | #9777 |
| reproducibility | #9778 |
| sepsis | #9802 |
| 210 | #9803 |
| absence | #9813 |
| straightforward | #9814 |
| easily | #9817 |
| precise | #9817 |
| coa reductase | #9828 |
| nmol | #9828 |
| classification | #9836 |
| 212 | #9839 |
| craniotomy | #9839 |
| 0006 | #9849 |
| utility | #9855 |
| danish | #9857 |
| labile | #9865 |
| nonhuman primates | #9871 |
| heterozygotes | #9871 |
| discordant | #9908 |
| moderately | #9919 |
| cmv | #9930 |
| 60 years | #9933 |
| lower limb | #9936 |
| promise | #9937 |
| 2003 | #9941 |
| degradation | #9941 |
| tomography | #9944 |
| treatment strategy | #9951 |
| 216 | #9958 |
| low dose | #9971 |
| investigator | #9983 |
| detecting | #9992 |
| regimen | #9995 |
| 12 hours | #9997 |
| casecontrol studies | #9997 |
| pancreatic | #9997 |
| 213 | #10000 |
| neoplasm metastasis | #10001 |
| chance | #10008 |
| physician | #10015 |
| extending | #10027 |
| informative | #10028 |
| hereditary | #10041 |
| obstacles | #10045 |
| protective | #10045 |
| addressing | #10051 |
| medication adherence | #10052 |
| mthfr | #10079 |
| presentations | #10082 |
| familial | #10087 |
| higher prevalence | #10089 |
| chart | #10108 |
| recipients | #10113 |
| qualitative | #10117 |
| 1980 | #10134 |
| completely | #10145 |
| tested | #10150 |
| aged obesity | #10170 |
| 182 | #10176 |
| invasive | #10181 |
| abnormalities | #10186 |
| regularly | #10189 |
| cast | #10193 |
| multicentre | #10198 |
| cell activation | #10199 |
| investigations | #10199 |
| cardiovascular risk factors | #10209 |
| clinical data | #10213 |
| medical therapy | #10213 |
| tumor necrosis factoralpha | #10215 |
| replacement therapy | #10225 |
| routine | #10234 |
| syndrome humans | #10253 |
| heart failure | #10265 |
| 183 | #10280 |
| gaps | #10291 |
| blood transfusion | #10293 |
| hospitalization | #10293 |
| postpartum | #10305 |
| measuring | #10314 |
| aetiology | #10315 |
| 8 | #10318 |
| photon emission | #10329 |
| 032 | #10336 |
| dilution | #10336 |
| 667 | #10337 |
| worldwide | #10337 |
| greatly | #10352 |
| aorta | #10352 |
| indirectly | #10377 |
| restoration | #10378 |
| creatinine | #10381 |
| cardiopulmonary | #10385 |
| pneumonia viral | #10397 |
| medical management | #10404 |
| outcome measures | #10408 |
| p0003 | #10408 |
| tissue injury | #10411 |
| bidirectional | #10419 |
| reductase inhibitors | #10432 |
| circulation | #10432 |
| transfusion | #10435 |
| enrolment | #10446 |
| reflux | #10457 |
| priority | #10461 |
| patients age | #10461 |
| quality life | #10471 |
| phase 3 | #10481 |
| increased prevalence | #10489 |
| activity levels | #10489 |
| 1991 | #10491 |
| style | #10491 |
| 147 | #10501 |
| predictive factors | #10514 |
| sex age | #10526 |
| assessing | #10529 |
| necrosis | #10534 |
| matched | #10556 |
| lower rate | #10558 |
| portable | #10563 |
| patients moderate | #10570 |
| ray | #10570 |
| 125 | #10574 |
| p002 | #10576 |
| pulmonary artery | #10578 |
| inform | #10580 |
| antisense | #10583 |
| recurrences | #10583 |
| 293 | #10584 |
| 180 | #10598 |
| manifestations | #10601 |
| closer | #10602 |
| microvascular | #10605 |
| 159 | #10605 |
| vasoconstrictor | #10607 |
| hospitals | #10612 |
| medical oncology | #10615 |
| november | #10628 |
| percutaneous coronary | #10633 |
| persist | #10635 |
| fragments | #10637 |
| ascertained | #10641 |
| 1b | #10647 |
| publication administration | #10653 |
| postoperative | #10659 |
| held | #10674 |
| concerned | #10674 |
| pulmonary vascular | #10690 |
| discriminate | #10697 |
| term | #10697 |
| risk developing | #10704 |
| synergism | #10709 |
| multivariable analysis | #10713 |
| neutrophil | #10729 |
| consultation | #10735 |
| centres | #10751 |
| median duration | #10755 |
| decisions | #10759 |
| entire | #10774 |
| haemoglobin | #10797 |
| perioperative | #10798 |
| patients cirrhosis | #10804 |
| term mortality | #10829 |
| 300 | #10832 |
| 38 | #10849 |
| prospective observational | #10855 |
| sustained | #10865 |
| randomised controlled | #10867 |
| anatomical | #10873 |
| diagnoses | #10903 |
| airways | #10903 |
| neurosurgical | #10905 |
| monoclonal antibodies monoclonal | #10909 |
| coronavirus infections | #10921 |
| maximal | #10924 |
| threatening | #10963 |
| amniotic | #10987 |
| coronary intervention | #10989 |
| relative | #10990 |
| blocker | #10996 |
| needed | #11009 |
| obese | #11037 |
| neutropenia | #11057 |
| ischemic | #11057 |
| summarizes | #11062 |
| attained | #11062 |
| ethical | #11062 |
| treatment option | #11070 |
| balloon | #11071 |
| 12 weeks | #11074 |
| originally | #11083 |
| inability | #11108 |
| location | #11108 |
| catheters | #11143 |
| beta2 | #11159 |
| ischemic attack | #11165 |
| hematoma | #11189 |
| confirmation | #11199 |
| neoplasms risk | #11201 |
| metabolic syndrome | #11202 |
| iia | #11204 |
| strokes | #11217 |
| choice | #11228 |
| eligible patients | #11247 |
| risk groups | #11263 |
| 1992 | #11272 |
| cerebrovascular | #11281 |
| humans kidney | #11281 |
| waiting | #11282 |
| ≥1 | #11291 |
| endothelial function | #11297 |
| troponin | #11304 |
| determine | #11306 |
| 202 | #11308 |
| aged prevalence | #11331 |
| post | #11332 |
| adherent | #11338 |
| acute respiratory | #11345 |
| acute myocardial infarction | #11361 |
| event | #11363 |
| combination therapy | #11380 |
| glycoprotein | #11391 |
| factors smoking | #11395 |
| reconstructive | #11397 |
| apply | #11399 |
| developed | #11405 |
| 2005 | #11415 |
| competent | #11416 |
| medically | #11426 |
| treatment decisions | #11427 |
| prostaglandins | #11434 |
| diuretics | #11439 |
| hematological malignancies | #11443 |
| morbidity | #11445 |
| media | #11464 |
| protocol | #11487 |
| satisfying | #11502 |
| performances | #11525 |
| hospital admission | #11526 |
| occlusion | #11533 |
| placebo treatment | #11533 |
| multicenter study | #11542 |
| outflow | #11542 |
| enrolled | #11545 |
| humans intensive | #11570 |
| 55 | #11577 |
| chronic inflammation | #11600 |
| definitive | #11621 |
| baseline | #11624 |
| younger patients | #11624 |
| sct | #11638 |
| investigate | #11670 |
| normal controls | #11684 |
| contribution | #11687 |
| reference | #11694 |
| life qol | #11697 |
| lipopolysaccharides | #11699 |
| hypotension | #11715 |
| ascites | #11717 |
| myoglobin | #11741 |
| independent risk | #11745 |
| acute myocardial | #11753 |
| radiopharmaceuticals | #11783 |
| extent | #11786 |
| orally | #11790 |
| involving | #11792 |
| 2010 | #11802 |
| nonspecific | #11809 |
| vena cava | #11829 |
| distinction | #11841 |
| episodes | #11865 |
| eclampsia | #11872 |
| release | #11874 |
| woman | #11885 |
| 151 | #11891 |
| 006 | #11906 |
| elicited | #11912 |
| icu patients | #11915 |
| vasculitis | #11937 |
| activating | #11948 |
| age | #11953 |
| sulphate | #11955 |
| began | #11957 |
| lethality | #11967 |
| collectively | #11970 |
| inferior | #11978 |
| serum creatinine | #11979 |
| myocardial injury | #11980 |
| adp | #11981 |
| immunosorbent | #12006 |
| cardiovascular diseases | #12015 |
| mortality rate | #12041 |
| reduced | #12043 |
| thirds | #12057 |
| dietary intake | #12057 |
| minority | #12058 |
| monitored | #12061 |
| differently | #12066 |
| early pregnancy | #12076 |
| humanized | #12077 |
| wounds injuries | #12079 |
| fair | #12096 |
| thoracotomy | #12111 |
| evidenced | #12130 |
| 1995 | #12135 |
| elevated risk | #12140 |
| 085 | #12141 |
| profile | #12143 |
| prostate | #12153 |
| 149 | #12157 |
| 120 | #12170 |
| digoxin | #12177 |
| offset | #12179 |
| uncommon | #12187 |
| healthcare | #12202 |
| lung | #12208 |
| causality | #12208 |
| spent | #12219 |
| takes | #12233 |
| tendency | #12271 |
| pregnancy risk | #12276 |
| expectancy | #12281 |
| resolve | #12300 |
| flaps | #12302 |
| micromol | #12326 |
| mismatch | #12335 |
| favored | #12342 |
| births | #12351 |
| obstructive pulmonary | #12358 |
| epinephrine | #12365 |
| dependently | #12372 |
| prescription | #12394 |
| registration | #12398 |
| incremental | #12399 |
| switzerland | #12409 |
| inflammatory response | #12409 |
| consistent | #12418 |
| potential confounders | #12425 |
| echocardiographic | #12450 |
| fifty patients | #12451 |
| arginine | #12475 |
| patient discharge | #12480 |
| apparent | #12483 |
| prospective randomized | #12486 |
| sensitivity analyses | #12490 |
| 117 | #12494 |
| switch | #12513 |
| 10 years | #12521 |
| standards | #12524 |
| guide | #12540 |
| requires | #12540 |
| statistically | #12548 |
| prognostic | #12579 |
| chronic obstructive | #12584 |
| monoclonal | #12589 |
| rapidly | #12597 |
| tomography ray | #12611 |
| lipoprotein | #12619 |
| literature | #12637 |
| repeat | #12653 |
| single dose | #12673 |
| drug interactions | #12680 |
| hypertension pulmonary | #12684 |
| physiological | #12687 |
| pharmacogenetics | #12706 |
| prostatic | #12708 |
| 45 | #12708 |
| endocrine | #12709 |
| ifngamma | #12722 |
| minute | #12733 |
| dosage | #12736 |
| congestive heart failure | #12747 |
| cardiac surgery | #12756 |
| personal | #12770 |
| estrogens | #12778 |
| animal model | #12796 |
| thyroid | #12808 |
| settings | #12820 |
| malignancies | #12823 |
| infections | #12836 |
| burden | #12849 |
| intraoperative complications | #12862 |
| cancer patient | #12864 |
| reporting | #12866 |
| 196 | #12881 |
| 1999 | #12904 |
| cvd | #12906 |
| raised | #12910 |
| endpoints | #12912 |
| extracted | #12940 |
| confirming | #12947 |
| 18 years | #12976 |
| ray computed | #12983 |
| postoperative complications | #12990 |
| filters | #13009 |
| monotherapy | #13017 |
| transiently | #13024 |
| oral administration | #13041 |
| instance | #13041 |
| located | #13049 |
| tumor angiogenesis | #13067 |
| based cohort | #13094 |
| fold | #13100 |
| severity | #13106 |
| cancer risk | #13107 |
| escalation | #13107 |
| physical | #13112 |
| vomiting | #13112 |
| latin | #13125 |
| sexes | #13143 |
| drug therapy | #13144 |
| 0 | #13145 |
| ratio | #13159 |
| focused | #13189 |
| appearance | #13195 |
| compliance | #13199 |
| pregnant women | #13202 |
| optimal | #13213 |
| expensive | #13226 |
| support | #13231 |
| exist | #13235 |
| 142 | #13236 |
| lack | #13240 |
| narcotic | #13261 |
| formal | #13262 |
| commercially | #13265 |
| participant | #13273 |
| median follow | #13286 |
| indirect | #13288 |
| emission computed | #13352 |
| mediator | #13366 |
| maintain | #13391 |
| electronic databases | #13394 |
| hypothesized | #13395 |
| advantage | #13432 |
| admitted | #13437 |
| p00001 | #13442 |
| anti | #13455 |
| reliably | #13459 |
| surveys | #13463 |
| endothelial dysfunction | #13466 |
| transient | #13478 |
| patients experienced | #13481 |
| provided | #13489 |
| crosssectional study | #13491 |
| patients patient | #13494 |
| surrogate | #13537 |
| vivo | #13545 |
| retrospectively | #13548 |
| maintained | #13555 |
| 195 | #13556 |
| accurate | #13563 |
| pulmonary hypertension | #13563 |
| longterm outcomes | #13585 |
| monitoring | #13620 |
| laboratory | #13629 |
| elucidated | #13643 |
| abdominal | #13652 |
| whilst | #13665 |
| mitral | #13682 |
| north america | #13705 |
| marker | #13707 |
| competence | #13708 |
| vascular | #13708 |
| 45 years | #13716 |
| 2009 | #13734 |
| icu | #13748 |
| drug effects | #13753 |
| medicine | #13755 |
| healthy individuals | #13758 |
| inhibitory effects | #13763 |
| establishing | #13766 |
| pelvic | #13773 |
| explanation | #13773 |
| participating | #13774 |
| phospholipid | #13776 |
| heart diseases | #13789 |
| women risk | #13816 |
| conservative | #13820 |
| circulating | #13824 |
| condition | #13859 |
| kidney diseases | #13860 |
| systematically | #13868 |
| tissue | #13876 |
| coronary angiography | #13889 |
| internal | #13916 |
| techniques | #13923 |
| microparticles | #13927 |
| dissemination | #13928 |
| 1993 | #13939 |
| 176 | #13979 |
| require | #13986 |
| castration | #13998 |
| radioisotopes | #14011 |
| 48 patients | #14013 |
| insufficiency | #14022 |
| algorithms | #14029 |
| members | #14033 |
| risk death | #14033 |
| requirement | #14046 |
| independent predictors | #14058 |
| continuous | #14060 |
| organ failure | #14072 |
| focus | #14084 |
| situations | #14084 |
| vasoconstriction | #14119 |
| offer | #14137 |
| supporting | #14164 |
| activates | #14188 |
| cardiac output | #14194 |
| leukocyte | #14204 |
| mitral valve | #14205 |
| sensitivities | #14216 |
| document | #14242 |
| primary prevention | #14248 |
| newborns | #14256 |
| nausea | #14276 |
| making | #14285 |
| effectiveness | #14304 |
| independent | #14342 |
| inhibition | #14357 |
| 4 years | #14367 |
| meaningful | #14371 |
| pathologic | #14372 |
| female fetal | #14377 |
| acquired | #14378 |
| 6 patients | #14391 |
| min1 | #14391 |
| amniotic fluid | #14403 |
| substances | #14409 |
| pregnant | #14423 |
| disease chronic | #14460 |
| interleukin1 | #14489 |
| infarction | #14491 |
| influence | #14509 |
| interventions | #14510 |
| costeffectiveness | #14535 |
| locations | #14586 |
| participated | #14592 |
| similarities | #14608 |
| 205 | #14632 |
| statistics | #14637 |
| renal insufficiency | #14637 |
| reasonable | #14646 |
| comparative | #14648 |
| natural | #14667 |
| blood samples | #14672 |
| surgery patients | #14696 |
| entered | #14698 |
| pandemics | #14707 |
| classify | #14715 |
| institutes | #14736 |
| surveyed | #14741 |
| 39 patients | #14742 |
| sampled | #14749 |
| 2017 | #14783 |
| arms | #14785 |
| validity | #14787 |
| independent predictor | #14787 |
| databases | #14808 |
| heart association | #14814 |
| white matter | #14816 |
| complete | #14819 |
| stable | #14828 |
| cox proportional | #14835 |
| pge2 | #14844 |
| duplex | #14845 |
| population | #14872 |
| contribute | #14928 |
| retest | #14931 |
| criteria | #14938 |
| premature | #14952 |
| critical illness | #15004 |
| phospholipids | #15030 |
| european society | #15041 |
| cardiac catheterization | #15042 |
| prostheses | #15059 |
| questionnaires | #15082 |
| treatment failure | #15087 |
| sf36 | #15089 |
| elective surgical | #15107 |
| controlled clinical | #15109 |
| flight | #15110 |
| ldl | #15120 |
| relate | #15127 |
| health costs | #15128 |
| initiation | #15140 |
| obstruction | #15142 |
| obstructive | #15146 |
| stratification | #15164 |
| proper | #15177 |
| selection | #15187 |
| registries | #15197 |
| decrease | #15201 |
| copd | #15201 |
| randomized controlled trial | #15210 |
| unilateral | #15223 |
| ongoing | #15230 |
| induces | #15231 |
| individuals | #15239 |
| young patients | #15247 |
| previous | #15250 |
| methods retrospective | #15255 |
| drug | #15278 |
| disorders | #15278 |
| myocardial | #15279 |
| 4 weeks | #15296 |
| quantitation | #15298 |
| fewer | #15300 |
| hospital discharge | #15328 |
| quantify | #15340 |
| activators | #15356 |
| neonates | #15370 |
| consequence | #15405 |
| locally | #15441 |
| impaired | #15446 |
| pedigree | #15471 |
| randomised controlled trial | #15474 |
| women age | #15474 |
| grafts | #15484 |
| zealand | #15509 |
| asthma | #15511 |
| undetectable | #15512 |
| current literature | #15513 |
| records | #15520 |
| 1994 | #15522 |
| aggregation | #15535 |
| thrombocytopenia | #15537 |
| implementation | #15538 |
| pa | #15540 |
| intended | #15567 |
| reviewed | #15577 |
| surgery | #15590 |
| updated | #15592 |
| discharged | #15616 |
| immunoenzyme | #15617 |
| purpose | #15634 |
| heterozygosity | #15660 |
| centre | #15666 |
| standard | #15679 |
| patients admitted | #15702 |
| perinatal | #15711 |
| explain | #15726 |
| view | #15729 |
| unexpected | #15737 |
| detection | #15766 |
| start | #15808 |
| effectively | #15813 |
| examination | #15813 |
| prescribing | #15823 |
| vary | #15829 |
| febrile | #15847 |
| confer | #15849 |
| serologic | #15853 |
| reach | #15876 |
| interpretation | #15881 |
| janus | #15892 |
| numerous | #15899 |
| inter | #15907 |
| quality adjusted | #15919 |
| dyslipidemia | #15942 |
| prominent | #15961 |
| blocked | #15985 |
| discuss | #15997 |
| severely | #15997 |
| alanine | #15998 |
| external | #16007 |
| causal | #16021 |
| hepatectomy | #16025 |
| complication | #16054 |
| compared controls | #16057 |
| rarely | #16076 |
| systemic inflammation | #16077 |
| fever | #16082 |
| metabolic | #16112 |
| demonstrates | #16117 |
| insensitive | #16125 |
| affect | #16135 |
| conditional | #16136 |
| basis | #16144 |
| carotid | #16168 |
| bypass | #16221 |
| early | #16262 |
| antiretroviral | #16271 |
| neoplasms | #16294 |
| hospital | #16314 |
| special | #16336 |
| signs | #16384 |
| cost | #16418 |
| recommendations | #16420 |
| aimed | #16432 |
| area | #16442 |
| syndromes | #16485 |
| unable | #16508 |
| prevented | #16513 |
| develop | #16513 |
| cancer treatment | #16516 |
| 106 | #16543 |
| radiography | #16545 |
| calibrated | #16568 |
| multivariable | #16576 |
| 2021 | #16583 |
| descriptive | #16618 |
| alternatives | #16629 |
| integrins | #16641 |
| creactive protein | #16645 |
| gained | #16652 |
| consists | #16666 |
| weeks | #16674 |
| downregulation | #16681 |
| residual | #16708 |
| prior | #16725 |
| explained | #16763 |
| fat | #16775 |
| electrocardiography | #16807 |
| epidemiology | #16821 |
| potent | #16848 |
| thought | #16868 |
| genetic risk | #16876 |
| survival | #16892 |
| 093 | #16911 |
| humans liver | #16932 |
| constitute | #16939 |
| gestational age | #16946 |
| vasodilator | #16950 |
| driven | #16958 |
| critically patients | #16965 |
| enable | #16976 |
| verify | #16984 |
| smokers | #16998 |
| inherent | #17023 |
| carotid artery | #17040 |
| apolipoproteins | #17063 |
| individual patients | #17078 |
| markedly | #17097 |
| units | #17139 |
| estimates | #17144 |
| assayed | #17145 |
| elderly patients | #17150 |
| regard | #17197 |
| critically | #17220 |
| adjustment | #17237 |
| lung neoplasms | #17262 |
| cooperative | #17262 |
| estimated | #17274 |
| largest | #17288 |
| acute phase | #17288 |
| 400 | #17295 |
| clinician | #17339 |
| desirable | #17347 |
| 2019 | #17393 |
| limb | #17439 |
| dilated | #17443 |
| disease cvd | #17451 |
| synthetic | #17459 |
| increasingly | #17488 |
| kinds | #17510 |
| antibodies | #17538 |
| prompt | #17565 |
| demographics | #17584 |
| cirrhosis | #17586 |
| 0002 | #17604 |
| finding | #17620 |
| applicable | #17636 |
| obtaining | #17637 |
| coronary | #17653 |
| sex factors | #17688 |
| prosthesis | #17710 |
| independent risk factor | #17712 |
| distal | #17714 |
| multivariate analysis | #17792 |
| gastrointestinal | #17804 |
| selecting | #17815 |
| 3 years | #17833 |
| 2006 | #17840 |
| illustrated | #17852 |
| 1 | #17853 |
| hemorrhagic | #17855 |
| drugs | #17878 |
| current evidence | #17881 |
| undergone | #17883 |
| marked | #17903 |
| epidemiologic | #17920 |
| hospitalizations | #17922 |
| nationwide | #17924 |
| global | #17933 |
| percutaneous | #17942 |
| essential | #17964 |
| corticosteroids | #17975 |
| distant | #18007 |
| intensive | #18031 |
| reductase | #18047 |
| verified | #18052 |
| peptide | #18060 |
| defects | #18070 |
| 000 | #18092 |
| operated | #18111 |
| trend | #18115 |
| centers | #18134 |
| protein crp | #18152 |
| clinical significance | #18164 |
| consistently | #18169 |
| quality | #18175 |
| chemotherapy | #18203 |
| prenatal | #18250 |
| participate | #18252 |
| deaths | #18263 |
| year follow | #18286 |
| metastases | #18296 |
| ventricular function | #18296 |
| inflammatory bowel | #18314 |
| gestation | #18344 |
| tolerated | #18425 |
| attributable | #18434 |
| and or | #18480 |
| coa | #18497 |
| larger | #18513 |
| mutations | #18533 |
| humans hypertension | #18543 |
| stratified | #18569 |
| heart disease | #18579 |
| commercial | #18589 |
| bayes | #18675 |
| ≥ | #18700 |
| extra | #18726 |
| mechanisms | #18742 |
| questions | #18760 |
| plasma | #18797 |
| conventional | #18799 |
| monoclonal antibodies | #18844 |
| increases | #18850 |
| life | #18851 |
| vessel | #18855 |
| oligopeptides | #18887 |
| clearance | #18903 |
| validation | #18907 |
| classical | #18919 |
| hormone | #18938 |
| molecular basis | #19034 |
| single | #19069 |
| worse | #19094 |
| statistical | #19103 |
| soluble | #19124 |
| simultaneously | #19131 |
| tailored | #19134 |
| real | #19158 |
| 5 years | #19189 |
| variable | #19205 |
| moderate | #19239 |
| contributes | #19241 |
| decade | #19291 |
| infarct | #19308 |
| ages | #19312 |
| pubmed | #19345 |
| 0005 | #19412 |
| essentially | #19469 |
| ventricular | #19481 |
| investigates | #19493 |
| 2 3 | #19507 |
| therapies | #19511 |
| called | #19515 |
| partially | #19535 |
| explore | #19544 |
| endothelium | #19553 |
| systemic | #19561 |
| january | #19567 |
| uterine | #19582 |
| reversed | #19601 |
| procedures | #19611 |
| tka | #19675 |
| etiology | #19677 |
| operating | #19692 |
| guided | #19709 |
| histology | #19727 |
| characterised | #19753 |
| inflammation | #19779 |
| median followup | #19863 |
| exclusively | #19881 |
| autologous | #19886 |
| graft | #19904 |
| endothelial cell | #19986 |
| controlled trial | #20019 |
| comorbidities | #20045 |
| 2002 | #20050 |
| gestational | #20050 |
| additionally | #20057 |
| cytokines | #20058 |
| salvage | #20102 |
| inversely | #20149 |
| concentration | #20153 |
| predisposition disease | #20162 |
| diastolic | #20170 |
| small | #20201 |
| alterations | #20228 |
| body | #20230 |
| alpha | #20261 |
| polymorphism genetic | #20264 |
| variables | #20277 |
| subjects | #20283 |
| combine | #20369 |
| adjusting | #20377 |
| catheterization | #20391 |
| introduced | #20458 |
| 1 3 | #20492 |
| younger | #20499 |
| hormones | #20508 |
| length | #20512 |
| theoretically | #20515 |
| ability | #20536 |
| analyses | #20553 |
| clarify | #20561 |
| persistent | #20562 |
| elisa | #20562 |
| improves | #20570 |
| september | #20598 |
| persons | #20696 |
| humans models | #20753 |
| active | #20756 |
| observational | #20823 |
| incorporated | #20843 |
| prognosis | #20934 |
| fetal | #20955 |
| reduce | #21005 |
| measure | #21033 |
| auc | #21046 |
| report | #21048 |
| intrinsic | #21055 |
| responsible | #21081 |
| constructed | #21098 |
| innate | #21135 |
| attenuated | #21137 |
| operative | #21137 |
| 1 year | #21144 |
| designated | #21167 |
| october | #21177 |
| performing | #21185 |
| × | #21191 |
| upper | #21226 |
| reflecting | #21230 |
| selected | #21264 |
| depending | #21267 |
| preschool female | #21270 |
| 005 | #21324 |
| hemodynamics humans | #21403 |
| symptoms | #21425 |
| center | #21469 |
| differed | #21501 |
| 1990 | #21507 |
| 0004 | #21546 |
| logistic | #21639 |
| explored | #21757 |
| animals antibodies | #21767 |
| young | #21860 |
| 139 | #21894 |
| majority | #21894 |
| observe | #21969 |
| facilitate | #21994 |
| decreased | #22047 |
| progression | #22078 |
| genotype | #22116 |
| imaging | #22125 |
| coronary disease | #22178 |
| tract | #22180 |
| neoadjuvant | #22207 |
| generally | #22291 |
| regression | #22321 |
| surgical procedures | #22327 |
| authors | #22330 |
| demonstrated | #22352 |
| inhibiting | #22426 |
| newborn male | #22473 |
| varying | #22556 |
| significance | #22586 |
| represented | #22593 |
| slower | #22607 |
| allogeneic | #22614 |
| grade | #22615 |
| phase | #22698 |
| older | #22831 |
| differential | #22835 |
| july | #22843 |
| modified | #22851 |
| march | #22907 |
| application | #22920 |
| combining | #22961 |
| ratios | #22986 |
| 2012 | #23037 |
| anti inflammatory | #23123 |
| offered | #23214 |
| protocols | #23283 |
| 2016 | #23284 |
| challenging | #23285 |
| yielding | #23334 |
| prevents | #23432 |
| resting | #23488 |
| includes | #23496 |
| renal | #23566 |
| median | #23599 |
| inhibits | #23686 |
| inbred c57bl mice | #23705 |
| increasing | #23723 |
| endopeptidases | #23727 |
| advanced | #23745 |
| adverse | #23767 |
| naive | #23767 |
| reactive protein | #23807 |
| minimal | #23827 |
| interestingly | #23831 |
| showing | #23885 |
| longer | #23967 |
| surgical | #24020 |
| vascular endothelial | #24085 |
| prolonged | #24478 |
| generate | #24487 |
| count | #24514 |
| december | #24569 |
| unrelated | #24572 |
| determining | #24577 |
| activity | #24581 |
| changed | #24651 |
| implies | #24682 |
| underlying | #24749 |
| suggests | #24813 |
| august | #24821 |
| linearly | #24940 |
| february | #24945 |
| frequent | #25109 |
| june | #25175 |
| representing | #25214 |
| acceptable | #25300 |
| carried | #25310 |
| illness | #25373 |
| suitable | #25501 |
| enhance | #25503 |
| 0003 | #25598 |
| linked | #25616 |
| local | #25663 |
| mm | #25732 |
| fully | #25888 |
| reducing | #25912 |
| describes | #25923 |
| difficult | #26054 |
| supported | #26091 |
| scanning | #26181 |
| differentiate | #26212 |
| respect | #26378 |
| promising | #26384 |
| asked | #26410 |
| define | #26421 |
| defective | #26510 |
| female heart | #26685 |
| dependent | #26722 |
| leading | #26774 |
| improving | #27057 |
| contained | #27059 |
| national | #27215 |
| strongest | #27229 |
| quantitatively | #27333 |
| recognized | #27386 |
| mass bmi | #27411 |
| commonly | #27411 |
| implicated | #27484 |
| caused | #27495 |
| remain | #27689 |
| correlate | #27710 |
| artery | #27999 |
| cross | #28142 |
| recorded | #28182 |
| detected | #28405 |
| inflammatory | #28439 |
| multivariate | #28454 |
| examine | #28475 |
| beta | #28655 |
| allowed | #28793 |
| hypothesis | #28801 |
| improved | #28920 |
| required | #29047 |
| large | #29116 |
| chemically | #29137 |
| short | #29272 |
| patients chronic | #29316 |
| genetic predisposition | #29434 |
| bmi | #29470 |
| female health | #29531 |
| achieved | #29589 |
| 001 | #29634 |
| underwent | #29797 |
| 2011 | #30149 |
| indicating | #30233 |
| approved | #30511 |
| declined | #30756 |
| participants | #30828 |
| predisposition | #30981 |
| genotype humans | #31051 |
| aims | #31216 |
| measured | #31265 |
| antineoplastic agents | #31706 |
| expected | #31791 |
| specific | #31901 |
| endothelial | #32294 |
| modality | #32386 |
| inhibit | #32629 |
| conducted | #32675 |
| predicted | #32889 |
| inhibited | #33631 |
| agreement | #33673 |
| sensitive | #34362 |
| antineoplastic | #34560 |
| correlated | #34744 |
| greater | #34856 |
| poor | #35078 |
| neoplasms male | #35230 |
| humans magnetic | #35433 |
| 0001 | #35646 |
| free | #35793 |
| sectional | #35852 |
| include | #39773 |
| collected | #40746 |
| examined | #41010 |
| mediated | #41310 |
| neoplasm | #47468 |
Sacar un reporte | |
Prominent publications by Harry Roger Büller
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
[ PUBLICATION ]
BACKGROUND: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been suboptimal worldwide.
OBJECTIVES: To establish a common international consensus addressing practical, clinically relevant questions in this setting.
METHODS: An international consensus working group of experts was set up to develop guidelines according to an evidence-based medicine approach, using the GRADE system.
RESULTS: For the ...
| Conocido por Vte Patients | Venous Thromboembolism | Prophylaxis Lmwh | 3 Months | Practice Guidelines |
KOL-Index: 20177
OBJECTIVES: The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of patients with atrial fibrillation (AF) undergoing anticoagulation.
BACKGROUND: Three bleeding risk-prediction schemes have been derived for and validated in patients with AF: HEMORR(2)HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall ...
| Conocido por Atrial Fibrillation | Bled Bleeding | Hemorr2hages Atria | Intracranial Hemorrhage | Topic Risk |
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
[ PUBLICATION ]
This chapter about antithrombotic therapy for venous thromboembolic disease is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2004; 126:179S-187S). Among the key ...
| Conocido por Antithrombotic Therapy | Grade 1a | Venous Thromboembolic Disease | Vka Lmwh | Inr Range |
KOL-Index: 16684
PURPOSE: Initial heparinization followed by vitamin K antagonists is the treatment of choice for patients with venous thromboembolism. There is controversy whether known malignancy is a risk factor for recurrences and bleeding complications during this treatment. Furthermore, the incidence of such events in these patients is dependent on the achieved International Normalized Ratio (INR). The aim of this study was to assess the incidence of venous thromboembolic recurrence and major ...
| Conocido por Venous Thromboembolism | Bleeding Complications | Patients Malignancy | Retrospective Analysis | International Normalized |
KOL-Index: 16378
BACKGROUND: Venous thromboembolism occurs commonly in patients with cancer. Direct oral anticoagulants are non-inferior to conventional anticoagulants for the treatment of venous thromboembolism. We hypothesised that edoxaban, a direct oral inhibitor of activated clotting factor Xa, might be more suitable than conventional anticoagulants in the management of cancer-associated venous thromboembolism. The aim of this study was to assess the efficacy and safety of edoxaban compared with ...
| Conocido por Venous Thromboembolism | Patients Cancer | Hazard Ratio | Clinically Relevant Bleeding | Factor Inhibitors |
KOL-Index: 15975
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.
METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), ...
| Conocido por Warfarin Patients | Hazard Ratio | Venous Thromboembolism | Pulmonary Embolism | Primary Efficacy Outcome |
ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer
[ PUBLICATION ]
ESSENTIALS: Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop VTE. von Willebrand factor (VWF) levels were higher if compared with controls and correlated with cancer stage. VWF and ADAMTS-13 are associated with the occurrence of VTE in cancer.
BACKGROUND: Patients with cancer are at high risk of venous thromboembolism (VTE). ADAMTS-13 regulates von Willebrand factor (VWF) activity, which ...
| Conocido por Willebrand Factor | Venous Thromboembolism | Vte Cancer | Vwf Adamts13 | Khorana Score |
KOL-Index: 15571
BACKGROUND: Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need for laboratory monitoring.
METHODS: We conducted an open-label, randomized, event-driven, noninferiority study that compared oral rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous enoxaparin followed by a vitamin K antagonist (either warfarin or ...
| Conocido por Oral Rivaroxaban | Venous Thromboembolism | Vitamin Antagonist | Continued Treatment | Hazard Ratio |
KOL-Index: 15512
BACKGROUND: After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.
METHODS: In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after ...
| Conocido por Hip Replacement | Dabigatran Enoxaparin | Venous Thromboembolism | Etexilate Versus | Primary Efficacy Outcome |
KOL-Index: 15505
CONTEXT: Previous studies have evaluated the safety of relatively complex combinations of clinical decision rules and diagnostic tests in patients with suspected pulmonary embolism.
OBJECTIVE: To assess the clinical effectiveness of a simplified algorithm using a dichotomized clinical decision rule, D-dimer testing, and computed tomography (CT) in patients with suspected pulmonary embolism.
DESIGN, SETTING, AND PATIENTS: Prospective cohort study of consecutive patients with clinically ...
| Conocido por Pulmonary Embolism | Computed Tomography | Dimer Testing | Patients Suspected | 3 Months |
KOL-Index: 15415
BACKGROUND: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following orthopedic surgery.
METHODS: In a multicenter, parallel-group, double-blind study, 1973 patients undergoing total hip or knee replacement were randomized to 6-10 days of oral dabigatran etexilate (50, 150 mg twice daily, 300 mg once daily, 225 mg twice daily), starting 1-4 h after surgery, or subcutaneous enoxaparin (40 mg once daily) ...
| Conocido por Total Hip | Dabigatran Etexilate | Thromboembolic Events | Knee Replacement | Vte Patients |
KOL-Index: 14849
BACKGROUND: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer potential for prophylaxis against venous thromboembolism (VTE) after total knee replacement surgery.
METHODS: In this randomized, double-blind study, 2076 patients undergoing total knee replacement received dabigatran etexilate, 150 mg or 220 mg once-daily, starting with a half-dose 1-4 hours after surgery, or subcutaneous enoxaparin ...
| Conocido por Subcutaneous Enoxaparin | Oral Dabigatran | Total Knee Replacement | Venous Thromboembolism | Prevention Vte |
Subcutaneous Fondaparinux versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism
[ PUBLICATION ]
BACKGROUND: The standard initial treatment of hemodynamically stable patients with pulmonary embolism is intravenous unfractionated heparin, requiring laboratory monitoring and hospitalization.
METHODS: We conducted a randomized, open-label trial involving 2213 patients with acute symptomatic pulmonary embolism to compare the efficacy and safety of the synthetic antithrombotic agent fondaparinux with those of unfractionated heparin and to document noninferiority in terms of efficacy. ...
| Conocido por Unfractionated Heparin | Pulmonary Embolism | Initial Treatment | Subcutaneous Fondaparinux | Intravenous Injections |
KOL-Index: 14727
OBJECTIVES: To determine the rate of a first recurrent venous thromboembolism (VTE) event after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked VTE, and the cumulative incidence for recurrent VTE up to 10 years.
DESIGN: Systematic review and meta-analysis.
DATA SOURCES: Medline, Embase, and the Cochrane Central Register of Controlled Trials (from inception to 15 March 2019).
STUDY SELECTION: Randomised controlled trials and prospective cohort ...
| Conocido por Anticoagulant Treatment | Recurrent Vte | Unprovoked Venous | 10 Years | 95 Confidence Interval |
Gente clave para Pulmonary Embolism
Los KOLs mas influyentes del mundo
Seleccione una frase de búsqueda pulmonary embolism , pulmonary embolism patients , pulmonary embolism 95 , pulmonary embolism diagnosis , pulmonary embolism treatment
Harry Roger Büller:Impacto experto
Conceptos para los cualesHarry Roger Büllertiene influencia directa:Pulmonary embolism, Venous thromboembolism, Venous thrombosis, Major bleeding, Deep vein thrombosis, Atrial fibrillation, Vein thrombosis.
Harry Roger Büller:Impacto de Kol
Conceptos relacionados con el trabajo de otros autores para los cualesfor which Harry Roger Büller tiene influencia:Venous thromboembolism, Pulmonary embolism, Atrial fibrillation, Deep vein thrombosis, Oral anticoagulants, Major bleeding, Vte patients.
Tools
¿Es este tu perfil? Reclama tu perfil Copiar URL Incrustar el enlace a su perfil |